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PREFACE
The triennial Surveillance project, initiated in 1998 by Drs.
Howard Jones, Jr and Jean Cohen, continues to evolve, now with
a new name, the International Federation of Fertility Societies’
Surveillance (IFFS) 2019: Global Trends in Reproductive Policy
and Practice, 8th Edition. The new name more accurately reflects
the scope and focus of the project, and makes the report more
accessible to a global audience, particularly those seeking this
information online. IFFS is a non-state actor (NSA) in official
relations with the World Health Organization (WHO), and the
publication of Surveillance serves as part of the IFFS’ WHO
mandate.
The 2019 version has several major changes. Some chapters
have been expanded, and some topics have been combined to
eliminate redundancies. The number of chapters has been
reduced from 24 to 18, but all previous topics and questions have
been retained.
The 2018 online questionnaire was the sole source of data for
IFFS Surveillance 2019: Global Trends in Reproductive Policy
and Practice, 8th Edition. The online questionnaire was further
refined, and was again administered by Medtech for Solutions®.
The refined questionnaire consisted of 94 questions, in English,
with translated versions available. On average, it took 90minutes
(cumulative on-site time) to complete. The survey was accessible
online from February 1 through March 31, 2018.
Although a few responses were accepted shortly after the
deadline, they reflect the practices of assisted reproductive tech-
nology (ART) (also called assisted reproductive treatment)
through that time. Respondents representing 97 countries (22
more than in 2015) registered online at the website, and all
provided at least some responses to the 2018 questionnaire,
enough to be included in the analysis. There were 27 more usable
responses than in the 2015 survey, in which 26 responses
were new to Surveillance. Responses were not received for all
questions, and this is reflected in the variations in amount of data
submitted for the individual queries. The percent positive
response is given for all answers, for that particular query. For
specific questions, participants could answer “yes’, “no” or
“unknown” if the respondent did not know the answer to a
particular query.
Many individuals contributed to the success of this project. I
am profoundly grateful for the efforts of the 191 respondents,
representing 97 countries, who completed the survey. The ques-
tionnaire is lengthy, and the answers to some questions are not
readily accessible. The diligence and commitment of a wide array
of colleagues around the world was essential to the successful
completion of the publication.
Although Surveillance 2019 is a global project, relying on
many individuals from many nations, the ultimate success in
engaging such a diverse representation hinged on personal rela-
tionships. To this end, many IFFS officers and representatives
gave generously of their time, contacting and enlisting many
international colleagues who were new to Surveillance. I would
particularly like to acknowledge the efforts of Drs. Silke Dyer and
Fernando Zegers, who issued countless personal appeals; they
deserve a large share of the credit for the increased representation
this year. Closer to home, our administrative assistant, Leila
Grass, resorted to extensive social media searches to identify ART
centres in countries that we had previously been unable to engage;
her efforts were ultimately successful. The Surveillance Editorial
Board worked tirelessly; all had roles in developing the 2018
questionnaire, reformatting the organization of Surveillance, and
conducting data analysis, and were also involved in chapter
preparation and editing.
Special recognition is due Drs. Edgar Mocanu and Marcos
Horton. The Assistant Editor, Dr. Horton, worked relentlessly, as
he did in previous editions, andwas particularly invaluable in this
capacity. OurManaging Editor, Dr. KathleenMiller, deserves the
greatest accolades for her passionate pursuit of a comprehensive,
high-quality product. Finally, I would like to recognize the con-
tinuing support, encouragement, and participation of the IFFS
officers and Board of Directors, and the administrative staff of the
IFFS Secretariat, for their essential roles in the project’s successful
completion.
Surveillance 2019 presents a more comprehensive global
assessment of the status of reproductive policy and practice than
previous editions, drawing input from 97 of the 132 countries
believed to offer ART services. Data collection was improved by
further refinements in the questionnaire, a more robust process
for identifying and engaging prospective participants, and many
local and regional developments that facilitated cooperation and
participation. Consequently, Surveillance 2019 depicts a further
maturation of the field, with wide adoption of technologic
advances, and an emerging consensus regarding some of the more
controversial aspects of ART.
Significant limitations remain, however. Although the report
refers to practices and policies of countries, responses for most of
the participating countries were provided by a single well-
informed, responsible individual. The responses have not been
validated for the majority, andmay include inherent inaccuracies.
Some respondents were not able to provide complete data sets.
Some ART practices have undoubtedly changed since the survey
was completed and answers may not reflect current practices. For
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these reasons, caution should be exercised in interpreting the
data. When feasible, responses from previous triennial surveys
and multiple respondents have been compared. When dis-
crepancies were identified among multiple respondents, or from
other published reports, the editors adjudicated the incon-
sistencies. However, this occurred infrequently.
IFFS Surveillance 2019: Global Trends in Reproductive Policy
and Practice, 8th Edition is unique in its depiction of world-wide
ART policy and practice. This report attests to the dynamic,
ongoing growth of the practice of ART, the local and regional
differences, and the continued international collaboration that
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CHAPTER 1: NUMBER OF CENTRES
As noted in previous editions, compiling a reliable estimate of the
number of ART centres in any country entails considerable
methodologic limitations. The total number of ART programmes
in theworld is dynamic; newARTprogrammes are emerging, and
some centres are consolidating or closing. As we noted in 2016,
“significant global progress in establishing registries and over-
sight has been made over the intervening three years, and the
2016 data for these countries may represent a more accurate and
complete estimate than previous estimates. However, there are
still many countries in which this information is collected spor-
adically, if at all, and there are no reliable estimates.”
These conclusions remain valid three years later. The numbers
cited herein represent the best estimate of the nations’ respon-
dents when the questionnaire was completed. In countries with
national registries, accurate estimates are a matter of public
record and are easily accessible. Compiling a list of centres in
countries with more limited ART resources, but a more finite
roster of known facilities, is often a less arduous task, and those
reports are probably more reliable. For countries such as China
and India, known to have many centres, but lacking compre-
hensive registries and validation mechanisms, compiling accurate
estimates is considerably more challenging.
The 2018 questionnaire used to compile Surveillance 2019:
Global Trends in Reproductive Policy and Practice, 8th Edition
reveals that progress has been made in developing registries,
monitoring ART activities, and, in many countries, tracking the
number of centres. In 2018, we engaged 97 countries to register
on our website and provide some ART data for their respective
Preface. Table 1
(Continued)
Participant Name Participant Country
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Preface. Table 1
(Continued)
Participant Name Participant Country
Mehmet Ertan Kervancioglu Turkey
Sezgin Gunes Turkey
Zehra Sema Ozkan Turkey
Mark Muyingo Uganda
Eugenia (Ievgeniia) Zhylkova Ukraine
Sanne F. Biesemans United Arab Emirates
Marta Jansa Perez United Kingdom of Great
Britain and Northern Ireland
Bruce Rose The United States of America
Carolina Sueldo The United States of America
David Adamson The United States of America
David Albertini The United States of America
Dmitry Kissin The United States of America
Joanne Kwak-Kim The United States of America
Jose Carugno The United States of America
Meike Uhler The United States of America




Vo Thanh Lien Anh Vietnam
Vuong Thi Ngoc Lan Vietnam
Mhlanga Tinovimba Zimbabwe
Rumbidzai Majangara Zimbabwe
*Reporting separately for this report.
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Chapter 1. Table 1
Registered countries.
Algeria+ China Greece Latvia+ Paraguay Switzerland
Argentina Colombia Guatemala Lithuania+ Peru Taiwan (China*)
Armenia+ Congo Hong Kong (China*) Malaysia Philippines Thailand+
Australia Costa Rica+ Hungary Mali Poland Togo+
Austria Côte d’Ivoire+ Iceland+ Mexico Portugal Trinidad and Tobago
Bangladesh Czechia India Moldova+ Romania Tunisia
Barbados Dominican Republic Indonesia Mongolia+ Russian Federation Turkey
Belarus Ecuador Iran Montenegro+ Senegal Uganda+
Belgium Egypt+ Iraq Myanmar Serbia+ Ukraine+
Bolivia+ El Salvador+ Ireland Namibia+ Singapore United Arab Emirates+ (UAE)
Botswana+ Estonia Israel Netherlands Slovenia United Kingdom of Great Britain and Northern Ireland (UK)
Brazil Finland Italy New Zealand+ South Africa The United States of America (USA)
Bulgaria France Japan Nicaragua+ The Republic of Korea Uruguay
Burkina Faso+ Georgia+ Jordan Nigeria Spain Venezuela
Cameroon Germany Kazakhstan Norway Sri Lanka Viet Nam+
Canada Ghana+ Kenya Panama Sweden Zimbabwe+
Chile
+ Denotes countries new to Surveillance.
*Reporting separately for this report.
Chapter 1. Chart 1. Participating and non-participating countries.
Chapter 1. Table 2
Countries without ART.
Andorra Dominica Holy See Mauritania Saint Kitts and Nevis South Sudan
Angola Equatorial Guinea Kiribati Micronesia Saint Lucia Suriname
Antigua & Barbuda Eritrea Kyrgyzstan Monaco Saint Vincent and the Grenadines Eswatini
Belize Ethiopia Lesotho Mozambique Samoa Tajikistan
Benin Fiji Liberia Nauru San Marino Timor-Leste
Burundi Gabon Liechtenstein Niger Sao Tome and Principe Tonga
Cabo Verde Gambia Luxembourg Palau Seychelles Turkmenistan
Central African Republic Grenada Malawi State of Palestine Sierra Leone Tuvalu
Chad Guinea Maldives Papua New Guinea Solomon Islands Uzbekistan
Comoros Guinea-Bissau Malta Congo Somalia Vanuatu
Djibouti Guyana Marshall Islands
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Chapter 1. Table 3
Non-responding countries with ART.
Afghanistan Cambodia Kosovo Morocco Saudi Arabia
Albania Croatia Kuwait Nepal Slovak Republic
Azerbaijan Cuba The Lao People’s Democratic Republic The Democratic People’s Republic of Korea Sudan
Bahamas Cyprus Lebanon Oman Syria
Bahrain Denmark Libya Pakistan United Republic of Tanzania
Bhutan Haiti The former Yugoslav Republic of Macedonia Qatar Yemen
Bosnia and Herzegovina Honduras Madagascar Rwanda Zambia
Brunei Darussalam Jamaica Mauritius
Chapter 1. Table 4
Number of centres.
Reporting Year 2019 Type of Centre















Algeria Did not report Did not report Did not report 2
Argentina 23-25 30-44 60 65 37 1 2 2
Armenia Did not report Did not report Did not report 6 6
Australia 63 Did not report 76 100 100
Austria 25 25 27 28 17 3 5 2 0
Bangladesh Did not report Did not report 12 11 9 2
Barbados Did not report Did not report 1 1 1
Belarus 4 4 8 8 5 3
Belgium 16-29 31 34 10 0 0 6 4 0
Bolivia Did not report Did not report Did not report 10 10 0 0 0 0
Botswana Did not report Did not report Did not report 1 1
Brazil 150 200 180 200 141 10 5 4
Bulgaria 16 23 31 37 13 7 1 3 13
Burkina Faso Did not report Did not report Did not report 1 6 60 1 12
Cameroon 2 2 2 3 2 1
Canada Did not report Did not report 32 34 31 0 0 3
Chile 8-9 7 9 12 5 3 4
China 102-300 > 200 358 400 400
Colombia 19-21 27 25 23 15 3 0 0 5
Costa Rica Did not report Did not report Did not report 2 2 0 0 0 0
Côte d’Ivoire 3 2 Did not report 4 0 3 0 1 0
Croatia 7-11 13 12 Did not report
Czechia 30 38 42 42 27 5 5 3 2
Denmark 18-22 18-21 21 Did not report
Dominican
Republic
4 5 Did not report 7 7 0 0 0 10
Congo 1 1 Did not report 3 3
Ecuador 6-8 11 10 12 12
Egypt 52-55 58 Did not report 70 40 10 5 3 12
El Salvador Did not report Did not report 0 2 30 0 0 0 30
Estonia Did not report Did not report 4 6 3 1 2
Finland 19-20 18 24 21 11 9 1
France 90-106 100 104 101 50 50
Georgia Did not report Did not report Did not report 9 4 5 0 0 0
Germany Did not report Did not report 134 125 110 10 5
Ghana Did not report Did not report Did not report 18 18 0 0
Greece 50-60 ~60 66 50 5 8 4 6 3
Guatemala Did not report Did not report 3 4 3 0 0 0 50
Honduras Did not report Did not report 2 Did not report
Hong Kong
(China*)
7 9-12 11 42 18 4 2 7 11
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Chapter 1. Table 4
(Continued)
Reporting Year 2019 Type of Centre















Hungary 12 14 13 11 7 3 1 0
Iceland 1 1 Did not report 1 1 0 0 0 0
India 500 500-600 1000 1500 350 100 5 10 1000
Indonesia Did not report Did not report 26 32 0 23 6 3 0
Iran Did not report Did not report 62 60
Iraq Did not report Did not report 13 5
Ireland 7 7-8 28 8 7 1
Israel 24-30 29 34 23 19 4
Italy 360 350 350 350 200 150 100 100 100
Japan 606-618 591 587 574 44 71 10 400
Jordan Did not report Did not report 20 22 20 55 7 20 400
Kazakhstan Did not report 12 19 23 2 2 3 16
Kenya Did not report Did not report 5 9 8 1 0 0 4
Latvia 4-5 4 Did not report 7 7
Lithuania Did not report Did not report Did not report 6 3 0 0 1 2
Malaysia Did not report Did not report 36 12
Mali Did not report Did not report 1 1 3 13
Mexico "Uncertain" ~30 48 81 70 8 1 2
Moldova Did not report Did not report Did not report 1
Mongolia Did not report Did not report Did not report 4 3 1
Montenegro Did not report Did not report Did not report 5 3 1 1
Myanmar Did not report Did not report 1 2 1 1
Namibia Did not report Did not report Did not report 2 1 1 0 0 0
Netherlands Did not report Did not report 13 15 1 1 8 5 0
New Zealand 7 7 9 8 7 0 0 1 0
Nicaragua Did not report Did not report Did not report 1 1
Nigeria Did not report Did not report 50 36 3 30 2 1 0
Norway 11 10 12 10 5 0 0 5 0
Oman Did not report Did not report 14 Did not report
Panama 7 9 12 10 3 3 0 1 3
Paraguay Did not report Did not report 2 2 2 0 0 0 0
Peru 5-7 6 12 18 17 0 0 1 0
Philippines 4 5 6 7
Poland Did not report Did not report 50 70 50 20
Portugal 24 28 24 24
Romania Did not report Did not report 21 23 21 3 2
Russian
Federation
80 110-130 170 200
Saudi Arabia 24-30 30 50 Did not report
Senegal 2 2 2 100 118 5 1 20 450
Serbia Did not report Did not report Did not report 15 8 0 4 1 2
Singapore 9 11 11 11 2 5 0 3 1
Slovak
Republic
Did not report Did not report 9 Did not report
Slovenia 3 3 3 3 0 1 2 0 0
South Africa 12-15 15 20 22 19 3 0
The Republic
of Korea
142 150 148 154 59 53 42 0 0
Spain 177-203 > 100 371 150 110 40
Sri Lanka Did not report Did not report 6 110 50 30 4 35 20
Sweden 15-16 16 17 10 3 4 3
Switzerland 26 26 25 29 16 1 5 6 1
72-78 76 79 78 7 29 19 5 18
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countries (Table 1, Chart 1). This represents 19 more registrant
countries and 23 more total responses than the 2015 ques-
tionnaire, and includes 28 countries new to Surveillance.
Unfortunately, six countries in the 2016 report (Croatia,
Denmark, Guatemala, Oman, Saudi Arabia, and the Slovak
Republic) did not respond to the current survey. In 2018, we
compiled for the first time a list of countries that we believe
currently have no ART activity. Countries were included in this
list after a diligent effort was made to confirm the absence of ART
services. This entailed contacting allied health professionals in the
country, health ministry officials, fertility specialists in neigh-
boring countries or within the region, and social media profiles.
As many of these sources were used as was feasible.
We compiled a list of 63 countries that did not appear to have
ART programmes as of March 31, 2018 (Table 2). This inclusion
overcomes some of the limitations of previous surveys. We
identified another 39 countries that are known to provide ART
services, but that we were unable to recruit for our survey
(Table 3). We included all 195 countries currently recognized by
the United Nations in one of the three categories depicted in the
three tables.
In 2018, all 97 countries that registered on our site provided
some data regarding the number of ART centres in their countries
(Table 4). Several countries were able to provide only estimates,
but in aggregate these figures are consistent with previous totals.
The estimated total number of ART facilities in the 2018 tally was
6,201, compared to 5,353 centres calculated in 2016. However,
this figure does not include six countries that responded in 2015
but not in 2018 (previous total number of those centres was 108),
but does include the 28 new respondents. Their inclusion added
334 centres. The new countries with the largest number of ART
programmes were Egypt, Thailand, and Ukraine, with 70, 75,
and 40 centres, respectively. Twenty-four of the 28 respondents
new to Surveillance noted the presence of ten or fewer centres,
suggesting that ART has only recently become available in some
of these countries.
Many countries (34) reported a modest increase or no sig-
nificant change in the number of centres over the triennial, but 22
countries recorded a decrease. Of particular note, India reported
an increase in centres, from 1,000 to 1,500; Senegal, from 2 to
110; and Sri Lanka, from 6 to 110 centres. Conversely, Belgium
saw a decrease, from 34 to 10 centres, as did Spain, from 371 to
150. It is not clear whether these changes are real, or if they reflect
different methodologies or inclusion criteria for the tabulation.
Nor is it clear what might have accounted for the differences, if
they are actual changes.
We also queried about the type of ART programme, i.e., private
physician clinic, private hospital-based clinic, private or public uni-
versity-based clinic, public hospital-based clinic, or sole practitioner
clinic. While not all respondents provided data regarding the
breakdown for type of clinic, the solo practitioner and private phy-
sician clinics appear to be the predominant clinic models (Table 4).
The popularity of the sole physician model represents a striking
change from 2016, when it was the least commonly utilized.
Summary
Overall, the 2018 questionnaire results reflect a more modest
increase in the total number of ART centres than noted in
Chapter 1. Table 4
(Continued)
Reporting Year 2019 Type of Centre

















Thailand Did not report Did not report Did not report 75 30 27 11 2 5
Togo 1 1 Did not report 2 2
Trinidad and
Tobago
Did not report Did not report 1 1 1 1 0 0 0
Tunisia 8 12 9 13 10 0 0 3
Turkey 112-116 131 153 154 30 71 36 13 4
Uganda 1 2 Did not report 6 2 4 0 0 0
Ukraine Did not report Did not report Did not report 40 20 5 4 3 8
United Arab
Emirates
Did not report Did not report Did not report 10 100 50 5 5 150
UK 66 71-117 78 82 82
USA 450-480 430 410 450 200 90 100 10 50
Uruguay 4 4 3 3 3
Venezuela 17-18 10 30 22 14 8 0 0 0
Viet Nam 11-12 13 Did not report 26 0 12 4 10 0
Zimbabwe Did not report Did not report Did not report 2 0 1 0 0 1
Totals 3524-3870 3701-3890 5335 6201 2245 1075 529 914 2775
*Reporting separately for this report.
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previous surveys: from 5,353 to 6,201, with 500 centres alone
accounted for by India’s putative increase. An apparent reduction
in the number of clinics in some developed countries is a new and
provocative finding. If validated, this reduction might be due to
consolidation, declining populations, or other economic drivers,
and should be a topic for future queries. Priorities for the next
edition of Surveillance will be to engage as many of the non-
responding countries as is feasible, and to continue to refine our
list of countries that are not performing ART procedures.
CHAPTER 2: LEGISLATION, POLICY, AND
GUIDELINES
Introduction
The 2019 Surveillance Survey provides a unique comparison of
governance systems among different countries. Data from
respondents in 89 countries covered modes of regulation, gov-
ernance, and oversight. The overall trend appears to be one of
increasing uniformity, and some form of regulation now exists in
most countries where ART is available. Most often the regulation
consists of legislative requirements that establish the boundaries
of practice. The legal framework often is supplemented with
guidelines promulgated by the government, or by professional
societies; many countries also have provisions for licensing and
agency oversight.
The limits of such regulation are determined by the local sta-
keholders, including patient advocacy groups, local health care
providers, professional organizations, local and national gov-
ernment agencies, legislative bodies, religious organizations, and
insurance companies and other organizations responsible for
payment. The position adopted for various issues is dependent on
different social, cultural, and political norms, and is discussed in
greater detail in later chapters of this report. Topics of extensive
attention over the past three years include advances in the genetic
assessment of embryos, trends in cross-border reproductive care,
ethical controversies regarding the appropriateness of preserving
anonymity for gamete donation, access to ART services for sin-
gles and for individuals in same-sex relationships, and proscrip-
tions on commercial surrogacy.
Analysis of the survey
The 89 respondents reported as follows: 77 (87%): the practice of
ART was regulated by legislation, guidelines, or both; 57 (64%):
legislation existed in their country to regulate ART; and 29
(33%): no legislation existed. Respondents in two countries
replied “Unknown”. In the 2016 Surveillance report, respondents
from 40 countries (57%) reported having legislation; that was
fewer countries than did so in the 2018 survey (Table 1).
Of the 57 respondents that had legislation in 2018, 38 (67%)
reported federal laws; 18 (32%) had both federal and state/pro-
vincial/regional laws; and one had state/provincial laws only. In
addition, most respondents, 49 (86%), had some form of agency
oversight, licensing body, or professional standards and guide-
lines: of these 49,14 (29%) had all three; 26 (53%) had agency
oversight and licensing body (2); agency oversight and profes-
sional standards and guidelines (1); licensing body and profes-
sional standards and guidelines (23); and 15 (31%) had one of the
following: agency oversight (1); licensing (5); professional stan-
dards/guidelines (9).
Of the 32 respondents who reported no legislation in their
country, 20 (62.5%) acknowledged having some other form of
regulation: 2 (6.0%), all three regulations; 12 (37.5%), two of the
following: agency oversight and licensing body (3); agency
oversight and professional standards and guidelines (3); licensing
body and professional standards and guidelines (6); 10 (31%),
one regulation: one had licensing, nine had a regulation related to
professional standards or guidelines.
There were 64 countries that responded to the 2018 survey,
and had also participated in the 2015 survey; 21 (33%) of these
countries reported intervening updates to legislation, and 32
(50%) reported no changes since the previous survey. The 11
remaining respondents (17%) were unsure whether updates had
occurred (Chart 1).
Table 2 lists the various aspects of ART addressed by legisla-
tion in the past three years, in rank order, illustrating the most
prevalent topics in new legislation.
When the countries were queried about incidents in which
national ART policies had been violated, 86 responded, as fol-
lows: violations had taken place in 13 countries (15%), and none
had occurred in 50 (58%); the response from the remaining 23
countries (27%) was, “Unknown”. Respondents also were asked
about specific licensing criteria and credentialing bodies, and
were questioned about the monitoring of governance pertaining
to ART centres, physicians specializing in reproductive medicine,
obstetrician/gynecologist specialists practicing ART, the ART
laboratory, and the laboratory director and staff.
The ART centre
The survey noted that out of 88 countries, 63 (72%) required
ART centres to be licensed. Most of these countries, 44 (70%),
had multiple licensing requirements; only 3 (5%) had just one.
Of the 63 countries with multiple requirements, 3 (5%)
required an examination or certification procedure; 10 (16%), an
on-site inspection; and 21 (31%), continuing education.
ART centres were monitored in 56 of the countries (64%). Of
the countries with monitoring systems in place, the principal
mechanisms used were: a national registry, in 45 (80%); an on-
site inspection, in 42 (75%); and a periodic report, in 32 (57%).
Twenty-one of the countries (37%) also submitted their data to
an international registry.
Government employees were responsible for monitoring ART
centres in 30 of the 56 countries (53%), independent agencies
monitored in 8 countries (14%), and medical officers did so in 16
countries (28.5%). Again, some countries used more than one
method ofmonitoring. Thirteen countries (23%) reported that no
one was responsible for monitoring.
Reproductive medicine physicians
Of the 89 countries responding, 45 (51%) had mechanisms for licen-
sing or credentialing physicians in reproductive medicine, or endocri-
nologists who had special training in ART. In 40 of these 45 countries
(89%), the mechanisms used were examination and certification.
In 87 of the 89 countries, 36 respondents (41%) said that ongoing
monitoring of physicians in reproductive medicine was performed
primarily by government agencies, medical officials, or both, but
some physicians were monitored by an independent agency.
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29
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Chapter 2. Table 1




















Argentina No Yes Yes No No Yes Yes
Armenia Yes Yes
Australia Yes Yes Yes Yes Yes
Austria No Yes Yes Yes Yes Yes Yes
Bangladesh Yes No No No No No No
Barbados Yes
Belarus No Yes Yes Yes Yes No
Belgium No Yes No No No Yes Yes
Bolivia Yes Yes Yes
Botswana Yes Yes
Brazil Yes No No Yes Yes Yes
Bulgaria No Yes No No Yes No No
Burkina Faso No No No No No No No
Cameroon Yes No No No No No Yes
Canada No Yes Yes No No No Yes
Chile No Yes No No Yes Yes Yes
China Yes Yes Yes Unknown Unknown Unknown Unknown
Colombia Yes No No No Yes Yes Yes
Costa Rica No Yes No No Yes Yes Yes
Côte d’Ivoire Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Czechia No Yes Yes No Yes Unknown Yes
Congo No
Ecuador Yes No No No No No Yes
Egypt Yes Yes
El Salvador Yes Unknown Unknown Unknown Yes Yes Yes
Estonia No Yes No No No No No
Finland No Yes No No No Yes Yes
France No Yes No No Yes Yes No
Georgia Yes
Germany Yes Yes Yes Yes
Ghana Yes No No No No No Yes
Greece Yes Yes No No No No Yes
Guatemala Yes No No No No No No
Hong Kong
(China*)
No Yes Yes No No Yes Yes
Hungary No Yes No No No Yes Yes
Iceland No Yes No No No Yes Yes
India Yes Unknown Yes
Indonesia No Yes Yes Unknown Unknown Yes
Ireland No Yes No No Yes Yes Yes
Israel Yes
Italy No Yes Yes Yes Yes Yes No
Japan No No No No No No Yes
Jordan Yes Unknown No No No Yes Yes
Kazakhstan No Yes No No No Yes No
Kenya Yes Yes Yes
Latvia No Yes No No Yes Yes Yes
Lithuania No Yes No No No Yes Yes
Mali No Yes
Mexico Yes No No No No No
Mongolia Yes Yes No No No Yes Yes
Montenegro No Yes Yes
Namibia Yes Yes Yes
Netherlands No Yes No No No No Yes
New Zealand Yes No No No Yes Yes
Nicaragua Yes Yes
Nigeria No No No No No Yes No
Norway No Yes No No No Yes Yes
Panama No
Paraguay No No No No No No No
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Peru Yes No No No No No Yes
Philippines No No No No Yes Yes
Poland No Yes Yes Yes Unknown Unknown Yes
Portugal No Yes No Yes Yes Yes
Romania Yes No No No Yes Yes No
Russian
Federation
Yes Yes No Yes Yes Yes
Senegal Yes No No No No No Yes
Serbia No Yes No No Yes Yes Yes
Singapore Yes Yes
Slovenia No Yes No No No Yes Yes
South Africa No Yes Yes No No Yes Yes
The Republic
of Korea
No Yes No No No No Yes
Spain No Yes Yes Yes Yes Yes Yes
Sri Lanka No No No No Yes No Yes
Sweden No Yes Yes No Yes Yes Yes
Switzerland No Yes No No Unknown Unknown Yes
Taiwan
(China*)
No Yes No No No No No
Thailand Yes Yes Yes
Togo Yes No No No No Yes
Trinidad and
Tobago
Yes No No No No No No
Tunisia Yes No No No No Yes Yes
Turkey No Yes No No No No No
Uganda No No No No No No
United Arab
Emirates
No Yes Yes No No Yes Yes
UK No Yes No No No Yes Yes
USA No Yes Yes No Yes Yes Yes
Uruguay No Yes No No Yes Yes Yes
Venezuela Yes No No No No No Yes
Viet Nam No Yes No No No No Yes
Zimbabwe No No No No No No No



















Same sex/single parenting policy
Number of embryos for transfer
Cross Border Reproduction
Surrogacy




Chapter 2. Chart 1. % of countries reporting legislation changes since 2016 (more than one topic may have been modified per country).
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The obstetrician/gynecologist practicing ART
For physicians in this category, licensing criteria were in place in
44 of the 89 countries responding (49%). In 35 of the countries
(79.5%), examination or certification was the criterion for
licensing; 28 of the 44 countries (64%) also required continuing
education. The survey did not query respondents about whether
they had separate sub-specialization fellowship programmes for
reproductive medicine specialists. Overlap likely exists between
the categories of obstetrician/gynecologist, with and without
further fellowship qualifications.
The ART laboratory
Of the 89 countries, 52 (58%) reported licensing requirements
specific to the ART laboratory. In all but 2 cases, this was in
addition to the licensing requirements for the whole centre. Of
those 52 countries with ART-specific requirements, 41 (79%)
relied on a certification system; 42 (81%) required an on-site
inspection; and 23 (44%) called for a periodic report. Most
countries indicated they had a combination of such licensing
requirements.
Of the 87 respondents with ongoingmonitoring, 51 (58%) had
ongoing monitoring criteria for the ART labs, and 39 (76%) used
on-site inspection for this process. Others used a combination of
periodic reporting, registry, and re-certification. Twenty-four
respondents (47%) indicated the monitoring was performed by
government employees, 22 (43%) said it was by medical officials,
and 7 (14%) indicated it was by independent agencies. Again,
some respondents used more than one such monitoring method.
Lab director and lab staff
Thirty-three of 88 respondents (37%) reported licensing criteria
for the lab director, and 38 of 85 (45%) did so for the lab staff.
Examination, certification, and continuing education were the
criteria specified in more than 80% of these cases. Twenty-nine
out of 84 (34%) reported using ongoing monitoring for the lab
director; and 31 out of 87 (35%) used it for lab staff, with
mechanisms similar to those of the original licensing criteria.
Penalties for violation of governance, licensure, or
credentialing
Of 86 respondents, 51 (59%) indicated penalties existed for
violations of governance, licensure, or credentialing. Twenty-nine
of 86 respondents (34%) said no penalties were in place; and 6 of
86 (7%) answered “unknown”.
The respondent countries described various types of penalties,
including those listed below:
• admonishment;
• administrative penalties;
• publication of deficiencies;
• reporting to medical board (with possible sanctions);
• suspension of ART license;
• refusal of registration renewal;
• revocation of ART license;
• closure of the ART centre;
• financial penalties (fines);
• criminal charges against the person responsible;
• criminal penalties (including incarceration). The sanctions
used most often were financial penalties, loss of license, and
the possibility of criminal prosecution.
Summary
Eighty-nine country respondents to the 2018 IFFS Surveillance
questionnaire provided data about the regulatory system gov-
erning the practice of ART, using monitoring, governance,
oversight, or penalties. The response from the 89 countries was
greater than the 2016 response of 70 countries, and greater than
the 2013 response of 60 countries. The 2019 survey revealed a
clear trend favoring some form of regulation, indicated by
86.5%. New or expanded areas for ART regulation included
continued attention to anonymous donation, cross-border
reproduction, IVF surrogacy, pre-implantation genetic diagnosis,
experimentation on embryos, micromanipulation, marital status,
and same-sex parenting. Other important topics: more active
regulation of ART centres, professionals, laboratories, and
staff, via extensive licensing and monitoring requirements.
Certification, examination, continuing education, and periodic
reporting featured prominently in the responses.
CHAPTER 3: INSURANCE COVERAGE
Introduction
Eighty-five responding countries submitted data on the extent of
insurance coverage, a 21% increase (70 to 85) over the 2016 IFFS
Surveillance report. The 2018 questions pertaining to insurance
coverage sought information related to changes since the 2016
Chapter 2. Table 2
Main modification to legislation in last 3 years.
Main Modification (In rank order)
% of Countries that Reported Legislation Change Out of 89 Countries (More than One Topic May have been
Modified Per Country)
General changes to legislation and guidelines 29%
Donation 29%
IVF surrogacy 19%
Pre-implantation genetic diagnosis 19%
Experimentation on the embryo 14%




Cross border reproduction 5%
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Chapter 3. Table 1

















Argentina Yes Yes No No Yes No No
Armenia No No No No No No No
Australia Yes Yes Yes Yes
Austria Yes No No No No No Yes
Bangladesh No No No No No No No
Barbados No No No No No No No
Belarus No No No No No
Belgium Yes No No No No No No
Bolivia No No No No No No No
Botswana No No No No No No No
Brazil No No No No No No No
Bulgaria Yes Yes Yes No Yes No No
Burkina Faso No No No No No No No
Cameroon No No No No No No Yes
Canada No Yes No No No No No
Chile Yes No No No No No No
China No No No No No No No
Colombia No No No No No No No
Congo No No No No No No No
Côte d’Ivoire Yes Unknown Unknown Yes Yes Unknown Yes
Czechia Unknown Yes No No No No No
Ecuador No No No No No No No
Egypt No No No No No Yes No
El Salvador No No No No No No No
Finland Yes No No No No No
France Yes No No No No No No
Georgia No No No No No No No
Germany Yes Yes Yes No No No No
Ghana No No No No No No No
Greece No No No No No Yes No
Guatemala No No No No No No No
Hong Kong
(China*)
No No No No Yes No No
Hungary Yes No No No No No Yes
Iceland Yes No No No No No No
India No No No No No No No
Ireland Yes No No No No No No
Israel Yes Yes
Italy Yes Yes Yes Yes Yes Yes No
Jordan No No No No No Yes Yes
Kazakhstan Yes Unknown Unknown Unknown Unknown Unknown Yes
Kenya Yes No No No No No No
Latvia Yes No No No No No No
Lithuania Yes No No No No No Yes
Mali No No No No No No No
Mexico No No No No No No Yes
Mongolia Yes No No No Yes No No
Montenegro Yes
Namibia Unknown Unknown Unknown Unknown Unknown Unknown Yes
Netherlands Yes No No No No No No
New Zealand No No No No Yes No No
Nicaragua No No No No No No No
Nigeria No No No No No No No
Norway Yes No No No No No
Panama No No No No No No No
Paraguay No No No No No No No
Peru No No No No No No No
Philippines No No No No No No No
Poland No Yes Yes No Unknown Unknown Unknown
Portugal Yes No No No Yes No Yes
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report, availability of funding for infertility treatments, existence
of regulation governing the reimbursement of ART, extent of
coverage and services covered by insurance, mode of reimburse-
ment, and specifics related to demographics and good clinical
practice.
Analysis of the survey
In 2018, 85 countries responded to a question about whether
either insurance coverage or government funding was available
for infertility treatment. Forty countries (47%) reportedly did
provide such funding, compared to 37 in 2015. Moreover, 45 of
the 85 countries responding (53%) did not offer any type of
financial support. For the 2012 and 2015 questionnaires, the
figures were 40% providing some funding, and 36% not offering
any financial support.
Regarding other changes since previous reporting, Japan and
the United Kingdom of Great Britain and Northern Ireland noted
decreased financial support for ART, 16 countries reported
expanded financial support, and 42 countries indicated no
changes from three years ago. Notably, in Africa, Cameroon, and
Senegal are progressing ART legislation, Burkina Faso is
beginning to fund insurance and, in Asia, India has introduced
restrictions for international patients seeking surrogacy access.
In Europe, Montenegro offered coverage for 3 full, fresh cycles
of IVF; and in Slovenia, ART coverage spans 6 cycles for 1 live
birth, and 4 for the next live birth, provided that single ET is used.
The United States of America has seen an increase in access for
small, selected populations, and increased coverage by some large
employers.
Where ART reimbursement is in place, some countries regulate
associated finances, as follows: at the national or federal level, 36
of 85 countries (42%); regional, 16 of 83 countries (19%);
municipal, 5 of 81 countries (6%); and by religious decree, 2 of 79
countries (3%). Other countries regulate reimbursement through
dedicated agencies, 11 of 82 countries (13%), or professional
organizations, 14 of 79 countries (18%) (Table 1).
The extent of coverage for ART services varies with location.
For this report, coverage was divided as complete coverage and
partial reimbursement. When reimbursement or coverage was at
a national level, 15 of 38 countries (39%) offered complete
coverage, and 23 of 38 countries (61%) offered partial reim-
bursement. Where a regional plan was in place, 3 of the 15
countries responding (20%) offered complete coverage, and 12
(80%) offered partial coverage. Of note, private insurance offers


















Romania Yes No No No No No No
Russian
Federation
Yes Yes No No No No No
Senegal No No No No No No No
Serbia Yes No Yes No No No Yes
Singapore Yes
Slovenia Yes Yes No No No No Yes
South Africa Yes No No No No No No
The Republic
of Korea
No No No No No No No
Spain Yes Yes No No Yes No
Sri Lanka No No No No No No No
Sweden No No No No No No Yes
Switzerland No No No No No No No
Taiwan
(China*)
No Unknown No No No No No
Thailand No No No No No No No
Togo No No No No No No No
Trinidad and
Tobago
No No No No No No No
Tunisia Yes Yes No No No No No
Turkey Yes No No No No No No
Uganda No No No No No No No
United Arab
Emirates
Yes Yes Unknown Unknown Unknown Unknown Unknown
UK No Yes No No No No No
USA Yes Yes No No Yes No No
Uruguay Yes No No No Yes No No
Venezuela No No No No No No No
Viet Nam No No No No No No No
Zimbabwe No No No No No No No
*Reporting separately for this report.
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Chapter 3. Table 2
What is the coverage or reimbursement of ART services by health plans?
Country National Health Plan
State/Provincial/Regional




Argentina Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement No Coverage or Reimbursement
Australia Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Austria Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Bangladesh No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Barbados No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Belarus No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Belgium Partial Coverage or Reimbursement No Coverage or Reimbursement Unknown Unknown
Bolivia Partial Coverage or Reimbursement
Brazil No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Bulgaria Complete Coverage or Reimbursement Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Burkina Faso Unknown Unknown Unknown No Coverage or Reimbursement
Cameroon No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Canada Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Chile Complete Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
China Unknown Unknown Unknown Unknown
Colombia No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Czechia Complete Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Congo Unknown Unknown Unknown Unknown
Ecuador No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Finland Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
France Complete Coverage or Reimbursement
Georgia No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Germany Partial Coverage or Reimbursement Partial Coverage or Reimbursement Complete Coverage or Reimbursement Complete Coverage or Reimbursement




Partial Coverage or Reimbursement Partial Coverage or Reimbursement Unknown Unknown
Hungary Complete Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Iceland Partial Coverage or Reimbursement
India No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Ireland Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Israel Complete Coverage or Reimbursement Partial Coverage or Reimbursement
Italy No Coverage or Reimbursement Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Côte d’Ivoire Unknown Unknown Unknown Unknown
Japan Partial Coverage or Reimbursement Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Jordan No Coverage or Reimbursement Unknown Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Kazakhstan Partial Coverage or Reimbursement Unknown Unknown Unknown
Kenya Partial Coverage or Reimbursement Unknown Partial Coverage or Reimbursement Unknown
Latvia Complete Coverage or Reimbursement No Coverage or Reimbursement Unknown No Coverage or Reimbursement
Lithuania Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Mali Unknown Unknown Unknown Unknown
Mexico No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Mongolia No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Montenegro Complete Coverage or Reimbursement
Namibia No Coverage or Reimbursement No Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Netherlands Complete Coverage or Reimbursement Complete Coverage or Reimbursement
New Zealand Partial Coverage or Reimbursement No Coverage or Reimbursement
Nicaragua No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Nigeria No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Norway Partial Coverage or Reimbursement
Panama No Coverage or Reimbursement No Coverage or Reimbursement Partial Coverage or Reimbursement No Coverage or Reimbursement
Paraguay No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Peru No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Philippines Unknown Unknown No Coverage or Reimbursement Unknown
Poland No Coverage or Reimbursement Partial Coverage or Reimbursement Unknown No Coverage or Reimbursement
Portugal Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Romania No Coverage or Reimbursement No Coverage or Reimbursement Partial Coverage or Reimbursement
Russian
Federation
Complete Coverage or Reimbursement Complete Coverage or Reimbursement Unknown No Coverage or Reimbursement
Senegal No Coverage or Reimbursement No Coverage or Reimbursement Complete Coverage or Reimbursement No Coverage or Reimbursement
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Chapter 3. Table 2
(Continued)
Country National Health Plan
State/Provincial/Regional




Serbia Complete Coverage or Reimbursement Unknown Complete Coverage or Reimbursement Unknown
Singapore Partial Coverage or Reimbursement
Slovenia Complete Coverage or Reimbursement
South Africa No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
The Republic
of Korea
Partial Coverage or Reimbursement
Spain Complete Coverage or Reimbursement Complete Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Sri Lanka No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Sweden Complete Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Taiwan
(China*)
No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Thailand No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Togo No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Tunisia Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Turkey Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Uganda Unknown Unknown Unknown Unknown
UAE Complete Coverage or Reimbursement Complete Coverage or Reimbursement Complete Coverage or Reimbursement Unknown
UK Partial Coverage or Reimbursement Partial Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
USA No Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Uruguay Partial Coverage or Reimbursement no Coverage or Reimbursement Partial Coverage or Reimbursement Partial Coverage or Reimbursement
Venezuela No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
Viet Nam Unknown Unknown Unknown Partial Coverage or Reimbursement
Zimbabwe No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement No Coverage or Reimbursement
*Reporting separately for this report.
Chapter 3. Table 3a
If there are programs for coverage or reimbursement of ART services, which of the following do they include?
Country Diagnostic Evaluation Fertility Medications Intrauterine Insemination















Austria No coverage National health plan No coverage
Bangladesh No coverage No coverage No coverage
Barbados No coverage No coverage No coverage
Belarus National health plan
State/Provincial/Regional health plan
Private insurance
No coverage No coverage
Belgium National health plan National health plan National health plan
Bolivia No coverage No coverage No coverage
Botswana No coverage No coverage No coverage
Brazil Private insurance No coverage No coverage
Bulgaria No coverage National health plan
State/Provincial/Regional health plan
State/Provincial/Regional health plan
Burkina Faso Private insurance No coverage No coverage
Cameroon Private insurance No coverage No coverage
Canada National health plan Private insurance National health plan





China No coverage No coverage
Colombia No coverage No coverage No coverage
Congo No coverage No coverage No coverage
Côte d’Ivoire Private insurance Unknown Unknown
Czechia National health plan National health plan National health plan
Ecuador Private insurance
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Chapter 3. Table 3a
(Continued)
Country Diagnostic Evaluation Fertility Medications Intrauterine Insemination
El Salvador No coverage No coverage No coverage
Finland National health plan National health plan National health plan
France National health plan National health plan National health plan
Georgia No coverage No coverage No coverage





Ghana No coverage No coverage No coverage
Greece No coverage No coverage No coverage
Guatemala Private insurance No coverage No coverage









Hungary National health plan National health plan National health plan
Iceland National health plan No coverage
India No coverage No coverage No coverage
Ireland Private insurance National health plan Private insurance
Israel National health plan National health plan National health plan
Italy State/Provincial/Regional health plan National health plan
Jordan No coverage No coverage No coverage
Kazakhstan No coverage National health plan No coverage





Latvia National health plan National health plan National health plan
Lithuania National health plan National health plan No coverage





Mexico No coverage No coverage No coverage
Mongolia No coverage No coverage No coverage
Montenegro National health plan National health plan No coverage
Namibia State/Provincial/Regional health plan
Private insurance
No coverage No coverage






New Zealand National health plan National health plan National health plan
Nicaragua No coverage No coverage No coverage
Nigeria No coverage No coverage No coverage
Norway National health plan National health plan National health plan
Panama No coverage No coverage National health plan
Paraguay Private insurance No coverage No coverage
Peru No coverage No coverage No coverage
Philippines No coverage No coverage No coverage
Poland No coverage No coverage No coverage
Portugal National health plan
Private insurance
National health plan National health plan
Romania National health plan National health plan No coverage











Serbia National health plan National health plan National health plan
Singapore No coverage No coverage National health plan
Slovenia National health plan National health plan National health plan
South Africa State/Provincial/Regional health plan
Private insurance
No coverage No coverage
The Republic of Korea National health plan National health plan National health plan
Spain National health plan
Private insurance
National health plan National health plan
State/Provincial/Regional health plan
Private insurance
Sri Lanka No coverage No coverage No coverage
Sweden National health plan National health plan National health plan
Switzerland Private insurance Private insurance Private insurance
Taiwan (China*) National health plan No coverage No coverage
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Chapter 3. Table 3a
(Continued)
Country Diagnostic Evaluation Fertility Medications Intrauterine Insemination
Thailand No coverage No coverage No coverage
Togo No coverage No coverage No coverage
Trinidad and Tobago No coverage No coverage No coverage





Turkey National health plan National health plan National health plan
Uganda Unknown Unknown Unknown
UAE Private insurance Private insurance Private insurance
UK State/Provincial/Regional health plan State/Provincial/Regional health plan State/Provincial/Regional health plan







Uruguay National health plan National health plan Private insurance
Venezuela No coverage No coverage No coverage
Viet Nam No coverage No coverage No coverage
Zimbabwe Private insurance Private insurance Private insurance
*Reporting separately for this report.
Chapter 3. Table 3b
If there are programs for coverage or reimbursement of ART services, which of the following do they include?
Country IVF ICSI Assisted Hatching














Austria National health plan National health plan No coverage
Bangladesh No coverage No coverage No coverage
Barbados No coverage No coverage No coverage
Belarus No coverage No coverage No coverage
Belgium National health plan Unknown
Bolivia Private insurance Private insurance No coverage
Botswana No coverage No coverage No coverage
Brazil National health plan No coverage No coverage





Burkina Faso No coverage No coverage No coverage
Cameroon No coverage No coverage No coverage
Canada National health plan National health plan National health plan
Chile National health plan National health plan No coverage
China No coverage No coverage No coverage
Colombia No coverage No coverage No coverage
Czechia National health plan No coverage No coverage
Congo No coverage No coverage No coverage
El Salvador No coverage No coverage No coverage
Finland National health plan National health plan No coverage
France National health plan National health plan No coverage
Georgia No coverage No coverage No coverage





Ghana No coverage No coverage No coverage
Greece No coverage No coverage No coverage
Guatemala No coverage No coverage No coverage





Hungary National health plan National health plan National health plan
Iceland National health plan National health plan No coverage
India No coverage No coverage No coverage
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Chapter 3. Table 3b
(Continued)
Country IVF ICSI Assisted Hatching
Ireland Private insurance Private insurance Private insurance
Israel National health plan National health plan National health plan
Italy State/Provincial/Regional health plan State/Provincial/Regional health plan No coverage
Côte d’Ivoire Unknown Unknown Unknown
Jordan No coverage No coverage No coverage
Kazakhstan National health plan National health plan





Latvia National health plan National health plan No coverage
Lithuania National health plan National health plan No coverage
Mali No coverage No coverage No coverage
Mexico No coverage No coverage No coverage
Mongolia No coverage No coverage No coverage
Montenegro National health plan National health plan No coverage
Namibia No coverage No coverage No coverage





New Zealand National health plan National health plan No coverage
Nicaragua No coverage No coverage No coverage
Nigeria No coverage No coverage No coverage
Norway National health plan National health plan No coverage
Panama No coverage No coverage No coverage
Paraguay No coverage No coverage
Peru No coverage No coverage No coverage
Philippines No coverage No coverage No coverage
Poland No coverage No coverage No coverage
Portugal National health plan National health plan National health plan
Romania National health plan National health plan National health plan






Senegal Private insurance, No coverage Private insurance, No coverage Unknown
Serbia National health plan No coverage National health plan
Singapore National health plan National health plan National health plan
Slovenia National health plan National health plan
South Africa No coverage No coverage No coverage
The Republic of Korea National health plan National health plan National health plan








Sri Lanka No coverage No coverage No coverage
Sweden National health plan No coverage
Switzerland No coverage No coverage No coverage
Taiwan (China*) No coverage No coverage No coverage
Thailand No coverage No coverage No coverage
Togo No coverage No coverage No coverage
Trinidad and Tobago No coverage No coverage No coverage






Turkey National health plan National health plan National health plan
Uganda Unknown Unknown Unknown
UAE Private insurance Private insurance Private insurance
UK State/Provincial/Regional health plan State/Provincial/Regional health plan No coverage
USA State/Provincial/Regional health plan
Private insurance
State/Provincial/Regional health plan Private insurance State/Provincial/Regional health plan
Private insurance
Uruguay National health plan National health plan National health plan
Venezuela No coverage No coverage No coverage
Viet Nam No coverage No coverage No coverage
Zimbabwe No coverage No coverage No coverage
*Reporting separately for this report.
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full coverage in 5 of the 19 countries (26%) and partial coverage
in 15 of the 19 (74%) (Table 2). Tables 3a–h lists full details of
services covered at these multiple levels. Additional information
regarding coverage is presented in Chart 1.
The report also probed to determine which specific fertility
procedures and therapies are reimbursed, such as diagnostic
evaluation; fertility medications; intrauterine insemination (IUI);
in vitro fertilization (IVF); intracytoplasmic sperm injection
(ICSI); assisted hatching; use of donor sperm, eggs or embryos;
use of surrogacy; and use of fertility preservation (sperm, oocytes,
embryos, tissue) for medical (“social”) and non-medical indica-
tions (Charts 3–5).
Additional data accrued addressed coverage for cryopre-
servation of oocytes or embryos for ART cycles, in which
Chapter 3. Table 3c
If there are programs for coverage or reimbursement of ART




Oocytes from an IVF Cycle
Cryopreservation of
Supernumerary Embryos
from an IVF Cycle








Australia No coverage No coverage
Austria No coverage No coverage
Bangladesh No coverage No coverage
Barbados No coverage No coverage
Belarus No coverage No coverage
Belgium National health plan National health plan
Bolivia No coverage
Botswana No coverage No coverage
Brazil No coverage No coverage
Bulgaria No coverage National health plan
State/Provincial/Regional
health plan
Burkina Faso No coverage No coverage
Cameroon No coverage No coverage
Canada National health plan National health plan
Chile No coverage No coverage
China No coverage No coverage
Colombia No coverage No coverage
Congo No coverage No coverage
Côte d’Ivoire Unknown Unknown
Czechia No coverage No coverage
El Salvador No coverage No coverage
Finland No coverage National health plan
France National health plan National health plan
Georgia No coverage No coverage
Germany No coverage No coverage
Ghana No coverage No coverage
Greece No coverage No coverage
Guatemala No coverage No coverage
Hong Kong (China*) No coverage No coverage
Hungary National health plan National health plan
Iceland No coverage National health plan
India No coverage No coverage
Ireland Private insurance Private insurance
Israel National health plan National health plan
Italy No coverage No coverage
Jordan No coverage National health plan
Kazakhstan No coverage No coverage
Kenya Unknown Unknown
Latvia No coverage National health plan
Lithuania No coverage No coverage
Mali No coverage No coverage
Mexico No coverage No coverage
Mongolia No coverage No coverage
Montenegro No coverage No coverage
Namibia No coverage No coverage




New Zealand National health plan National health plan
Nicaragua No coverage No coverage
Nigeria No coverage No coverage
Norway National health plan National health plan
Panama No coverage No coverage
Paraguay No coverage No coverage
Peru No coverage No coverage





Oocytes from an IVF Cycle
Cryopreservation of
Supernumerary Embryos
from an IVF Cycle
Philippines No coverage No coverage
Poland No coverage No coverage
Portugal National health plan National health plan
Romania No coverage No coverage











Singapore National health plan National health plan
Slovenia National health plan National health plan
South Africa No coverage No coverage
The Republic of Korea National health plan National health plan








Sri Lanka No coverage No coverage
Sweden National health plan National health plan
Switzerland No coverage No coverage
Taiwan (China*) No coverage No coverage
Thailand No coverage No coverage
Togo No coverage No coverage
Trinidad and Tobago No coverage No coverage
Tunisia No coverage No coverage
Turkey No coverage National health plan
Uganda Unknown Unknown
United Arab Emirates Private insurance Private insurance









Uruguay No coverage National health plan
Venezuela No coverage No coverage
Viet Nam No coverage No coverage
Zimbabwe No coverage No coverage
*Reporting separately for this report.
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embryos are screened for chromosome abnormalities and genetic
diseases. These procedures include preimplantation genetic
screening (PGS), preimplantation genetic diagnosis (PGD), com-
prehensive chromosome screening (CCS), preimplantation
genetic testing (PGT), and the PGT subtypes, PGT-Mand PGT-A.
(PGT-M refers to monogenic/single-gene disorders; the A in PGT-
A is for aneuploidy, indicating an abnormal number of chro-
mosomes.) The two tests offer at-risk patients an opportunity to
select embryos that carry a reduced risk of birth defects.
Tables 4a–d present details of insurance coverage for fertility
treatments. Of 83 responses, only 37 countries (45%) provide
reimbursement for IVF/ICSI. The patient’s demographic back-
ground affects the extent of ART support. As for infertility status
(primary, secondary, or family-building), many countries set
specific limits for ART funding (Table 5, Chart 2). Of 79 coun-
tries responding, 28 (35%) cover patients with primary infertility,
while 23 of 77 countries queried (30%) cover secondary inferti-
lity. Of 75 countries responding to a query about family-building
coverage, 25 (33%) say that they offer it.
Female age is also a determinant factor for reimbursement in
40 countries, with 31 respondents (78%) providing data. The
lowest age limit for coverage, 38 years, was cited for Latvia and
Lithuania; the highest was age 50, in Australia. Only two coun-
tries impose an age limit for males: Austria and Germany, both
50 years. Coverage also is influenced by duration of infertility.
According to 5 responses from 40 countries reporting (12.5%),
minimum duration varies widely, from 1 year in The United
Chapter 3. Table 3d
If there are programs for coverage or reimbursement of ART
services, which of the following do they include?
Country PGT-M PGT-A
Argentina No coverage No coverage
Australia No coverage No coverage
Austria No coverage No coverage
Bangladesh No coverage No coverage
Barbados No coverage No coverage
Belarus No coverage No coverage
Belgium Unknown Unknown
Bolivia No coverage No coverage
Botswana No coverage No coverage
Brazil No coverage No coverage
Bulgaria No coverage No coverage
Burkina Faso No coverage No coverage
Cameroon No coverage No coverage
Canada No coverage No coverage
Chile No coverage No coverage
China No coverage No coverage
Colombia No coverage No coverage
Czechia National health plan National health plan
Congo No coverage No coverage
El Salvador No coverage No coverage
Finland No coverage No coverage
France No coverage No coverage
Georgia No coverage No coverage
Germany No coverage No coverage
Ghana No coverage No coverage
Greece No coverage No coverage
Guatemala No coverage No coverage
Hong Kong (China*) No coverage No coverage
Hungary No coverage No coverage
Iceland Unknown Unknown
India No coverage No coverage
Ireland Unknown Unknown
Israel National health plan Private insurance
Italy No coverage No coverage
Côte d’Ivoire No coverage No coverage
Jordan No coverage No coverage
Kazakhstan No coverage
Kenya Unknown Unknown
Latvia No coverage No coverage
Lithuania National health plan No coverage
Mali No coverage No coverage
Mexico No coverage No coverage
Mongolia No coverage No coverage
Montenegro No coverage No coverage
Namibia No coverage No coverage
Netherlands National health plan
Private insurance
New Zealand National health plan No coverage
Nicaragua No coverage No coverage
Nigeria No coverage No coverage
Norway National health plan No coverage
Panama No coverage No coverage
Paraguay No coverage No coverage
Peru No coverage No coverage
Philippines No coverage No coverage
Poland No coverage No coverage
Portugal National health plan National health plan
Romania No coverage No coverage
Russian Federation No coverage No coverage
Senegal Unknown Unknown
Serbia National health plan No coverage
Chapter 3. Table 3d
(Continued)
Country PGT-M PGT-A
Singapore National health plan National health plan
Slovenia National health plan No coverage
South Africa No coverage No coverage
The Republic of Korea No coverage No coverage





Sri Lanka No coverage No coverage
Sweden National health plan No coverage
Switzerland No coverage No coverage
Taiwan (China*) No coverage No coverage
Thailand No coverage No coverage
Togo No coverage No coverage
Trinidad and Tobago No coverage No coverage
Tunisia No coverage No coverage
Turkey National health plan No coverage
Uganda Unknown Unknown










Uruguay No coverage No coverage
Venezuela No coverage No coverage
Viet Nam No coverage No coverage
Zimbabwe No coverage No coverage
*Reporting separately for this report.
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States of America and United Kingdom of Great Britain and
Northern Ireland, to 2 years in Romania and 3 in Turkey
(Chart 6).
In 40 reporting countries, 3 replies (8%) indicate that reim-
bursement for ART is contingent upon personal income: Japan,
The Republic of Korea and the United Arab Emirates. The 2015
survey listed only 3 of 35 responding countries (9%) with this
contingency: Canada, Italy, and The Republic of Korea.
In 40 reporting countries, 9 replies (22.5%) indicate that
reimbursement for ART is contingent upon the number of
embryos transferred. The 9 countries are Australia, Belgium,
Canada, Czechia, Iceland, Israel, Netherlands, Turkey and The
United States of America. The 2015 survey listed only 7 of 38
responding countries (18%) with this contingency: Belgium,
Canada, Czechia, Israel, Netherlands, Turkey and The United
States of America.
Chapter 3. Table 3e
If there are programs for coverage or reimbursement of ART
services, which of the following do they include?



















Austria No coverage No coverage No coverage
Bangladesh No coverage No coverage No coverage
Barbados No coverage No coverage No coverage
Belarus No coverage No coverage No coverage
Belgium Unknown Unknown Unknown
Bolivia No coverage No coverage No coverage
Botswana No coverage No coverage No coverage
Brazil No coverage No coverage No coverage






Burkina Faso No coverage No coverage No coverage
Cameroon No coverage No coverage
Canada No coverage No coverage No coverage
Chile No coverage No coverage No coverage
China No coverage No coverage No coverage
Colombia No coverage No coverage No coverage
Congo No coverage No coverage No coverage
Côte d’Ivoire No coverage No coverage No coverage
Czechia No coverage No coverage No coverage
El Salvador No coverage No coverage No coverage
Finland No coverage No coverage No coverage
France National health plan National health plan National health plan
Georgia No coverage No coverage No coverage
Germany No coverage No coverage No coverage
Ghana No coverage No coverage No coverage
Greece No coverage No coverage No coverage
Guatemala No coverage No coverage No coverage
Hong Kong
(China*)
No coverage No coverage No coverage
Hungary National health plan National health plan National health plan
Iceland No coverage No coverage National health plan
India No coverage No coverage No coverage
Ireland Private insurance
No coverage
No coverage No coverage
Israel No coverage Private insurance No coverage
Italy No coverage No coverage
Jordan No coverage No coverage No coverage
Kazakhstan No coverage No coverage No coverage
Kenya No coverage No coverage No coverage
Latvia No coverage No coverage No coverage
Lithuania No coverage No coverage No coverage
Mali No coverage No coverage No coverage
Mexico No coverage No coverage No coverage
Mongolia No coverage No coverage No coverage
Montenegro No coverage No coverage No coverage
Namibia No coverage No coverage No coverage
Netherlands No coverage Private insurance National health plan
Private insurance
New Zealand National health plan National health plan National health plan
Nicaragua No coverage No coverage No coverage
Nigeria No coverage No coverage No coverage
Norway National health plan No coverage No coverage
Panama No coverage No coverage No coverage
Paraguay No coverage No coverage No coverage
Chapter 3. Table 3e
(Continued)
Country Donor Sperm Donor Egg Donor Embryos
Peru No coverage No coverage
Philippines No coverage No coverage
Poland No coverage No coverage No coverage
Portugal National health plan National health plan National health plan
Romania No coverage No coverage No coverage
Russian
Federation
No coverage No coverage No coverage
Senegal Unknown Unknown Unknown
Serbia No coverage No coverage No coverage
Singapore No coverage National health plan National health plan
Slovenia National health plan National health plan No coverage
South Africa No coverage No coverage No coverage
The Republic of
Korea
No coverage No coverage No coverage











Sri Lanka No coverage No coverage No coverage
Sweden National health plan National health plan National health plan
Switzerland No coverage No coverage No coverage
Taiwan (China*) No coverage No coverage No coverage
Thailand No coverage No coverage No coverage
Togo No coverage No coverage No coverage
Trinidad and
Tobago
No coverage No coverage No coverage
Tunisia No coverage No coverage No coverage
Turkey No coverage No coverage No coverage
Uganda Unknown Unknown Unknown
United Arab
Emirates










USA No coverage No coverage No coverage
Uruguay National health plan National health plan National health plan
Venezuela No coverage No coverage No coverage
Viet Nam No coverage No coverage No coverage
Zimbabwe No coverage No coverage No coverage
*Reporting separately for this report.
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29 Global Reproductive Health
22
Regarding a limit on the number of cycles covered by insur-
ance, out of 39 countries surveyed, 36 (92%) responded.
Australia, Israel, and the Russian Federation do not limit the
number of cycles for reimbursement. Canada, Chile, Kenya, New
Zealand, Romania, Senegal, Tunisia, and United Arab Emirates
Chapter 3. Table 3f
If there are programs for coverage or reimbursement




















Argentina No coverage No coverage No coverage No coverage
Australia No coverage No coverage No coverage No coverage
Austria No coverage No coverage No coverage No coverage
Bangladesh No coverage No coverage No coverage No coverage
Belarus No coverage No coverage No coverage No coverage
Belgium Unknown Unknown Unknown Unknown
Bolivia No coverage No coverage No coverage No coverage
Botswana No coverage No coverage No coverage No coverage
Brazil No coverage No coverage No coverage No coverage
Bulgaria No coverage No coverage No coverage No coverage
Burkina Faso No coverage No coverage No coverage No coverage
Cameroon No coverage No coverage No coverage Private
insurance
Canada Unknown Unknown Unknown Unknown
Chile No coverage No coverage No coverage No coverage
China No coverage No coverage No coverage No coverage
Colombia No coverage No coverage No coverage No coverage
Congo No coverage No coverage No coverage No coverage
Côte d’Ivoire No coverage No coverage No coverage No coverage
Czechia No coverage No coverage No coverage No coverage
El Salvador No coverage No coverage No coverage No coverage
Finland No coverage No coverage No coverage No coverage
France No coverage No coverage No coverage No coverage
Georgia No coverage No coverage No coverage No coverage
Germany No coverage No coverage No coverage No coverage
Ghana No coverage No coverage No coverage No coverage
Greece No coverage No coverage No coverage No coverage
Guatemala No coverage No coverage No coverage No coverage
Hong Kong
(China*)
No coverage No coverage No coverage No coverage
Hungary No coverage National
health plan
No coverage No coverage
Iceland No coverage No coverage No coverage No coverage
India No coverage No coverage No coverage No coverage
Ireland No coverage No coverage No coverage No coverage
Israel No coverage No coverage No coverage No coverage
Italy No coverage No coverage No coverage No coverage
Jordan No coverage No coverage No coverage National health
plan
No coverage
Kazakhstan No coverage No coverage No coverage No coverage
Kenya No coverage No coverage No coverage No coverage
Latvia No coverage No coverage No coverage No coverage
Lithuania No coverage No coverage No coverage No coverage
Mali No coverage No coverage No coverage No coverage
Mexico No coverage No coverage No coverage No coverage
Mongolia No coverage No coverage No coverage No coverage
Montenegro No coverage No coverage No coverage No coverage
Namibia No coverage No coverage No coverage No coverage













Nicaragua No coverage No coverage No coverage No coverage
Nigeria No coverage No coverage No coverage No coverage
Norway No coverage No coverage No coverage





















Panama No coverage No coverage No coverage No coverage
Paraguay No coverage No coverage No coverage
Peru No coverage No coverage No coverage No coverage
Philippines No coverage No coverage No coverage No coverage













Romania No coverage No coverage No coverage No coverage
Russian
Federation








Serbia No coverage No coverage No coverage No coverage
Singapore No coverage No coverage No coverage No coverage
Slovenia No coverage No coverage No coverage
South Africa No coverage No coverage No coverage No coverage
The Republic
of Korea
No coverage No coverage No coverage No coverage
Spain No coverage No coverage No coverage No coverage
Sri Lanka No coverage No coverage No coverage
Sweden No coverage No coverage No coverage No coverage
Switzerland No coverage No coverage No coverage No coverage
Taiwan
(China*)
No coverage No coverage No coverage No coverage
Thailand No coverage No coverage No coverage No coverage
Togo No coverage No coverage No coverage No coverage
Trinidad and
Tobago





















Turkey No coverage No coverage No coverage No coverage
Uganda Unknown Unknown Unknown Unknown
United Arab
Emirates
No coverage No coverage No coverage No coverage
UK No coverage No coverage No coverage No coverage











Venezuela No coverage No coverage No coverage No coverage
Viet Nam No coverage No coverage No coverage No coverage
Zimbabwe No coverage No coverage No coverage No coverage
*Reporting separately for this report.
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Chapter 3. Table 3g
If there are programs for coverage or reimbursement of ART services, which of the following do they include?
Cryopreservation for Fertility Preservation for Medical Indications
Country Oocytes Sperm Embryos Testicular Tissue Ovarian Tissue




















Austria No coverage No coverage No coverage No coverage No coverage
Bangladesh No coverage No coverage No coverage No coverage No coverage
Barbados No coverage No coverage No coverage No coverage No coverage
Belarus No coverage No coverage No coverage No coverage No coverage
Belgium Unknown Unknown Unknown Unknown Unknown
Bolivia No coverage No coverage No coverage No coverage No coverage
Botswana No coverage No coverage No coverage No coverage No coverage
Brazil No coverage No coverage No coverage No coverage No coverage
Bulgaria National health plan No coverage No coverage No coverage No coverage
Burkina Faso No coverage No coverage No coverage No coverage No coverage
Cameroon No coverage No coverage No coverage No coverage No coverage
Canada National health plan National health plan National health plan National health plan Unknown
Chile No coverage No coverage No coverage No coverage No coverage
China No coverage No coverage No coverage No coverage No coverage
Colombia No coverage No coverage No coverage No coverage No coverage
Congo No coverage No coverage No coverage No coverage No coverage
Côte d’Ivoire No coverage No coverage No coverage No coverage No coverage
Czechia No coverage National health plan No coverage No coverage No coverage
El Salvador No coverage No coverage No coverage No coverage No coverage
Finland National health plan National health plan National health plan National health plan National health plan
France National health plan National health plan National health plan National health plan National health plan
Georgia No coverage No coverage No coverage No coverage No coverage
Germany No coverage No coverage No coverage No coverage No coverage
Ghana No coverage No coverage No coverage No coverage No coverage
Greece No coverage No coverage No coverage No coverage No coverage
Guatemala No coverage No coverage No coverage No coverage No coverage
Hong Kong (China*) No coverage No coverage No coverage No coverage No coverage
Hungary No coverage No coverage No coverage No coverage No coverage
Iceland No coverage No coverage National health plan No coverage No coverage
India No coverage No coverage No coverage No coverage No coverage
Ireland Private insurance Private insurance National health plan
Private insurance
No coverage No coverage





No coverage No coverage State/Provincial/Regional
health plan
Jordan No coverage No coverage No coverage No coverage
Kazakhstan No coverage No coverage No coverage No coverage No coverage
Kenya No coverage No coverage No coverage No coverage No coverage
Latvia No coverage No coverage No coverage No coverage No coverage
Lithuania No coverage No coverage No coverage No coverage No coverage
Mali No coverage No coverage No coverage No coverage No coverage
Mexico No coverage No coverage No coverage No coverage No coverage
Mongolia No coverage No coverage No coverage No coverage No coverage
Montenegro No coverage No coverage No coverage No coverage No coverage
Namibia No coverage No coverage No coverage No coverage No coverage






No coverage No coverage
New Zealand National health plan National health plan National health plan National health plan No coverage
Nicaragua No coverage No coverage No coverage No coverage No coverage
Nigeria No coverage No coverage No coverage No coverage No coverage
Norway National health plan National health plan National health plan Unknown National health plan
Panama No coverage No coverage No coverage No coverage No coverage
Paraguay No coverage No coverage No coverage No coverage No coverage
Peru No coverage No coverage No coverage No coverage No coverage
Philippines No coverage No coverage No coverage No coverage No coverage
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Chapter 3. Table 3g
(Continued)
Cryopreservation for Fertility Preservation for Medical Indications
Country Oocytes Sperm Embryos Testicular Tissue Ovarian Tissue
Poland No coverage No coverage No coverage No coverage No coverage
Portugal National health plan National health plan National health plan National health plan National health plan
Romania No coverage No coverage No coverage No coverage No coverage
Russian Federation No coverage No coverage No coverage No coverage No coverage







Serbia No coverage No coverage No coverage No coverage No coverage
Singapore No coverage No coverage National health plan No coverage No coverage
Slovenia National health plan National health plan National health plan National health plan National health plan
South Africa No coverage No coverage No coverage No coverage No coverage
The Republic of
Korea
No coverage No coverage No coverage No coverage No coverage




















Sri Lanka No coverage No coverage No coverage No coverage No coverage
Sweden National health plan National health plan National health plan National health plan National health plan
Switzerland No coverage No coverage No coverage No coverage No coverage
Taiwan (China*) No coverage No coverage No coverage No coverage No coverage
Thailand No coverage No coverage No coverage No coverage No coverage
Togo No coverage No coverage No coverage No coverage No coverage
Trinidad and
Tobago
No coverage No coverage No coverage No coverage No coverage
Tunisia No coverage No coverage No coverage No coverage No coverage
Turkey National health plan National health plan National health plan National health plan National health plan
Uganda Unknown Unknown Unknown Unknown Unknown







No coverage No coverage
USA Private insurance Private insurance Private insurance Private insurance Private insurance
Uruguay No coverage No coverage National health plan National health plan No coverage
Venezuela No coverage No coverage No coverage No coverage No coverage
Viet Nam No coverage No coverage No coverage No coverage No coverage
Zimbabwe No coverage No coverage No coverage No coverage No coverage
*Reporting separately for this report.
Chapter 3. Table 3h
If there are programs for coverage or reimbursement of ART services, which of the following do they include?
Cryopreservation for Fertility Preservation for Nonmedical Indications
Country Oocytes Sperm Embryos Testicular Tissue Ovarian Tissue
Argentina No coverage No coverage No coverage No coverage No coverage
Australia No coverage No coverage No coverage No coverage No coverage
Austria No coverage No coverage No coverage No coverage No coverage
Bangladesh No coverage No coverage No coverage No coverage No coverage
Barbados No coverage No coverage No coverage No coverage No coverage
Belarus No coverage No coverage No coverage No coverage No coverage
Belgium Unknown Unknown Unknown Unknown Unknown
Bolivia No coverage No coverage No coverage No coverage No coverage
Botswana No coverage No coverage No coverage No coverage No coverage
Brazil No coverage No coverage No coverage No coverage No coverage
Bulgaria No coverage No coverage No coverage No coverage No coverage
Burkina Faso No coverage No coverage No coverage No coverage No coverage
Cameroon No coverage No coverage No coverage No coverage No coverage
Canada Private insurance Private insurance Private insurance Private insurance Unknown
Chile No coverage No coverage No coverage No coverage No coverage
China No coverage No coverage No coverage No coverage No coverage
Colombia No coverage No coverage No coverage No coverage No coverage
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Chapter 3. Table 3h
(Continued)
Cryopreservation for Fertility Preservation for Nonmedical Indications
Country Oocytes Sperm Embryos Testicular Tissue Ovarian Tissue
Congo No coverage No coverage No coverage No coverage No coverage
Côte d’Ivoire No coverage No coverage No coverage No coverage No coverage
Czechia No coverage No coverage No coverage No coverage No coverage
El Salvador No coverage No coverage No coverage No coverage No coverage
Finland No coverage No coverage No coverage No coverage No coverage
France No coverage National health plan No coverage No coverage No coverage
Georgia No coverage No coverage No coverage No coverage No coverage
Germany No coverage No coverage No coverage No coverage No coverage
Ghana No coverage No coverage No coverage No coverage No coverage
Greece No coverage No coverage No coverage No coverage No coverage
Guatemala No coverage No coverage No coverage No coverage No coverage
Hong Kong (China*) No coverage No coverage No coverage No coverage No coverage
Hungary No coverage No coverage No coverage No coverage No coverage
Iceland No coverage No coverage National health plan No coverage No coverage
India No coverage No coverage No coverage No coverage No coverage
Ireland Private insurance Private insurance Private insurance No coverage No coverage
Israel Private insurance Private insurance Private insurance Private insurance Private insurance
Italy No coverage No coverage No coverage State/Provincial/Regional health plan No coverage
Jordan No coverage No coverage No coverage No coverage No coverage
Kazakhstan No coverage No coverage No coverage No coverage No coverage
Kenya No coverage No coverage No coverage No coverage
Latvia No coverage No coverage No coverage No coverage No coverage
Lithuania No coverage No coverage No coverage No coverage No coverage
Mali No coverage No coverage No coverage No coverage No coverage
Mexico No coverage No coverage No coverage No coverage No coverage
Mongolia No coverage No coverage No coverage No coverage No coverage
Montenegro No coverage No coverage No coverage No coverage No coverage
Namibia No coverage No coverage No coverage No coverage No coverage
Netherlands No coverage No coverage No coverage No coverage No coverage
New Zealand No coverage No coverage No coverage No coverage No coverage
Nicaragua No coverage No coverage No coverage No coverage No coverage
Nigeria No coverage No coverage No coverage No coverage No coverage
Norway No coverage No coverage No coverage Unknown No coverage
Panama No coverage No coverage No coverage No coverage No coverage
Paraguay No coverage No coverage No coverage No coverage No coverage
Peru No coverage No coverage No coverage No coverage No coverage
Philippines No coverage No coverage No coverage No coverage No coverage
Poland No coverage No coverage No coverage No coverage No coverage
Portugal Unknown Unknown Unknown Unknown Unknown
Romania No coverage No coverage No coverage No coverage No coverage
Russian Federation No coverage No coverage No coverage No coverage No coverage







Serbia No coverage No coverage No coverage No coverage No coverage
Singapore No coverage No coverage No coverage No coverage No coverage
Slovenia No coverage No coverage No coverage National health plan No coverage
South Africa No coverage No coverage No coverage No coverage No coverage
The Republic of Korea No coverage No coverage No coverage No coverage No coverage
Spain No coverage No coverage No coverage No coverage No coverage
Sri Lanka No coverage No coverage No coverage No coverage No coverage
Sweden No coverage No coverage No coverage No coverage No coverage
Switzerland No coverage No coverage No coverage No coverage No coverage
Taiwan (China*) No coverage No coverage No coverage No coverage No coverage
Thailand No coverage No coverage No coverage No coverage No coverage
Togo No coverage No coverage No coverage No coverage No coverage
Trinidad and Tobago No coverage No coverage No coverage No coverage No coverage
Tunisia No coverage No coverage No coverage No coverage No coverage
Turkey No coverage No coverage No coverage No coverage No coverage
Uganda Unknown Unknown Unknown Unknown Unknown
United Arab Emirates Unknown Private insurance Unknown Private insurance Unknown
UK No coverage No coverage No coverage No coverage No coverage
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reimbursed 1 cycle only; and Belgium, Japan, Singapore, and The
United States of America provide up to 6 reimbursed treatments.
In 2015, no country reported reimbursement for cryopreserva-
tion of either oocyte or ovarian tissue for non-medical reasons. But
in 2018, Canada, Ireland, Israel, and The United States of America
reported private insurance covering oocyte cryopreservation. Israel
and some American insurers covered ovarian tissue cryopre-
servation for non-medical indications. Of note, elective (“non-
medically indicated”) sperm cryopreservation is covered in
Canada, France, Ireland, Israel, Senegal, United Arab Emirates;
and support for non-medically indicated testicular tissue cryopre-
servation is offered in Canada, Israel, Senegal, Slovenia, The
United States of America, and United Arab Emirates.
Discussion
In the 2018 questionnaire, 85 countries were surveyed about
funding for infertility treatment; 40 (47%) replied that some
funding was available. As the tables attest, considerable inter-
national variation exists in the level of support available and
requirements for obtaining it.
Minimal change was noted in the number of countries man-
dating single embryo transfer (eSET), or otherwise limiting the
number of embryos transferred (see Chapter 5). The policy for
ART reimbursement for the same policy increased 18% in 2015,
and 23% in 2018. Multiple subsequent pregnancies resulting
from transfer of an inappropriate number of embryos has long
been recognized as the most significant complication of ART. The
small number of positive responses to the question of multiple
embryo transfer may, in part, reflect other mechanisms or sanc-
tions already in place, addressing the problem. But it also suggests
that the problem remains significant, and offers considerable
room for improvement.
In contrast, support for genetic testing of embryos, both PGT-M
and PGT-A, seems to have increased, but there has been little
change in funding support for either (14 responses out of 83 for
PGT-M [17%]; 5 responses out of 81 for PGT-A [6%]). Modest
progress has beenmade for funding non-medical cryopreservation.
While current data may be more reliable, due to the familiarity
and greater experience with the survey of many of the respon-
dents, caution should be taken when interpreting the data. There
are limitations in the completeness and accessibility of the data
included.
Summary
A minority of countries provide insurance coverage for ART.
Only 47% give any support for infertility therapy. To date,
genetic screening appears to have greater support, but no sig-
nificant changes have occurred in the proportion of countries that













Combination of government health plan and private
insurance
Private insurance
A state provinicial regional health plan
A national health plan
Yes No Unknown
Chapter 3. Chart 1. What type of coverage or reimbursement?
Chapter 3. Table 3h
(Continued)
Cryopreservation for Fertility Preservation for Nonmedical Indications
Country Oocytes Sperm Embryos Testicular Tissue Ovarian Tissue
USA Private insurance Private insurance Private insurance Private insurance Private insurance
Uruguay No coverage No coverage National health plan No coverage No coverage
Venezuela No coverage No coverage No coverage No coverage No coverage
Viet Nam No coverage No coverage No coverage No coverage No coverage
Zimbabwe No coverage No coverage No coverage No coverage No coverage
*Reporting separately for this report.

















Gestational surrogacy using donated ova & donated sperm
Gestational surrogacy using commissioning couples ova & sperm





















































Chapter 3. Chart 3. What does insurance coverage or government funding cover?
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Chapter 3. Table 4a
Does insurance coverage or government funding typically cover the following ART services?
Country Diagnostic Evaluation Fertility Medications Intrauterine Insemination IVF ICSI Assisted Hatching
Argentina Yes Yes Yes Yes Yes Yes
Armenia No No No No No
Australia Yes Yes Yes Yes Yes Unknown
Austria No Yes No Yes Yes No
Bangladesh No No No No No No
Barbados No No No No No No
Belarus Yes No No No No No
Belgium Yes Yes Yes Yes Yes Unknown
Bolivia No No No No No No
Botswana Yes No No No No No
Brazil Yes No No No No No
Bulgaria No Yes No Yes Yes No
Burkina Faso Yes No No No No No
Cameroon Yes No No No No No
Canada Yes No Yes Yes Yes No
Chile Yes Yes Yes Yes Yes No
China No No No No No No
Colombia No No No No No No
Czechia Yes Yes Yes Yes No No
Congo No No No No No No
Ecuador Yes No No No No No
El Salvador No No No No No No
Finland Yes Yes Yes Yes Yes No
France Yes Yes Yes Yes Yes No
Georgia No No No No No No
Germany Yes Yes Yes Yes Yes No
Greece No No No No No No
Guatemala No No No No No No
Hong Kong (China*) Yes Yes Yes Yes Yes No
Hungary Yes Yes Yes Yes Yes Yes
Iceland No Yes No Yes Yes No
India No No No No No No
Ireland Yes Yes Yes Yes Yes Yes
Israel Yes Yes Yes Yes Yes Yes
Italy Yes Yes No No No
Côte d’Ivoire Yes Unknown Unknown Unknown Unknown Unknown
Japan Yes Yes No Yes Yes



























Cryo of ovarian tissue for fertility preservation for nonmedical indications
Cryo of ovarian tissue for fertility preservation for medical indications
Cryo of testicular tissue for fertility preservation for nonmedical indications
Cryo of testicular tissue for fertility preservation for medical indications
Cryo of embryos for fertility preservation for nonmedical indications
Cryo of embryos for fertility preservation for medical indications
Cryo of sperm for fertility preservation for nonmedical indications
Cryo of sperm for fertility preservation for medical indications
Cryo of oocytes for fertility preservation for nonmedical indications
No Yes Unknown
Chapter 3. Chart 5. What does insurance coverage or government funding cover?
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Chapter 3. Table 4a
(Continued)
Country Diagnostic Evaluation Fertility Medications Intrauterine Insemination IVF ICSI Assisted Hatching
Kazakhstan No No No No No No
Kenya No No No Yes Yes Unknown
Latvia Yes Yes Yes Yes Yes No
Lithuania Yes Yes No Yes Yes No
Mali Yes Yes No No No No
Mexico No No No No No No
Mongolia No No No No No No
Montenegro Yes Yes No Yes Yes No
Namibia Yes No No No No No
Netherlands Yes Yes Yes Yes Yes No
New Zealand Yes Yes Yes Yes Yes No
Nicaragua No No No No No No
Nigeria No No No No No No
Norway Yes Yes Yes Yes Yes Unknown
Panama No No Yes No No No
Paraguay No No No No No No
Peru No No No No No No
Philippines No No No No No No
Poland No No No No No No
Portugal Yes Yes Yes Yes Yes Yes
Romania No No No Yes Yes Yes
Russian Federation Yes Yes No Yes Yes Yes
Senegal Yes Yes Yes Yes Yes Unknown
Serbia Yes Yes Yes Yes Yes Yes
Singapore No No Yes Yes Yes Yes
Slovenia Yes Yes Yes Yes Yes No
South Africa Yes No No No No No
The Republic of Korea Yes Yes Yes Yes Yes Yes
Spain Yes Yes Yes Yes Yes Yes
Sri Lanka No No No No No No
Sweden No No Yes No No No
Switzerland Yes Yes Yes No No No
Taiwan (China*) Yes No No No No No
Thailand No No No No No No
Togo No No No No No No
Trinidad and Tobago No No No No No No
Tunisia Yes Yes No Yes Yes Yes
Turkey Yes Yes Yes Yes Yes Yes
Uganda No No No No No No
United Arab Emirates Yes Yes Yes Yes Yes Yes
UK Yes Yes Yes Yes Yes No
USA Yes No No No No No
Uruguay Yes Yes Yes Yes Yes Yes
Venezuela No No No No No No
Viet Nam No No No No No No
Zimbabwe Yes Yes Yes No No No
*Reporting separately for this report.
Chapter 3. Table 4b




Oocytes from an IVF Cycle
Cryopreservation of
Supernumerary
Embryos from an IVF Cycle PGT-M PGT-A
Argentina Yes Yes No No
Armenia No No No No
Australia No No No No
Austria No No No No
Bangladesh No No No No
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Oocytes from an IVF Cycle
Cryopreservation of
Supernumerary
Embryos from an IVF Cycle PGT-M PGT-A
Barbados No No No No
Belarus No No No No
Belgium Yes Yes Unknown Unknown
Bolivia No No No No
Botswana No No No No
Brazil No No No No
Bulgaria No Yes No No
Burkina Faso No No No No
Cameroon No No No No
Canada No No No
Chile No No No No
China No No No No
Colombia No No No No
Congo No No No No
Côte d’Ivoire Unknown Unknown No
Czechia No No Yes Yes
Ecuador No No No No
El Salvador No No No No
Finland No Yes No No
France Yes Yes No No
Georgia No No No No
Germany No No No No
Greece No No No No
Guatemala No No No No
Hong Kong (China*) No No No No
Hungary Yes Yes No No
Iceland No Yes No No
India No No No No
Ireland Yes Yes Unknown Unknown
Israel Yes Yes Yes No
Italy No No No No
Jordan No No No No
Kazakhstan No No No No
Kenya Yes Yes Unknown Unknown
Latvia No Yes No No
Lithuania No No Yes No
Mali No No No No
Mexico No No No No
Mongolia No No No No
Montenegro No No No No
Namibia No No No No
Netherlands Yes Yes Yes No
New Zealand Yes Yes Yes No
Nicaragua No No No No
Nigeria No No No No
Norway Yes Yes Yes No
Panama No No No No
Paraguay No No No No
Peru No No No No
Philippines No No No No
Poland No No No No
Portugal Yes Yes Yes Yes
Romania No No No No
Russian Federation Yes Yes No No
Senegal Unknown Unknown Unknown Unknown
Serbia Yes Yes Yes Yes
Singapore Yes Yes Yes Yes
Slovenia Yes Yes Yes No
South Africa No No No No
The Republic of Korea No No No No
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Oocytes from an IVF Cycle
Cryopreservation of
Supernumerary
Embryos from an IVF Cycle PGT-M PGT-A
Spain Yes Yes Yes No
Sri Lanka No No No No
Sweden No No No No
Switzerland No No No No
Taiwan (China*) No No No No
Thailand No No No No
Togo No No No No
Trinidad and Tobago No No No No
Tunisia No No No
Turkey No Yes Yes No
Uganda No No No No
United Arab Emirates Yes Yes Yes Yes
UK No Yes Yes No
USA No No No No
Uruguay No Yes No No
Venezuela No No No No
Viet Nam No No No No
Zimbabwe No No No No
*Reporting separately for this report.
Chapter 3. Table 4c
























Argentina Yes Yes Yes No No No No
Armenia No No No No No No No
Australia Yes Yes Yes No No No No
Austria No No No No No No No
Bangladesh No No No No No No No
Barbados No No No No No No No
Belarus No No No No No No No
Belgium Yes No No No No No No
Bolivia No No No No No No No
Botswana No No No No No No No
Brazil No No No No No No No
Bulgaria No No No No No No No
Burkina Faso No No No No No No No
Cameroon No No No No No No No
Canada No No No Yes Yes Yes Yes
Chile No No No No No No No
China No No No No No No No
Colombia No No No No No No No
Congo No No No No No No No
Côte d’Ivoire No No No No No No No
Czechia No No No No No No No
Ecuador No No No No No No No
El Salvador No No No No No No No
Finland No No No No No No No
France Yes Yes Yes No No No No
Georgia No No No No No No No
Germany No No No No No No No
Greece No No No No No No No
Guatemala No No No No No No No
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Hong Kong (China*) No No No No No No No
Hungary Yes Yes Yes No Yes No No
Iceland No No No No No No No
India No No No No No No No
Ireland No No No No No No No
Israel No No No No No No
Italy No No No No No No No
Jordan No No No No No No
Kazakhstan No No No No No No No
Kenya No No No No No No No
Latvia No No No No No No No
Lithuania No No No No No No No
Mali No No No No No No No
Mexico No No No No No No No
Mongolia No No No No No No No
Montenegro No No No
Namibia No No No No No No No
Netherlands Yes Yes Yes Unknown No Yes No
New Zealand Yes Yes Yes Yes Yes Yes Yes
Nicaragua No No No No No No No
Nigeria No No No No No No No
Norway Yes No No No No No No
Panama No No No No No No No
Paraguay No No No No No No No
Peru No No No No No No No
Philippines No No No No No No No
Poland No No No No No No No
Portugal Yes Yes Yes Yes Yes Yes Yes
Romania No No No No No No No
Russian Federation No No No No No No No
Senegal No No No No Yes Yes Yes
Serbia No No No No No No No
Singapore No Yes Yes No No No No
Slovenia Yes Yes No No No No No
South Africa No No No No No No No
The Republic of Korea No No No No No No No
Spain Yes Yes No No No No No
Sri Lanka No No No No No No No
Sweden No No No No No No No
Switzerland No No No No No No No
Taiwan (China*) No No No No No No No
Thailand No No No No No No No
Togo No No No No No No No
Trinidad and Tobago No No No No No No No
Tunisia No No No Yes Yes Yes No
Turkey No No No No No No No
Uganda No No No No No No No
United Arab Emirates No No No No No No No
UK Yes Yes Yes No No No No
USA No No No No No No No
Uruguay Yes Yes Yes Yes Yes Yes No
Venezuela No No No No No No No
Viet Nam No No No No No No No
Zimbabwe No No No No No No No
*Reporting separately for this report.
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Chapter 3. Table 4d
Does insurance coverage or government funding typically cover the following ART services?
Cryopreservation for Fertility Preservation for Medical Indications Cryopreservation for Fertility Preservation for Nonmedical Indications









Argentina Yes Yes Yes Yes No No No No No No
Armenia No No No No No No No No No No
Australia No No No Yes Yes No No No No No
Austria No No No No No No No No No No
Bangladesh No No No No No No No No No No
Barbados No No No No No No No No No No
Belarus No No No No No No No No No No
Belgium Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Bolivia No No No No No No No No No No
Botswana No No No No No No No No No No
Brazil No No No No No No No No No No
Bulgaria Yes No No No No No No No No No
Burkina Faso No No No No No No No No No No
Cameroon No No No No No No No No No No
Canada Yes Yes No Yes Unknown No No No No Unknown
Chile No Yes No No No No No No No No
China No No No No No No No No No No
Colombia No No No No No No No No No No
Congo No No No No No No No No No No
Côte d’Ivoire Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Czechia No Yes No No No No No No No No
Ecuador No No No No No No No No No No
El Salvador No No No No No No No No No No
Finland Yes Yes Yes Yes Yes No No No No No
France Yes Yes Yes Yes Yes No Yes No No No
Georgia No No No No No No No No No No
Germany No No No No No No No No No No
Greece No No No No No No No No No No
Guatemala No No No No No No No No No No
Hong Kong (China*) No No No No No No No No No No
Hungary No No No No No No No No No No
Iceland No No Yes Yes Yes No No Yes No No
India No No No No No No No No No No
Ireland Yes Yes Yes Unknown Unknown Yes Yes Yes Unknown Unknown
Israel Yes Yes Yes Yes Yes No No No No No
Italy No No No No No No No No No No
Jordan No No No No No No No No No No
Kazakhstan No No No No No No No No No No
Kenya No No No No No No No No No No
Latvia No No No No No No No No No No
Lithuania No No No No No No No No No No
Mali No No No No No No No No No No
Mexico No No No No No No No No No
Mongolia No No No No No No No No No No
Montenegro No No No No No No No No No No
Namibia No No No No No No No No No No
Netherlands Yes Yes Yes No No No No No No No
New Zealand Yes Yes Yes Yes No No No No No No
Nicaragua No No No No No No No No No No
Nigeria no No no no no no no no no no
Norway Yes Yes Yes Yes Yes No No No No No
Panama No No No No No No No No No No
Paraguay No No No No No No No No No No
Peru No No No No No No No No No No
Philippines No No No No No No No No No No
Poland No No No No No No No No No No
Portugal Yes Yes Yes Yes Yes No No No No No
Romania No No No No No No No No No No
Russian Federation No No No No No No No No No No
Senegal Unknown Yes Yes Yes Unknown Unknown Yes Yes Yes Unknown
Serbia No No No Unknown No No No No Unknown No
Singapore No No Yes No No No No No No No
Slovenia Yes Yes Yes Yes Yes No No No No No
South Africa No No No No No No No No No No
The Republic of Korea No No No No No No No
Spain Yes Yes Yes Yes Yes No No No No No
Sri Lanka No No No No No No No No No No
Sweden Yes Yes Yes Yes Yes No No No No No
Switzerland No No No No No No No No No No
Taiwan (China*) No No No No No No No No No No
Thailand No No No No No No No No No No
Togo No No No No No No No No No No
Trinidad and Tobago No No No No No No No No No No
Tunisia No No No No No No No No No No
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Chapter 3. Table 4d
(Continued)
Cryopreservation for Fertility Preservation for Medical Indications Cryopreservation for Fertility Preservation for Nonmedical Indications









Turkey Yes Yes Yes Yes Yes No No No No No
Uganda No No No No No No No No No No
United Arab Emirates Yes Yes Yes Yes Yes Yes Unknown Yes Unknown
UK Yes Yes Yes No No No No No No No
USA No No No No No No No No No No
Uruguay No No Yes Yes No No No Yes No No
Venezuela No No No No No No No No No No
Viet Nam No No No No No No No No No No
Zimbabwe No No No No No No No No No No
*Reporting separately for this report.
Chapter 3. Table 5
Is insurance coverage or government funding based on fertility status?
Country Primary Infertility Secondary Infertility Family Building
Argentina No No No
Armenia No No No
Australia Yes
Austria No No No
Bangladesh No No No
Barbados No No No
Belarus No No No
Belgium No No No
Bolivia No No No
Brazil No No No
Bulgaria No No No
Burkina Faso Unknown Unknown Unknown
Cameroon No No No
Canada Yes
Chile Yes Yes Unknown
China No No No
Colombia No No No
Congo No No No
Côte d’Ivoire Unknown Unknown Unknown
Czechia No No No
Ecuador No No No
El Salvador No No No
Finland Yes Yes Yes
France No No Yes
Georgia No No No
Germany Yes Yes Yes
Greece No No No
Hong Kong (China*) No No Yes
Hungary Yes Yes Yes
Iceland No No Yes
India No No No
Ireland Yes Yes Yes
Israel Yes Yes No
Italy No No
Japan No No No
Jordan No No No
Kazakhstan Yes Yes Yes
Kenya Yes Yes Yes
Latvia Yes Yes Unknown
Lithuania Yes Yes No
Mali No No No
Mexico No No No
Mongolia No No No
Montenegro Yes Yes Yes
Namibia No No Yes
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Chapter 3. Table 5
(Continued)
Country Primary Infertility Secondary Infertility Family Building
Netherlands No No No
New Zealand Yes Yes Yes
Nicaragua No No No
Nigeria no no no
Norway No No No
Panama No No No
Paraguay No No No
Peru No No No
Philippines Unknown Unknown Unknown
Poland No No
Portugal No No No
Romania Yes Yes Yes
Russian Federation Yes Yes Yes
Senegal No No No
Serbia Yes No Yes
Singapore Yes Yes Yes
Slovenia Yes Yes
South Africa No No No
The Republic of Korea Yes Yes Yes
Spain Yes Yes Yes
Sweden Yes
Switzerland Yes No No
Taiwan (China*) Yes Yes Yes
Thailand No No No
Togo No No No
Tunisia Yes Yes Yes
Turkey Yes No No
Uganda No No No
United Arab Emirates Yes Yes Yes
UK No No No
USA No No Yes
Uruguay Yes Yes Yes
Venezuela No No No
Viet Nam No No No
Zimbabwe Yes Yes Yes














Chapter 3. Chart 6. What is coverage or reimbursement based on?
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CHAPTER 4: MARITAL STATUS AND SAME SEX AND
SINGLE PARENTING POLICY
Introduction
This chapter addresses the availability and governance of ART
services as they relate to the marital status of a couple or a person
seeking ART.
The survey questions were intended to determine if a require-
ment existed for a specific type of relationship status (i.e., stable,
marital, or heterosexual) to access ART services, and within what
kind of relationship these services would be available, if a
restriction did exist. Respondents for the individual countries
were queried about these issues, and about specific potential
limitations for access to ART—limitations pertaining to gender
and to male and female same-sex relationships. The survey also
evaluated the access of single men, single women, and same-sex
couples to specific diagnostic or therapeutic interventions, and
assessed the status of a same-sex partner as a legal parent of a
resulting child.
Analysis of the survey
Respondents from 84 countries answered—partially or
completely—questions pertaining to this chapter. Regarding a
requirement for a recognized or stable relationship in order to
access ART services, 52 countries (62%) reported having no such
requirement; 32 (38%) said that their country did have such a
requirement (Chart 1). As for European countries, most respon-
ded that they did not require a recognized relationship for ART
access; exceptions included Czechia, France, Greece, Hungary,
Italy, Lithuania, Montenegro, Romania, Serbia, Slovenia,
Sweden, Switzerland, and Turkey—countries with federal laws,
statutes, or ordinances backing up the requirement. Other
countries not requiring a stable relationship for ART access
include Australia, Canada, India, New Zealand, The United
States of America, and most Latin American countries.
Most Asian countries do require a stable relationship, and have
laws, statutes, or oversight by professional organizations or
government agencies with jurisdiction. These countries include
China, Hong Kong [China, reporting separately for this report],
Singapore, Taiwan [China, reporting separately for this report],
Thailand, and Viet Nam. Countries where a stable relationship is
mandated by professional organizations, cultural practice, or
Chapter 4. Table 1a
Access to diagnostic and therapeutic interventions.
Country Diagnostic Evaluation Intrauterine Insemination
Argentina Single Women Single Women










Intersex Individuals Intersex Individuals
Armenia Single Women Single Women
Single Men Single Men
Australia Single Women Single Women










Intersex Individuals Intersex Individuals









Barbados Single Women Single Women, Single Men






Belarus Single Women Single Women
Single Men
Belgium Single Women Single Women








Bolivia Single Women Single Women










Intersex Individuals Intersex Individuals
Botswana Single Women Single Women
Single Men
Brazil Single Women Single Women










Intersex Individuals Intersex Individuals
Bulgaria Single Women Single Women
38%
62%
Require stable relationship Do not require stable relationship
Chapter 4. Chart 1. Requirement for a stable or recognized relationship to
access ART.
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Chapter 4. Table 1a
(Continued)
Country Diagnostic Evaluation Intrauterine Insemination
Single Men
Cameroon Single Women Single Women
Single Men
Canada Single Women Single Women










Intersex Individuals Intersex Individuals
China Single Women
Single Men
Colombia Single Women Single Women










Intersex Individuals Intersex Individuals
Congo Single Women Intersex Individuals
Intersex Individuals
Côte d’Ivoire Single Women Single Women
Single Men Single Men
Czechia Single Women
Single Men
Ecuador Single Women Single Women
El Salvador Single Women Single Women
Single Men Single Men
Finland Single Women Single Women











Georgia Single Women Single Women












Greece Single Women Single Women
Single Men
Guatemala Single Women Single Women












Chapter 4. Table 1a
(Continued)





Hungary Single Women Single Women
Iceland Single Women Single Women







India Single Women Single Women
Single Men Single Men
Ireland Single Women Single Women






Italy Single Women Single Women
Japan Single Women
Single Men
Kazakhstan Single Women Single Women
Single Men
Kenya Single Women Single Women
Single Men
Latvia Single Women Single Women
Single Men
Mali Single Women Single Women
Single Men





Montenegro Single Women Single Women





New Zealand Single Women Single Women










Nigeria Single Women Single Women









Paraguay Single Women Single Women










Intersex Individuals Intersex Individuals
Peru Single Women Single Women
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religious decree, include Bangladesh, Cameroon, Egypt, Japan,
the Philippines, Senegal, The Republic of Korea, and United Arab
Emirates.
The 52 countries with no requirement for a stable heterosexual
union for access to ART were surveyed as to whether services
were available for all the categories listed: single men, single
women, male and female same-sex couples, and transgender and
intersex individuals. Thirteen countries reported access for all,
including Argentina, Australia, Barbados, Bolivia, Brazil,
Chapter 4. Table 1a
(Continued)
Country Diagnostic Evaluation Intrauterine Insemination




Philippines Intersex Individuals Intersex Individuals
Poland Single Women Single Women
Single Men
Portugal Single Women Single Women








Romania Single Women Single Women
Single Men













South Africa Single Women Single Women










Intersex Individuals Intersex Individuals






Spain Single Women Single Women







Sweden Single Women Same Sex Female
Married Couple










Chapter 4. Table 1a
(Continued)
Country Diagnostic Evaluation Intrauterine Insemination
Single Men
Taiwan (China*) Single Women
Single Men
Togo Intersex Individuals Intersex Individuals






Intersex Individuals Intersex Individuals
Turkey Single Women
Single Men
Uganda Single Women Single Women




United Arab Emirates Single Women
Single Men
UK Single Women Single Women










Intersex Individuals Intersex Individuals
USA Single Women Single Women










Intersex Individuals Intersex Individuals














Zimbabwe Single Women Single Women
Single Men Single Men
*Reporting separately for this report.
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Chapter 4. Table 1b
Access to diagnostic and therapeutic interventions.
Country IVF PGT-M PGT-A
Argentina Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Armenia Single Women Single Women Single Women
Single Men Single Men Single Men
Australia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Austria Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Barbados Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Belarus Single Women Single Women Single Women
Belgium Single Women, Same Sex Female Married Couple
Bolivia Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Botswana Single Women, Single Men Single Women, Single Men Single Women
Brazil Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Bulgaria Single Women Single Women Single Women
Cameroon Single Women
Canada Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Colombia Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female
Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Congo Intersex Individuals
Côte d’Ivoire Single Women, Single Men
Ecuador Single Women Single Women Single Women
El Salvador Single Women, Single Men Single Women, Single Men
Finland Single Women, Same Sex Female Married Couple,
Same Sex Male Married Couple
Single Women, Same Sex Female Married Couple,
Same Sex Male Married Couple
Single Women, Same Sex Female Married Couple,
Same Sex Male Married Couple
Georgia Single Women Single Women Single Women
Germany Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Ghana Single Women, Single Men Single Women, Single Men Single Women, Single Men
Greece Single Women, Single Men Single Women, Single Men Single Women, Single Men
Guatemala Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple
Hungary Single Women
Iceland Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
India Single Women, Single Men Single Women, Single Men Single Women, Single Men
Ireland Single Women, Same Sex Female Married Couple
Italy Intersex Individuals Intersex Individuals
Kazakhstan Single Women Single Women Single Women
Kenya Single Women Single Women Single Women
Latvia Single Women Single Women Single Women
Mali Single Women, Single Men
Mexico Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple
Montenegro Single Women Single Women Single Women
Netherlands Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple
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Chapter 4. Table 1b
(Continued)
Country IVF PGT-M PGT-A
New Zealand Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female Married
Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Same Sex Female Married Couple,
Transgender, Intersex Individuals
Nigeria Single Women Single Women
Norway Same Sex Female Married Couple Same Sex Female Married Couple
Panama Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple
Paraguay Single Women, Single Men, Same Sex Female Married
Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female Married
Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Single Women, Single Men, Same Sex Female Married
Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Peru Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple Single Women, Same Sex Female Married Couple
Philippines Intersex Individuals Intersex Individuals Intersex Individuals
Poland Single Women, Single Men Single Women Single Women




Single Women Single Women Single Women
South Africa Single Women Single Women, Single Men, Same Sex Female Single Women, Single Men, Same Sex Female
Single Men Married Couple, Same Sex Male Married Married Couple, Same Sex Male Married Couple,
Transgender, Intersex Individuals
Same Sex Female Married Couple Couple, Transgender, Intersex Individuals
Same Sex Male Married Couple
Transgender
Intersex Individuals
Spain Single Women Single Women Single Women
Same Sex Female Married Couple Transgender Same Sex Female Married Couple Transgender Same Sex Female Married Couple
Intersex Individuals Intersex Individuals Transgender
Intersex Individuals
Sweden Same Sex Female Married Couple Single Women
Same Sex Male Married Couple Single Men
Transgender Same Sex Female Married Couple







Same Sex Female Married Couple
Transgender
Intersex Individuals
Uganda Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
UK Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
USA Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Uruguay Single Women Single Women Single Women
Same Sex Female Married Couple Transgender Same Sex Female Married Couple Same Sex Female Married Couple
Transgender Transgender
Viet Nam Single Women Single Women Single Women
Zimbabwe Single Women Single Women Single Women
Single Men Single Men Single Men
*Reporting separately for this report.
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29
41
Chapter 4. Table 1c
Access to diagnostic and therapeutic interventions.
Country Donor Sperm Donor Egg Donor Embryos
Argentina Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Armenia Single Women Single Women Single Women
Single Men
Australia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Austria Same Sex Female Married Couple Same Sex Female Married Couple
Barbados Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple
Belarus Single Women Single Women Single Women
Belgium Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Bolivia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Botswana Single Women Single Women Single Women
Single Men Single Men Single Men
Brazil Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Bulgaria Single Women Single Women Single Women
Canada Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Colombia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Congo Intersex Individuals Intersex Individuals Intersex Individuals
Côte d’Ivoire Single Men Single Women Single Women, Single Men
Ecuador Single Women Single Women Single Women
El Salvador Single Women Single Women Single Women
Single Men Single Men Single Men
Finland Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Georgia Single Women Single Women Single Women
Ghana Single Women Single Women Single Women
Single Men Single Men Single Men
Greece Single Women Single Women Single Women
Single Men Single Men Single Men
Guatemala Single Women Single Women Single Women
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Chapter 4. Table 1c
(Continued)
Country Donor Sperm Donor Egg Donor Embryos
Same Sex Female Married Couple Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple
Hungary Single Women Single Women
Iceland Single Women Single Women
Same Sex Female Married Couple Transgender Same Sex Female Married Couple Transgender
Intersex Individuals Intersex Individuals
India Single Women Single Women Single Women
Single Men Single Men Single Men
Ireland Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Kazakhstan Single Women Single Women Single Women
Kenya Single Women Single Women Single Women
Latvia Single Women Single Women Single Women
Mali Single Women Single Women Single Women
Mexico Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple
Montenegro Single Women Single Women
Netherlands Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple
New Zealand Single Women Single Women Single Women
Same Sex Female Married Couple Transgender Single Men Same Sex Female Married Couple
Intersex Individuals Same Sex Female Married Couple Transgender
Same Sex Male Married Couple Intersex Individuals
Transgender
Intersex Individuals
Nigeria Single Women Single Women Single Women
Norway Same Sex Female Married Couple
Panama Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Paraguay Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Peru Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Philippines Intersex Individuals Intersex Individuals Intersex Individuals
Poland Single Women
Portugal Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Romania Single Women
Russian Federation Single Women Single Women Single Women
South Africa Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Spain Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Single Men
Transgender Transgender Same Sex Female Married Couple
Intersex Individuals Intersex Individuals Transgender
Intersex Individuals
Togo Intersex Individuals Intersex Individuals Intersex Individuals
Trinidad and Tobago Single Women Single Women Single Women
Same Sex Female Married Couple Transgender Same Sex Female Married Couple Same Sex Female Married Couple
Intersex Individuals Transgender Transgender
Intersex Individuals Intersex Individuals
Uganda Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
UK Single Women Single Women Single Women
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Chapter 4. Table 1c
(Continued)
Country Donor Sperm Donor Egg Donor Embryos
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
USA Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Uruguay Single Women Single Women Single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Transgender Transgender Transgender
Viet Nam Single Women
Zimbabwe Single Women Single Women Single Women
Single Men Single Men Single Men
*Reporting separately for this report.
Chapter 4. Table 1d
Access to diagnostic and therapeutic interventions.
Country Traditional Surrogacy
Gestational Surrogacy Using Donated
Ova and Commissioning Persons Sperm
Gestational Surrogacy Using Donated
Ova and Donated Sperm
Argentina Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Armenia Single Women
Single Men
Australia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Belarus Single Women
Bolivia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Botswana Single Women Single Women Single Women
Single Men Single Men Single Men
Brazil Same Sex Male Married Couple
Canada Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Colombia Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
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Canada, Guatemala, Mongolia, New Zealand, Paraguay, South
Africa, The United States of America, and the United Kingdom of
Great Britain and Northern Ireland. Several countries reported
access to single individuals or same-sex couples, but responded
“unknown” regarding transgender and intersex individuals; they
were Colombia, Namibia, and Venezuela. Germany indicated
“unknown” for all categories. Bulgaria, Finland, and the
Netherlands responded that access to single men and male same-
sex couples was “unknown.”
Some countries reported access to ART services for single
women or female same-sex couples, but no access for single men
and same-sex male couples (Belgium, Ecuador, Iceland, Ireland,
Mexico, Peru, Portugal, Trinidad and Tobago, and Uruguay).
However, this dichotomy could apply to as many as 52 countries
out of 76 (68%) for single males and 60 countries (79%) for male
same-sex couples—if the “unknown” responses are included.
The following countries reported access to ART for single
women only, andmarked the rest of the categories as “no access”,
or “unknown”: Belarus, Cameroon, Guatemala, Congo,
Georgia, Hungary, Côte d’Ivoire, Kazakhstan, Kenya, Latvia,
Montenegro, Nigeria, Russian Federation, Uganda, and Viet
Nam. Finally, 22 countries reported “no access” for anyone not
in stable, heterosexual relationships: Bangladesh, Burkina Faso,
China, Czechia, Greece, Japan, Jordan, Lithuania, Nicaragua,
Chapter 4. Table 1d
(Continued)
Country Traditional Surrogacy
Gestational Surrogacy Using Donated
Ova and Commissioning Persons Sperm
Gestational Surrogacy Using Donated
Ova and Donated Sperm
Intersex Individuals Intersex Individuals Intersex Individuals
Ecuador Single Women Single Women Single Women
El Salvador Single Women Single Women Single Women
Single Men Single Men Single Men
Ghana Single Men Single Women Single Women
Single Men Single Men
Greece Single Women Single Women Single Women
Single Men Single Men Single Men
Guatemala Single Women Single Women
Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple
Kenya Single Women Single Women Single Women
Netherlands Same Sex Female Married Couple
New Zealand Single Men Single Men
Same Sex Female Married Couple Same Sex Male Married Couple
Same Sex Male Married Couple Transgender
Transgender Intersex Individuals
Intersex Individuals
Nigeria Single Women Single Women Single Women
Philippines Intersex Individuals Intersex Individuals Intersex Individuals
Russian Federation Single Women Single Women
South Africa Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Uganda Single Women, Same Sex Female Married Couple Single Women Single Women, Same Sex Female Married Couple
UK Single Men Single Men Single Women
Same Sex Male Married Couple Same Sex Male Married Couple Single Men
Transgender Transgender Same Sex Female Married Couple
Intersex Individuals Intersex Individuals Same Sex Male Married Couple
Transgender
Intersex Individuals
USA Single Women Single Women Single Women
Single Men Single Men Single Men
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Same Sex Male Married Couple Same Sex Male Married Couple Same Sex Male Married Couple
Transgender Transgender Transgender
Intersex Individuals Intersex Individuals Intersex Individuals
Uruguay Single Women Single Women single Women
Same Sex Female Married Couple Same Sex Female Married Couple Same Sex Female Married Couple
Zimbabwe Single Women Single Women Single Women
Single Men Single Men Single Men
*Reporting separately for this report.
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Philippines, Romania, Senegal, Serbia, Slovenia, The Republic of
Korea, Switzerland, Tunisia, Turkey, and United Arab Emirates.
Access for individuals and same-sex couples to various diag-
nostic and therapeutic interventions is depicted in Table 1.
Nineteen out of 70 countries (27%) reported offering diagnostic
evaluation in all categories surveyed (single women, single men,
female same-sex couples, male same-sex couples, and intersex
and transgender individuals), but only 7 of the 19 offering this
service reported access to treatments in all categories. The other
12 of the 19 countries responding provided access to treatment
primarily for single women or same-sex female couples; usually
they excluded single men, male same-sex couples, and intersex
and transgender individuals.
Forty-two countries reported limiting access to diagnostic or
therapeutic interventions primarily to single women or female
same-sex couples, excluding single men and intersex or trans-
gender individuals. Nine reported access to diagnostic evaluation
of single men or women, but no access to any treatment in the
other categories described.
The legal parenting status of the partner of a same-sex couple
was also surveyed. More than two-thirds of respondents did not
recognize a same-sex partner as a legal parent. This was the case
both in female same-sex couples, according to 57 of 85 respon-
dents (65%) and in male same-sex couples, according to 58 of 84
respondents (69%). Twenty-one of 85 (25%) recognize the
partner as a legal parent in female same-sex couples, but only 13
of 84 (15%) did so in male same-sex couples. Countries in this
category include Argentina, Australia, Brazil, Germany,
Guatemala, Italy, New Zealand, South Africa, Spain, Sweden,
The United States of America, United Kingdom of Great Britain
and Northern Ireland, and Uruguay. Another 6 countries
responded “unknown” to the question regarding the legal status
of the partner of a male same-sex couple: Armenia, Austria,
Colombia, Iceland, Netherlands, and Norway. Seven additional
countries reported “unknown” for both male and female same-
sex couples (Chart 2).
Summary
Most respondents–62%–do not require couples or individuals to
have a recognized or stable relationship in order to access ART
services. Treatment of single women is more widely accepted and
allowed than treatment of single men, according to 51 out of 75
respondents (68%). Treatment for female same-sex couples is
better accepted than treatment services for men, according to 24
of 76 respondents, and better accepted than treatment of male
same-sex couples, according to 16 out of 76 respondents (21%).
The situation is similar to that of the legal parenting status of
the partner of a same-sex couple: it is not recognized in more than
two-thirds of the countries surveyed.
CHAPTER 5: NUMBER OF EMBRYOS FOR TRANSFER
IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART)
Introduction
As ART professionals celebrated the 40th birthday of Louise
Brown, during the summer of 2018, the question of how many
embryos to transfer remained controversial. Louise Brown was
created from a single retrieved and fertilized oocyte, followed by
the first single blastocyst embryo transfer. As ART became more
widespread and more accessible, clinicians began to transfer
multiple embryos, increasing the chances of a successful preg-
nancy and delivery. Generally, the number of embryos that could
be transferred increased with the woman’s age, counteracting the
age-related decline in fertility. And now, multiple births have
plagued ART for three decades, and have resulted in unac-
ceptably high rates of fetal and maternal complications[1,2].
Multiple pregnancies remain the single greatest risk associated
with ART, despite great concern and efforts to reduce this risk,
ever since the technique’s inception.
The advent of blastocyst culture in the late 1990s allowed
many IVF programmes to transfer fewer embryos, yet increase
the rates of implantation and pregnancy. Using blastocyst culture
and implantation, embryologists were better able to choose good-
quality embryos, and to select for transfer a limited number that
could generate high implantation rates[3]. Over the last two
decades, numerous IVF centres have increased implantation rates
for both selected and non-selected patient groups, using blas-
tocyst-stage embryo transfer rather than day-3 embryo transfer.
The centres have also reduced the number of high-order multiple
pregnancies[4].
Following the success of reducing the incidence of high-order
multiple pregnancies, the focus of ART has switched to reducing
twin pregnancies. Single embryo transfer (SET) is still meeting
some resistance, despite the fact that several countries have leg-
islation or funding restrictions, and despite standard of care
guidelines regarding the number of embryos to transfer[5].
Several countries have firm guidelines or regulations mandat-
ing SET for women under 40. With the increased utilization of
pre-implantation genetic testing, aneuploidy screening in women
over 37, and the data suggesting that transferring a single euploid
embryo negates age-related infertility, SET has become the stan-
dard of care[6].
Analysis of the survey
Four questions were included in the 2018 survey to assess current
practices regarding the number of embryos to transfer.
In response to the question: “Are the number of embryos
transferred regulated in your country; if so, by what means”, 85
responded—a result very similar to the 2016 result of 84
respondents (59%).
Of the 85, 48 countries (56%) confirmed the existence of
guidelines or laws governing the number of embryos permitted
for transfer. Of 84 responders, 37 (44%) indicated that the
number of embryos for transfer was not regulated in their country













80% Recognized Not recognized
Chapter 4. Chart 2. Parenting legal status of the partner of a same sex couple.
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regulations or guidelines (70%) reported being regulated by
federal or national laws, statutes, or ordinances (50%), or by the
standards or guidelines of professional organizations (46%).
To the query, “If the number of embryos transferred is under
governance in your country, is there a penalty for violation?”
(Table 1), 49 responded. Seventeen of the 49 (35%) indicated
there was a penalty; 26 of the 49 (53%) noted that no penalty
existed; 4 (8%) responded “unknown”, and one country did not
answer.
To the question, “What is the maximum number of embryos
allowed to be transferred?” (Table 1), 70 countries had complete
answers from respondents, as follows:
• Oocyte age <35: 7 countries=Limited to 1 embryo, 18
countries=2 embryos, 15 countries=3 embryos, 2 countries=
4 embryos, 20 countries=not addressed, and 8 countries
responded “unknown”;
Chapter 5. Table 1
Are the number of embryos transferred regulated in your country
and is there a penalty for violation?
Country Governance Penalty
Argentina Professional Organization Standards/Guidelines No
Armenia Not regulated
Australia Professional Organization Standards/Guidelines No
Austria Professional Organization Standards/Guidelines No
Bangladesh Not regulated
Barbados Not regulated
Belarus Federal/National Laws/Statutes/Ordinances No
Belgium Federal/National Laws/Statutes/Ordinances Yes
Bolivia Not regulated No
Botswana Not regulated
Brazil Professional Organization Standards/Guidelines Yes
Bulgaria Federal/National Laws/Statutes/Ordinances Yes
Burkina Faso Not regulated
Cameroon State/Provincial/Regional Laws/Statutes/Ordinances No
Professional Organization Standards/Guidelines
Canada Not regulated No
Chile Not regulated
China Not regulated No
Professional Organization Standards/Guidelines
Cultural practice
Colombia Not regulated No
Congo Not regulated No
Côte d’Ivoire Not regulated Unknown
Czechia Professional Organization Standards/Guidelines No
Ecuador Not regulated No
Egypt Not regulated No
El Salvador Not regulated No
Finland Professional Organization Standards/Guidelines No
France Not regulated No
Georgia Not regulated
Germany Federal/National Laws/Statutes/Ordinances Unknown
Ghana Professional Organization Standards/Guidelines No
Greece Cultural practice No
Guatemala Not regulated No
Hong Kong (China*) Federal/National Laws/Statutes/Ordinances Yes
State/Provincial/Regional Laws/Statutes/Ordinances
Hungary Federal/National Laws/Statutes/Ordinances Yes
Professional Organization Standards/Guidelines
Iceland Federal/National Laws/Statutes/Ordinances No
India Not regulated
Ireland Not regulated Unknown
Italy Not regulated No
Japan Professional Organization Standards/Guidelines No
Jordan Not regulated No
Kazakhstan Cultural practice No
Kenya Not regulated
Latvia Federal/National Laws/Statutes/Ordinances Unknown
Lithuania Federal/National Laws/Statutes/Ordinances No
Mali Not regulated, Professional Organization No
Standards/Guidelines
Mexico Professional Organization Standards/Guidelines No
Mongolia Not regulated Unknown
Montenegro Professional Organization Standards/Guidelines No
Namibia Professional Organization Standards/Guidelines No
Netherlands Federal/National Laws/Statutes/Ordinances No
Professional Organization Standards/Guidelines
New Zealand Agency Regulations/Oversight No
Professional Organization Standards/Guidelines
Cultural practice
Nicaragua Federal/National Laws/Statutes/Ordinances Unknown
Nigeria Professional Organization Standards/Guidelines Unknown
Chapter 5. Table 1
(Continued)
Country Governance Penalty
Norway Not regulated No
Panama Not regulated No
Paraguay Not regulated No
Peru not regulated no
Philippines Not regulated No
Poland Professional Organization Standards/Guidelines No
Portugal Agency Regulations/Oversight Yes
Professional Organization Standards/Guidelines
Romania Not regulated No
Russian Federation Federal/National Laws/Statutes/Ordinances Yes
Professional Organization Standards/Guidelines
Senegal Not regulated Unknown
Serbia Federal/National Laws/Statutes/Ordinances No
Singapore Federal/National Laws/Statutes/Ordinances Yes
Slovenia Federal/National Laws/Statutes/Ordinances Yes
South Africa Federal/National Laws/Statutes/Ordinances Yes
Professional Organization Standards/Guidelines
The Republic of Korea Federal/National Laws/Statutes/Ordinances No
Spain Federal/National Laws/Statutes/Ordinances Yes
Sri Lanka Agency Regulations/Oversight
Professional Organization Standards/Guidelines
Sweden Federal/National Laws/Statutes/Ordinances Yes
Switzerland Federal/National Laws/Statutes/Ordinances Yes
Taiwan (China*) Federal/National Laws/Statutes/Ordinances Yes
Thailand Professional Organization Standards/Guidelines No
Togo Not regulated No
Trinidad and Tobago Not regulated
Tunisia Not regulated No
Turkey Federal/National Laws/Statutes/Ordinances Yes
Uganda Not regulated
United Arab Emirates Not regulated





USA Professional Organization Standards/Guidelines No
Uruguay Federal/National Laws/Statutes/Ordinances Yes
Agency Regulations/Oversight
Venezuela Professional Organization Standards/Guidelines No
Viet Nam Not regulated
Zimbabwe Not regulated No
*Reporting separately for this report.














Chapter 5. Chart 1. How are the number of embryos transferred in your country regulated? (More than one category may have been chosen per country).
Chapter 5. Table 2
What is the maximum number of embryos allowed to be








Argentina 2 2 3
Australia 1 1 1
Austria 2 2 3
Bangladesh 2 Enter max number
transferred
4
Belarus 2 3 3
Belgium 1 1 1
Bolivia Not addressed Not addressed Not addressed
Botswana Not addressed Not addressed Not addressed
Brazil 2 3 4
Bulgaria 3 3 4
Burkina Faso Unknown Unknown Unknown
Cameroon 3 3
Canada 1 1 2
China 2 2 3
Colombia 1 2 2
Congo Unknown Unknown Unknown
Côte d’Ivoire 3 3 2
Czechia Unknown Unknown Unknown
Ecuador 2 3 3
Finland 2 2 2
Georgia Not addressed Not addressed Not addressed
Germany Unknown Unknown Unknown
Ghana Not addressed Not addressed Not addressed
Greece 4 4 4
Guatemala Not addressed Not addressed Not addressed
Hong Kong (China*) 3 3 3
Hungary 3 3 4
Iceland Not addressed Not addressed Not addressed
Italy Not addressed Not addressed Not addressed
Japan 2 2 2
Jordan Not addressed Not addressed Not addressed
Kenya Not addressed Not addressed Not addressed
Latvia 3 3 3
Lithuania 3 3 3
Mali 3 3 3
Mexico 3 3 3









Mongolia Not addressed Not addressed Not addressed
Montenegro Unknown
Namibia 2 3 3
Netherlands 1 1 2
New Zealand 2 2 3
Nicaragua 3 3 3
Nigeria 2 3 3
Panama Not addressed Not addressed Not addressed
Peru Unknown Unknown Unknown
Poland Unknown Unknown Not addressed
Portugal 3 3 Not addressed
Romania Not addressed Not addressed Not addressed
Russian Federation Not addressed Not addressed Not addressed
Serbia 3 3 Unknown
Singapore 2 2 2
Slovenia 2 2 2
South Africa 3 3 3
The Republic of
Korea
Unknown Not addressed Not addressed
Spain 3 3 3
Sweden 1 1 1
Switzerland 3 3 3
Taiwan (China*) 4 4 4
Thailand 2 2 3
Togo Not addressed Not addressed Not addressed
Trinidad and
Tobago
Not addressed Not addressed Not addressed
Tunisia Not addressed Not addressed 3
Turkey 1 2 2
United Arab
Emirates
Not addressed Not addressed Not addressed
UK 2 2 3
USA 2 3 5
Uruguay 2 2 2
Venezuela Not addressed Not addressed Not addressed
Viet Nam Not addressed Not addressed Not addressed
Zimbabwe Not addressed Not addressed Not addressed
*Reporting separately for this report.
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• Oocyte age 35-39: 5 countries limited to 1 embryo, 13
countries=2 embryos, 21 countries=3 embryos, 2 countries=
4 embryos, 21 countries=not addressed, and 6 countries
responded “unknown”; and
• Oocytes age > 40: 3 countries limited to 1 embryo, 10
countries=2 embryos, 20 countries=3 embryos, 4 coun-
tries=4 embryos, 1 country=5 embryos, 2 countries=not
addressed, and 6 countries responded “unknown”.
To the question regarding existence of criteria for the number
of embryos to be transferred for donor oocyte recipients, 75
countries responded, as follows: “yes”, 28 countries (38%);
“no”, 19 countries (25%); “unknown”, 4 countries (5%); and
“not addressed”, 24 (32%).
When considering the age of the donor, 76 countries provided
responses: 27 countries (35.5%) answered “yes”, 18 answered
(24%) “no”, 5 answered (6.5%) “unknown”, and 26 answered
(34%) “not addressed”
Regarding the quality of the embryos as a determinant, 78
countries provided responses: 44 countries answered (56%)
“yes”, 12 answered (15%) “no”, 3 answered (5%) “unknown”,
and 19 answered (24%) “not addressed”.
Regarding the stage of the embryo (cleavage or blastocyst
stage), 78 countries provided responses: 45 countries answered
(58%) “yes”, 10 answered (13%) “no”, 4 answered (5%)
“unknown”, and 19 answered (24%) “not addressed”.
Table 3 lists the countries’ individual policies regarding the
number of embryos allowed for transfer.
Chapter 5. Table 3
What is the number of embryos to be transferred based on?
Country








Argentina No No No Yes
Armenia Yes Yes Yes Yes
Australia No No No No
Austria Not addressed Not addressed Yes Yes
Belarus Yes Not addressed Not addressed Not addressed
Belgium No No No No
Bolivia Yes Yes Yes Yes
Botswana Not addressed Not addressed Not addressed Not addressed
Brazil No Yes Yes Yes
Bulgaria Yes No No No
Burkina Faso Unknown Yes Yes No
Cameroon Yes No Yes Yes
Canada No Yes No Yes
China Yes
Colombia Yes No Yes Yes
Congo Unknown Unknown Unknown Unknown
Côte d’Ivoire Yes Yes Yes Yes
Czechia No No No No
Ecuador Yes Yes Yes Yes
El Salvador Not addressed Not addressed Not addressed Not addressed
Finland Yes No Yes Yes
Georgia Not addressed Not addressed Not addressed Not addressed
Germany Unknown Unknown Unknown Unknown
Ghana Yes Yes Yes Yes
Greece Yes Yes Yes Yes
Guatemala Yes Yes Yes Yes
Hong Kong
(China*)
Not addressed Not addressed Not addressed Not addressed
Hungary Not addressed Not addressed Not addressed Not addressed
Iceland Yes Yes Yes Yes
India Not addressed Not addressed Not addressed Not addressed
Ireland Not addressed Not addressed Yes Yes
Italy Yes Yes Yes Yes
Japan Not addressed Not addressed
Jordan Not addressed Not addressed Yes Yes
Kazakhstan Yes No Yes Yes
Kenya Not addressed Not addressed Not addressed Not addressed
Latvia Yes No Yes Yes
Lithuania Yes Not addressed Yes Yes
Mali No No Yes Yes
Mexico No Yes Yes Yes
Mongolia Not addressed Not addressed Not addressed Not addressed
Montenegro Yes Yes
Namibia No Yes Yes Yes
Netherlands Yes Yes Yes No
New Zealand No Yes Yes Yes
Nicaragua Yes Yes Yes Yes
Nigeria Yes Yes Yes Yes
Norway Yes Yes
Panama Not addressed Not addressed Not addressed Not addressed
Paraguay No Yes Yes Yes
Philippines Yes Yes Yes Yes
Poland Unknown Unknown Unknown Unknown
Portugal Yes Unknown Yes Yes
Romania Yes Yes Yes Yes
Russian
Federation
Not addressed Not addressed Not addressed Not addressed
Senegal Not addressed Not addressed Yes Yes
Serbia Yes Unknown Yes Yes
Singapore Yes No No Yes
Chapter 5. Table 3
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Country








Slovenia No Yes Yes Yes
South Africa Not addressed Not addressed Not addressed Not addressed
The Republic
of Korea
Not addressed Not addressed No Yes
Spain Yes No Yes Yes
Sri Lanka No No No No
Sweden No No No No
Switzerland No No No No
Taiwan
(China*)
Not addressed Not addressed Not addressed Not addressed
Thailand No No Yes Yes
Togo Not addressed Not addressed Not addressed Not addressed
Trinidad and
Tobago
Not addressed Not addressed Not addressed Not addressed
Tunisia Not addressed Not addressed Yes Yes
Turkey No No No No
Uganda Yes Yes Yes Yes
United Arab
Emirates
Not addressed Not addressed Yes Unknown
UK No Yes Yes Yes
USA No Yes Yes Yes
Uruguay Yes Yes Yes Yes
Venezuela Not addressed Not addressed Not addressed Not addressed
Viet Nam Not addressed Not addressed Not addressed Not addressed
Zimbabwe Not addressed Not addressed Not addressed Not addressed
*Reporting separately for this report.
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Discussion
In 2010, Turkey introduced legislation that mandates, regardless
of embryo quality, SET for the first one or two cycles in women
under the age of 35[7]. Similarly, Belgium, Canada, and Sweden
have comparable restrictions mandating SET in young
women[8,9]. In 2013, in an effort to reduce the twin birth rate to
10%[10,11], guidelines were issued in the United Kingdom of
Great Britain and Northern Ireland instructing clinicians to use
SET for first cycles for women under 37 years of age, and also for
second cycles, if a top-quality embryo is available. In Australia,
Denmark, Finland, NewZealand, and Norway, the vast majority
(85.2%) of embryo transfer cycles for women under 35 years of
age are currently conducted as SET[12,13].
In The United States of America, the guidelines of the American
Society for Reproductive Medicine (ASRM) state, for women
at any age: transfer only one euploid embryo[14,15]. For good
prognosis, patients under 35 years of age (first cycle of IVF, prior
IVF success, or good morphology embryos), transfer should be
limited to one embryo; patients between 35 to 37 years of age, SET
should be strongly suggested. Despite the stricter ASRM guidelines,
preliminary data from the 2016 Society for Assisted Reproductive
Technologies Clinic Summary Report show that fewer than 40% of
transfers performed in The United States of America were SET.[16]
Summary
The evidence from the 2018 IFFS Surveillance Survey shows no
meaningful increase in the proportion of countries with legisla-
tion or clinical guidelines restricting the number of embryos
permissible for transfer to women undergoing IVF/ART cycles:
59%, vs. 56% in 2015. More countries (35%, vs 24% in 2015)
now report the presence of penalties for non-compliance
regarding the number of embryos transferred.
Compared to 2016 data, progress in the actual reduction of the
number of embryos transferred has beenmore gradual, with 10%
of countries reporting mandatory SET for patients <35 years of
age, 7% of the countries reporting mandatory SET for patients
aged 35-39 years, and 6.5% of countries reporting mandatory
SET for patients > 40 years old.
Recent advances in embryo culture systems, embryo selection
methods, preimplantation genetic testing, and cryopreservation
technology are leading to improved embryo implantation rates,
but this putative advantage has not yet led to wider adoption
of SET.
References
[1] Office for National Statistics. Statistical bulletin: Childhood,
Infant and Perinatal Mortality in England and Wales: 2013;
March 2015.
[2] Kulkarni AD, JamiesonDJ, JonesHW, et al. Fertility treatments
andmultiple births in theUnited States.NEngl JMed 2013;369
(23):2218–2225. doi:10.1056/nejmoa1301467.
[3] Gardner DK, Lane M. Culture and selection of viable
blastocysts: a feasible proposition for human IVF? Hum
Reprod Update 1997;3:367–382.
[4] Gardner DK, Lane M, Stevens J, et al. Blastocyst score
affects implantation andpregnancy outcome: towards a single
blastocyst transfer. Fertil Steril 2000;73:1155–1158.
[5] Maheshwari A, Griffiths S, Bhattacharya S. Global variations
in the uptake of single embryo transfer. Hum Reprod Update
2011;17(1):107–120.
[6] Harton G, Munne S, Surrey M, et al. Diminished effect of
maternal age on implantation after preimplantation genetic
diagnosis with array comparative genomic hybridization.
Fertil Steril 2013;100:1695–1703.
[7] Ercan CM, Kerimoglu OS, Sakinci M, et al. Pregnancy
outcomes in a university hospital after legal requirement for
single-embryo transfer. Eur J Obstet Gynecol Reprod Biol
2014;175:163–166.
[8] Bissonnette F, Phillips SJ, Gunby J, et al. Working to elim-
inate multiple pregnancies: a success story in Québec.
Reprod BioMed Online 2011;23(4):500–504.
[9] Kupka MS, Ferraretti AP, de Mouzon J, et al. European IVF-
Monitoring Consortium, for the European Society of Human
Reproduction and Embryology. Assisted reproductive tech-
nology in Europe, 2010: results generated from European
registers by ESHRE. Hum Reprod 2014;29(10):2099–2113.
[10] NICE, 2013. Available at: www.nice.org.uk/guidance/
CG156/chapter/1-Recommendations#procedures-used-dur
ing-ivf-treatment. Accessed January 16, 2019.
[11] Harbottle S, Hughes C, Cutting R, et al. Association of Clinical
Embryologists (ACE) & The British Fertility Society (BFS).
Elective single embryo transfer: an update to UK Best Practice
Guidelines. Hum Fertil 2015;18(3):165–183.
[12] Maheshwari A, Griffiths S, Bhattacharya S. Global varia-
tions in the uptake of single embryo transfer. Hum Reprod
Update 2011;17(1):107–120.
[13] Macaldowie A, Wang Y, Chughtai A, et al. 2014. Assisted
Reproductive Technology in Australia and New Zealand
2012. National Perinatal Epidemiology and Statistics Unit.




Accessed January 16, 2019.
[14] Penzias A, Bendikson K, Butts S, et al. Guidance on the
limits to the number of embryos to transfer: a committee
opinion. Fertil Steril 2017;107(4):901–903. doi:10.1016/j.
fertnstert.2017.02.107.
[15] Practice Committee of the Society for Assisted Reproductive
Technology, Practice Committee of the American Society for
Reproductive Medicine. Elective single-embryo transfer.
Fertil Steril 2017;97:835–842.
[16] Society for Assisted Reproductive Technology. CSR 2016.
Available at: https://www.sartcorsonline.com/rptCSR_Public




Cryopreservation is one of the most significant recent advance-
ments in assisted reproduction technology (ART). Although
interest in human tissue cryopreservation has existed for more
than 200 years, significant progress in reproductive applications
has occurred only in the last two or three decades.
The development of slow-freezing techniques and vitrification
technology, and expansion in various combinations of newer cryo-
protectants, have considerably advanced the field of ART. Sperm,
oocytes, and embryos can now be frozen at various stages of devel-
opment, making treatment potentially safer and more effective[1].
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Chapter 6. Table 1
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Portugal Yes Yes Yes
Romania Yes Yes
Russian Federation Yes
Senegal Yes Yes Yes Yes Yes
Serbia Yes
Singapore Yes
Slovenia Yes Yes Yes
South Africa Yes








Trinidad and Tobago Yes
Turkey Yes Yes
Uganda Yes




































Greece Yes Yes Yes Yes Yes Yes Yes Yes
Guatemala Yes
Hong Kong (China*) Yes Yes
Hungary Yes Yes
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Portugal Yes Yes Yes
Romania Yes Yes
Russian Federation Yes
Senegal Yes Yes Yes
Serbia Yes
Singapore Yes
Slovenia Yes Yes Yes
South Africa Yes








Trinidad and Tobago Yes
Turkey Yes Yes
Uganda Yes














Australia Yes Yes Yes
Austria Yes
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Greece Yes Yes Yes
Guatemala Yes


























Portugal Yes Yes Yes
Romania Yes Yes
Russian Federation Yes
Senegal Yes Yes Yes Yes Yes
Singapore Yes
Slovenia Yes Yes Yes
South Africa Yes
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Trinidad and Tobago Yes
Turkey Yes Yes
Uganda Yes
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Trinidad and Tobago Yes
Uganda Yes
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Trinidad and Tobago Yes
Uganda Yes
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Trinidad and Tobago Yes
Uganda Yes












































New Zealand Yes Yes
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Trinidad and Tobago Yes
Tunisia
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New Zealand Yes Yes
Nicaragua Yes
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Trinidad and Tobago Yes
Turkey Yes
Uganda Yes
United Arab Emirates Yes Yes
UK Yes
USA Yes































IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29 Global Reproductive Health
64



















































































Trinidad and Tobago Yes
Tunisia
Turkey Yes
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Greece Yes Yes Yes Yes
Guatemala Yes





















Portugal Yes Yes Yes
Russian Federation Yes
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The chief objectives of cryopreservation are to make gametes
or embryos available for future use by individuals or couples
undergoing infertility treatment, and to preserve future fertility
options for individuals at risk of losing their reproductive
potential. Cryopreservation also offers the opportunity to
forestall pregnancy to a safer, more optimal time. This is
important for patients who are at risk of ovarian hyper-
stimulation syndrome (OHSS), or who have poor endometrial
receptivity.
Frozen embryo transfer (FET) is a procedure – a cycle – in
which frozen embryos are thawed, then transferred to a uterus.
The improved results of embryo cryopreservation have been an
essential component of preimplantation genetic diagnosis and
screening.
The improved results of embryo cryopreservation have been an
essential component for preimplantation genetic diagnosis/
screening, using trophectoderm biopsy and array comparative
genomic hybridization (CGH microarray) or Next Gen
Sequencing (NGS). Blastocysts can be frozen, and genetic testing
performed before the blastocysts are transferred[2]. Embryo
cryopreservation offers a way to avoid repeated ovarian stimu-
lation, optimizes achieving embryo-endometrial synchrony, and
aids in single embryo transfer (SET)[3].
Analysis of the survey
Cryopreservation for fertility treatment
None of the respondent countries cited explicit prohibition of
cryopreservation of sperm, oocytes, or pre-implantation embryos
for fertility treatment. Cryopreservation for fertility treatment
(Table 1) is expressly allowed or permitted for sperm in 71 of 83
(86%) of countries responding; for oocytes, in 68 of 82 (83%);
and in all stages of pre-implantation embryos, in 66 out of 82
(80%). There are no regulations for cryopreservation for fertility
treatment for sperm, according to 35 of 82 responders (43%); for
oocytes, in 33 of 82 (40%); and all stages of pre-implantation
embryos, in 32 of 82 (39%).
For countries that regulated cryopreservation for fertility
treatment, the following were used to govern:
• Federal/national laws/statutes/ordinances were used for sperm
in 39 of 82 (47.5%); to govern oocytes, only 3 of 82 (4%); and
all stages of pre-implantation embryos, 36 of 82 (44%);
• State/provincial/regional laws/statutes/ordinances: sperm,
oocytes, and all stages of pre-implantation embryos: 7 of 82
(8.5%);
• Municipal laws/statutes/ordinances: sperm and all stages of
pre-implantation embryos: only 2 of 82 respondents (2%) and
oocytes: only 3 of 82 (4%);


























































*Reporting separately for this report.
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Chapter 6. Table 2a
What is the maximum duration of storage?
Country










Argentina Not addressed Not addressed Not addressed Not addressed Not addressed
Armenia Unknown Not addressed Not addressed Not addressed Not addressed
Australia Not addressed Not addressed Not addressed Not addressed Not addressed
Austria No Limit No Limit No Limit No Limit No Limit
Bangladesh No Limit No Limit No Limit
Belarus No Limit No Limit No Limit No Limit No Limit
Belgium Unknown Unknown Unknown Unknown Unknown
Bolivia No Limit Not addressed No Limit No Limit No Limit
Botswana Not addressed Not addressed Not addressed Not addressed Unknown
Brazil No Limit No Limit No Limit No Limit No Limit
Bulgaria 5 y 5 y 5 y 5 y 5 y
Burkina Faso No Limit No Limit No Limit No Limit No Limit
Cameroon 5 y
Canada No Limit No Limit No Limit No Limit No Limit
Chile No Limit No Limit No Limit No Limit No Limit
China No Limit No Limit No Limit
Colombia No Limit No Limit No Limit No Limit No Limit
Czechia Unknown Unknown Unknown Unknown Unknown
Congo Not addressed Not addressed Not addressed Not addressed Unknown
Ecuador No Limit No Limit No Limit No Limit No Limit
Egypt No Limit No Limit No Limit No Limit No Limit
El Salvador No Limit No Limit No Limit
Finland No Limit No Limit No Limit No Limit No Limit
Georgia Not addressed Not addressed Not addressed Not addressed Not addressed
Germany Unknown Unknown Unknown Unknown Unknown
Ghana No Limit No Limit No Limit No Limit No Limit
Greece 25 y 25 y No Limit No Limit No Limit
Guatemala No Limit No Limit No Limit Not addressed Not addressed
Hong Kong (China*) 10 y Not addressed 10 y Not addressed 10 y
Hungary Unknown Not addressed Not addressed Not addressed Not addressed
Iceland 10 y 10 y 10 y 10 y 10 y
India Not addressed Not addressed Not addressed Not addressed Not addressed
Ireland 10 y 10 y 10 y Not addressed Not addressed
Italy Not addressed Not addressed Not addressed Not addressed Not addressed
Côte d’Ivoire No Limit Not addressed Not addressed Not addressed No Limit
Japan No Limit Not addressed No Limit Not addressed Not addressed
Jordan Not addressed Not addressed Not addressed Not addressed Not addressed
Kazakhstan No Limit No Limit No Limit No Limit No Limit
Kenya Not addressed Not addressed Not addressed Not addressed
Latvia No Limit No Limit No Limit No Limit No Limit
Lithuania No Limit Not addressed No Limit Not addressed Unknown
Mali No Limit Unknown Unknown Unknown Unknown
Mexico No Limit No Limit No Limit Not addressed Not addressed
Mongolia Not addressed Not addressed Not addressed Not addressed Not addressed
Montenegro No Limit No Limit No Limit No Limit No Limit
Namibia No Limit No Limit No Limit Not addressed Not addressed
Netherlands No Limit No Limit No Limit No Limit No Limit
New Zealand 10 y 10 y 10 y 10 y 10 y
Nicaragua 5 y 5 y 5 y 5 y 5 y
Nigeria Unknown
Norway Not addressed Not addressed
Panama Not addressed Not addressed Not addressed Not addressed Not addressed
Paraguay No Limit No Limit No Limit No Limit No Limit
Peru Unknown Unknown Unknown Unknown Unknown
Poland Unknown Unknown Unknown
Portugal 5 y 5 y 5 y 5 y 5 y
Romania Not addressed Not addressed Not addressed Not addressed Not addressed
Russian Federation No Limit No Limit No Limit No Limit No Limit
Senegal Not addressed Not addressed Not addressed Not addressed Not addressed
Serbia 2 y 2 y Unknown 1 y No Limit
Singapore 10 y 0 y 10 y 0 y 10 y
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Chapter 6. Table 2a
(Continued)
Country










Slovenia No Limit No Limit No Limit
South Africa No Limit No Limit No Limit No Limit No Limit
The Republic of Korea No Limit No Limit No Limit No Limit No Limit
Spain No Limit No Limit No Limit No Limit No Limit
Switzerland 10 y 10 y No Limit 10 y No Limit
Taiwan (China*) 10 y 10 y 10 y Not addressed Not addressed
Thailand No Limit No Limit No Limit No Limit No Limit
Togo No Limit Not addressed No Limit Not addressed No Limit
Trinidad and Tobago Not addressed Not addressed Not addressed Not addressed Not addressed
Turkey 5 y 5 y 5 y
Uganda 10 y 10 y 10 y Unknown Unknown
United Arab Emirates 5 y 5 y 5 y Unknown Unknown
UK 55 y 10 y 55 y No Limit No Limit
USA No Limit No Limit No Limit No Limit No Limit
Uruguay No Limit No Limit No Limit No Limit No Limit
Venezuela No Limit No Limit No Limit No Limit No Limit
Viet Nam Not addressed Not addressed Not addressed Not addressed Not addressed
Zimbabwe No Limit No Limit No Limit No Limit No Limit
*Reporting separately for this report.
Chapter 6. Table 2b
What is the maximum duration of storage?
Country










Argentina Not addressed Not addressed Not addressed Not addressed Not addressed
Armenia Not addressed Not addressed Not addressed Not addressed Not addressed
Australia Not addressed Not addressed Not addressed Not addressed Not addressed
Austria No Limit No Limit No Limit No Limit No Limit
Bangladesh No Limit No Limit No Limit
Belarus No Limit No Limit No Limit No Limit No Limit
Belgium Unknown Unknown Unknown Unknown Unknown
Bolivia No Limit No Limit No Limit No Limit No Limit
Botswana Not addressed Not addressed Not addressed Not addressed Not addressed
Brazil No Limit No Limit No Limit No Limit No Limit
Bulgaria 5 y 5 y 5 y Not addressed Not addressed
Burkina Faso No Limit No Limit No Limit Unknown
Canada No Limit No Limit No Limit No Limit No Limit
Chile No Limit No Limit No Limit No Limit No Limit
China No Limit No Limit No Limit
Colombia No Limit No Limit No Limit No Limit No Limit
Czechia Unknown Unknown Unknown Unknown Unknown
Congo Not addressed Not addressed Not addressed
Ecuador No Limit No Limit No Limit No Limit No Limit
Egypt No Limit No Limit No Limit No Limit No Limit
El Salvador No Limit No Limit No Limit
Finland No Limit No Limit No Limit No Limit No Limit
Georgia Not addressed Not addressed Not addressed Not addressed Not addressed
Germany Unknown Unknown Unknown Unknown Unknown
Ghana No Limit No Limit No Limit No Limit No Limit
Greece 25 y No Limit No Limit No Limit No Limit
Guatemala No Limit No Limit No Limit Not addressed Not addressed
Hong Kong (China*) 10 y Not addressed 10 y Not addressed 10 y
Hungary Not addressed Not addressed Not addressed Not addressed Not addressed
Iceland 10 y 10 y 10 y 10 y 10 y
India Not addressed Not addressed Not addressed Not addressed Not addressed
Ireland 10 y 10 y 10 y Not addressed Not addressed
Italy Not addressed No Limit No Limit No Limit Not addressed
Côte d’Ivoire Unknown Not addressed Not addressed Not addressed Not addressed
Japan No Limit Not addressed No Limit Not addressed No Limit
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• Agency regulations/oversight: sperm: 10 of 82 respondents
(12%); all stages of pre-implantation embryos, and oocytes as
well: 11 out of 82 (13%);
• Professional organization standards/guidelines: sperm, 24 of
82 respondents (29%); oocytes, 23 of 82 (28%); and all stages
of pre-implantation embryos: 21 of 82 (26%);
• Cultural practices to govern sperm: only 1 of 82 (1%), and all
stages of pre-implantation embryos andoocytes: 2 of 82 (2%); and
• Religious decree: oocytes: 1 out of 82 responders (1%).
Duration of storage for fertility treatment
Duration of storage for fertility treatment was not limited for
sperm in 38 out of 79 (48%); for oocytes, 36 out of 75 (48%); and
for all stages of pre-implantation embryos: 33 out of 76 (43%).
The duration of storage was limited for sperm in 17 of 79 (22%);
oocytes, 16 of 75 (21%); and all stages of pre-implantation
embryos: 19 of 76 (25%). The duration of storage was not
addressed for sperm in 16 of 79 (20%); for oocytes, in 17 of 75
(23%); and for all stages of pre-implantation embryos in 18 of 76
(24%). The duration of storage for sperm was unknown in 8 of
79 (10%); for oocytes, in 6 of 75 (8%); and in all stages of pre-
implantation embryos, 6 of 76 responders (8%).
The following durations were reported:
• Sperm: 2 years (Serbia); 5 years (Bulgaria, Cameroon,
Nicaragua, Portugal, Turkey, and United Arab Emirates);
10 years (Hong Kong [China, reporting separately for
this report], Iceland, Ireland, New Zealand, Singapore,
Chapter 6. Table 2b
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Country










Jordan Not addressed Not addressed Not addressed Not addressed Not addressed
Kazakhstan No Limit No Limit No Limit No Limit No Limit
Kenya Not addressed Not addressed Not addressed Not addressed
Latvia No Limit No Limit No Limit No Limit No Limit
Lithuania No Limit Not addressed No Limit No Limit Unknown
Mali 5 y Unknown Unknown Unknown Unknown
Mexico No Limit No Limit No Limit Not addressed Not addressed
Mongolia Not addressed Not addressed Not addressed Not addressed Not addressed
Montenegro No Limit No Limit No Limit No Limit No Limit
Namibia No Limit Not addressed Not addressed Not addressed Not addressed
Netherlands No Limit No Limit No Limit No Limit No Limit
New Zealand 10 y 10 y 10 y 10 y 10 y
Nicaragua 5 y 5 y 5 y 5 y
Nigeria Unknown
Norway Not addressed Not addressed Not addressed Unknown Not addressed
Panama Not addressed Not addressed Not addressed Not addressed Not addressed
Paraguay No Limit No Limit No Limit Not addressed Not addressed
Peru Unknown Unknown Unknown Unknown Unknown
Portugal 5 y 5 y 5 y 5 y 5 y
Romania Not addressed Not addressed Not addressed Not addressed Not addressed
Russian Federation No Limit No Limit No Limit No Limit No Limit
Senegal Not addressed Not addressed Not addressed Not addressed Not addressed
Serbia 2 y Not addressed Not addressed Not addressed
Singapore 10 y 0 y 10 y 0 y 10 y
Slovenia No Limit No Limit No Limit
South Africa No Limit No Limit No Limit No Limit No Limit
The Republic of Korea No Limit No Limit No Limit No Limit No Limit
Spain No Limit No Limit No Limit No Limit No Limit
Switzerland 10 y 10 y No Limit 10 y
Taiwan (China*) 10 y 10 y 10 y Not addressed Not addressed
Thailand No Limit No Limit No Limit No Limit No Limit
Togo No Limit Not addressed No Limit Not addressed Not addressed
Trinidad and Tobago Not addressed Not addressed Not addressed Not addressed Not addressed
Turkey 5 y 5 y 5 y
Uganda 10 y 10 y 10 y Unknown Unknown
United Arab Emirates 5 y Not addressed 5 y Unknown Unknown
United Kingdom of Great Britain
and Northern Ireland
10 y 10 y 55 y No Limit No Limit
The United States of America No Limit No Limit No Limit No Limit No Limit
Uruguay No Limit No Limit No Limit Not addressed No Limit
Venezuela No Limit No Limit No Limit No Limit No Limit
Viet Nam Not addressed Not addressed Not addressed Not addressed Not addressed
Zimbabwe No Limit No Limit No Limit No Limit No Limit
*Reporting separately for this report.
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Switzerland, Taiwan [China, reporting separately for this
report], and Uganda); 25 years (Greece); and 55 years
(United Kingdom of Great Britain and Northern Ireland)
(Table 2a).
• Oocytes: 2 years (Serbia); 5 years (Bulgaria, Mali, Portugal,
Turkey, and United Arab Emirates); 10 years (Hong Kong
[China, reporting separately for this report], Iceland, Ireland,
New Zealand, Singapore, Switzerland, Taiwan [China,
reporting separately for this report], Uganda, and United
Kingdom of Great Britain andNorthern Ireland); and 25 years
(Greece) (Table 2b); and
• All stages of preimplantation embryos: 5 years (Bulgaria,
Cameroon, Mali, Norway, and The Republic of Korea);
10 years (Australia, Austria, Hong Kong [China, reporting
separately for this report], Hungary, Iceland, Ireland, New
Zealand, Singapore, Slovenia, Switzerland, Taiwan [China,
reporting separately for this report], Uganda, and the United
Kingdom of Great Britain and Northern Ireland); and
25 years (Greece) (Table 2c).
Cryopreservation for fertility preservation, medical
indications
None of the respondent countries cited explicit prohibition of
cryopreservation of sperm, oocytes, or pre-implantation embryos
for fertility preservation. Cryopreservation for fertility preserva-
tion for medical indications (Table 1) is expressly allowed/per-
mitted for sperm in 68 of 81 (84%) of responding countries; for
Chapter 6. Table 2c














Argentina Not addressed Not addressed Not addressed
Armenia Not addressed Not addressed Not addressed
Australia 10 y Not addressed Not addressed
Austria 10 y Not addressed 10 y
Bangladesh No Limit No Limit
Belarus No Limit No Limit No Limit
Belgium Unknown Unknown Unknown
Bolivia No Limit No Limit No Limit
Botswana Not addressed Not addressed
Brazil No Limit No Limit No Limit
Bulgaria 5 y 5 y 5 y
Burkina Faso No Limit No Limit
Cameroon 5 y
Canada No Limit No Limit No Limit
Chile No Limit No Limit No Limit
China No Limit No Limit
Colombia No Limit No Limit No Limit
Czechia Unknown Unknown Unknown
Congo Not addressed Not addressed Not addressed
Ecuador No Limit No Limit
Egypt No Limit No Limit No Limit
El Salvador No Limit
Finland No Limit No Limit No Limit
Georgia Not addressed Not addressed Not addressed
Germany Unknown Unknown Unknown
Ghana No Limit No Limit No Limit
Greece 25 y No Limit No Limit
Guatemala No Limit No Limit No Limit
Hong Kong
(China*)
10 y Not addressed 10 y
Hungary 10 y Not addressed 10 y
Iceland 10 y 10 y 10 y
India Not addressed Not addressed Not addressed
Ireland 10 y 10 y 10 y
Italy Not addressed No Limit No Limit
Côte d’Ivoire No Limit Not addressed Not addressed
Japan No Limit Not addressed No Limit
Jordan Not addressed Not addressed Not addressed
Kazakhstan No Limit No Limit No Limit
Kenya Not addressed Not addressed Not addressed
Latvia No Limit No Limit No Limit
Lithuania No Limit Not addressed No Limit
Mali 5 y Unknown Unknown
Mexico Not addressed Not addressed Not addressed
Mongolia Not addressed Not addressed Not addressed
Montenegro No Limit No Limit No Limit
Namibia No Limit Not addressed Not addressed
Netherlands No Limit No Limit No Limit
New Zealand 10 y 10 y 10 y
Nicaragua Unknown Unknown Unknown
Nigeria Unknown
Norway 5 y 5 y
Panama Not addressed Not addressed Not addressed
Paraguay No Limit No Limit No Limit
Peru Unknown Unknown Unknown
Portugal Not addressed Not addressed Unknown
Romania Not addressed Not addressed Not addressed
Russian
Federation
No Limit No Limit No Limit















Senegal Not addressed Not addressed Not addressed
Serbia Not addressed Unknown
Singapore 10 y 0 y 10 y
Slovenia 10 y No Limit
South Africa No Limit No Limit No Limit
The Republic of
Korea
5 y 5 y 5 y
Spain No Limit No Limit No Limit
Switzerland 10 y 10 y 10 y
Taiwan (China*) 10 y 10 y 10 y
Thailand No Limit No Limit No Limit
Togo No Limit Not addressed Not addressed
Trinidad and
Tobago
Not addressed Not addressed Not addressed
Turkey Not addressed Not addressed
Uganda 10 y Unknown Unknown
United Arab
Emirates
Not addressed Not addressed Not addressed
UK 10 y 10 y 10 y
USA No Limit No Limit No Limit
Uruguay No Limit No Limit No Limit
Venezuela No Limit No Limit No Limit
Viet Nam Not addressed Not addressed Not addressed
Zimbabwe No Limit No Limit No Limit
*Reporting separately for this report.
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oocytes, in 60 of 83 (82%); for pre-implantation embryos (all
stages), in 62 of 82 (76%); for ovarian tissue, in 52 of 83 (65%);
and for testicular tissue, in 53 of 82 (65%).
Countries reporting that cryopreservation to maintain fertility
for medical indications is commonly performed for sperm in 28 of
439 countries (72%); for oocytes, in 18 out of 40 (45%); for all
stages of pre-implantation embryos, in 19 of 42 (45%); for
ovarian tissue, in 7 of 48 (14.5%); and for testicular tissue, 9 of 47
(19%).
Cryopreservation for fertility preservation, non-medical
indications
According to responders, cryopreservation in non-medical indica-
tions is specifically allowed/permitted for sperm in 60 of 82 (73%);
for oocytes, in 56 out of 81 (69%); for pre-implantation embryos
(all stages), 51 of 82 (62%); for ovarian tissue, 44 of 82 (54%); and
for testicular tissue, 45 of 83 (54%). Cryopreservation for fertility
preservation in non-medical indications is frequently performed as
follows: for sperm, 16 of 42 (38%); oocytes, 18 of 42 (43%); all
stages of pre-implantation embryos, 8 of 43 (19%); ovarian tissue,
3 of 48 (6%); and testicular tissue, 4 of 49 (8%).
In 80 countries surveyed, 33 (41%) have no regulations for
cryopreservation performed to preserve fertility for sperm and
oocytes in all stages of pre-implantation embryos; 31 (39%); 30
(37.5%) have none for ovarian tissue; and 31 (39%) have none
for testicular tissue.
Countries that regulated cryopreservation for fertility treat-
ment provided responses, summarized below, indicating how
uses were governed. (In all cases there were 80 responders):
• Federal/national laws/statutes/ordinances governed sperm
and oocyte cryopreservation in 28 (35%); pre-implantation
embryos, all stages, in 27 (34%); ovarian tissue, in 18 (23%);
and testicular tissue, in 17 (21%);
• State/provincial/regional laws/statutes/ordinances governed sperm
cryopreservation in 2 (3%); oocytes, in 3 (4%); and all stages of
pre-implantation embryos, ovarian tissue, and testicular tissue, in
1 (1%);
• Municipal laws/statutes/ordinances were used to govern
testicular tissue in 1 (1%);
• Agency regulations/oversight governed sperm in 6 (8%);
oocytes in 3 (4%); and pre-implantation embryos (all stages),
ovarian tissue, and testicular tissue in 4 (5%);
• Professional organization standards/guidelines were used to gov-
ern sperm in 20 (25%); oocytes, 19 (24%); pre-implantation
embryos, all stages, 18 (23%); ovarian tissue, 14 (18%); and
testicular, 15 (19%);
• Cultural practices governed sperm and oocytes in 2 (3%), and
in pre-implantation embryos (all stages), ovarian tissue, and
testicular tissue (1%); and
• Religious decree was used to govern ovarian tissue in 1
instance (1%).
Duration of storage for fertility treatment for medical
indications
Listed below is the duration of storage for fertility preservation
for medical indications. Storage duration was not limited for
sperm in 38 of 77 (49%) countries; for oocytes, in 38 of 74 (51%)
countries; for pre-implantation embryos (all stages), in 31 of 74
(42%), in ovarian tissue, in 30 of 74 (40%); and in testicular
tissue, in 35 of 74 (47%).
The duration of storage was limited for sperm in 13 of 77
(17%) countries; for oocytes, in 13 of 74 (18%); all stages of pre-
implantation embryos, in 18% of 74; for ovarian tissue, in 9% of
74, and for testicular tissue, in 11%. The duration of storage was
not addressed for sperm in 19 of 77 (25%); for oocytes, in 18 of
74 (24%); all stages of pre-implantation embryos, 21 of 74
(28%); ovarian tissue, 28 of 74 (38%); and testicular tissue, 21 of
74 (28%). The duration of storage was unknown for sperm in 7
of 77 countries (9%); for oocytes, in 5 of 74 (7%); for all stages of
pre-implantation embryos, in 9 of 74 (12%); for ovarian tissue, in
9 of 74 (12%); and for testicular tissue, in 10 in 74 (14%).
The following durations were reported:
• Sperm: 5 years (Bulgaria, Nicaragua, Portugal, Turkey, and
United Arab Emirates); 10 years (Hong Kong [China, reporting
separately for this report], Iceland, Ireland, New Zealand,
Singapore, Taiwan [China, reporting separately for this report],
and Uganda); and 55 years (United Kingdom of Great Britain
and Northern Ireland);
• Oocytes: 5 years (Bulgaria, Nicaragua, Portugal, Turkey, and
United Arab Emirates); 10 years (Hong Kong [China, report-
ing separately for this report], Iceland, Ireland, New Zealand,
Singapore, Taiwan [China, reporting separately for this
report], and Uganda); 55 years (United Kingdom of Great
Britain and Northern Ireland);
• All Stages of preimplantation embryos: 5 years (Bulgaria,
Norway, and TheRepublic of Korea); 10 years (Austria, Hong
Kong [China, reporting separately for this report], Iceland,
Ireland, New Zealand, Singapore, Switzerland, Taiwan
[China, reporting separately for this report], and the United
Kingdom of Great Britain and Northern Ireland);
• Ovarian Tissue: 5 years (Nicaragua, Portugal, and Turkey);
10 years (Hong Kong [China, reporting separately for this
report], Iceland, New Zealand, and Singapore); and
• Testicular tissue: 5 years (Bulgaria, Nicaragua, Portugal, and
Turkey); 10 years (Hong Kong [China, reporting separately
for this report], Iceland, New Zealand, and Singapore).
Duration of storage for fertility treatment for non-medical
indications
The duration of storage for fertility preservation for non-medical
indications was not limited, as follows: for sperm, in 29 of 70
(41%); for oocytes, in 30 of 70 (43%); in all stages of pre-
implantation embryos, in 26 of 68 (38%); in ovarian tissue, 28 of
69 (40%); and testicular tissue, in 28 of 69 (41%).
The duration of storage was limited, however, as follows: for
sperm, in 13 of 70 (19%); for oocytes, in 10 of 70 (14%); in all
stages of pre-implantation embryos, in 8 of 68 (12%); in ovarian
tissue, in 5 of 69 (7%); and in testicular tissue, in 7 out of 69
(10%).
The duration of storage was not addressed, as follows: for
sperm, in 22 of 70 (31%); for oocytes, in 25 of 70 (36%); all
stages of pre-implantation embryos, in 27 of 68 (40%); ovarian
tissue, 28 of 69 (40%); and testicular tissue in 27 of 69 (39%).
In some cases, the duration of storage was unknown. These
include: for sperm, 6 of 70 (8%); for oocytes, 5 of 70 (7%); for all
stages of pre-implantation embryos, 7 of 68 (10%); for ovarian
tissue, 8 of 69 (12%); and for testicular tissue, 7 of 69 (10%).
The following durations for storage were reported:
• Sperm: 2 years (Serbia); 5 years (Bulgaria, Nicaragua,
Portugal, and United Arab Emirates); 10 years (Iceland,
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Chapter 6. Table 3a
Is cryopreservation for fertility treatment or fertility preservation allowed/permitted or practiced/performed in your country?
Country










Argentina Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/ Allowed/Permitted





Armenia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Australia Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Austria Allowed/Permitted Never Practiced/
Performed
Allowed/Permitted Allowed/Permitted Allowed/Permitted
Commonly Practiced/Performed Commonly Practiced/
Performed
Never Practiced/Performed Infrequently Practiced/
Performed
Bangladesh Allowed/Permitted Never Practiced/
Performed
Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Barbados Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed







Commonly Practiced/Performed Practiced/Performed Commonly Practiced/
Performed
Infrequently Practiced/Performed Infrequently Practiced/
Performed
Belgium Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown Unknown




Infrequently Practiced/Performed Infrequently Practiced/
Performed




Commonly Practiced/Performed Practiced/Performed Commonly Practiced/
Performed
Infrequently Practiced/Performed Infrequently Practiced/
Performed
Bulgaria Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Burkina Faso Commonly Practiced/Performed Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Cameroon Allowed/Permitted Never Practiced/
Performed
Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Commonly Practiced/Performed Infrequently Practiced/
Performed
Canada Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Chile Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted, Commonly Allowed/Permitted





China Allowed/Permitted Never Practiced/
Performed
Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Infrequently Practiced/Performed Commonly Practiced/
Performed
Colombia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Czechia Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
Congo Allowed/Permitted Unknown Unknown Never Practiced/Performed
Ecuador Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Egypt Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown Allowed/Permitted
El Salvador Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Finland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Georgia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
Germany Unknown Unknown Commonly Practiced/
Performed
Unknown Unknown
Ghana Allowed/Permitted Allowed/Permitted Allowed/Permitted,
Commonly
Allowed/Permitted Allowed/Permitted
Commonly Practiced/Performed Commonly Practiced/
Performed
Practiced/Performed
Greece Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Guatemala Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
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Never Practiced/Performed Never Practiced/Performed
Hong Kong Allowed/Permitted Unknown Allowed/Permitted Unknown Allowed/Permitted




Hungary Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
Iceland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
India Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Ireland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
Italy Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Côte Allowed/Permitted Allowed/Permitted Unknown Never Practiced/Performed, Infrequently Practiced/
d’Ivoire Commonly Practiced/Performed Commonly Practiced/
Performed
Unknown Performed
Japan Allowed/Permitted Infrequently Practiced/
Performed
Allowed/Permitted Unknown Unknown
Jordan Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown Unknown
Commonly Practiced/Performed
Kazakhstan Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Latvia Allowed/Permitted Allowed/Permitted, Allowed/Permitted Allowed/Permitted, Unknown Allowed/Permitted, Unknown




Lithuania Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Never Practiced/
Performed




Never Practiced/Performed Never Practiced/Performed
Mexico Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
Mongolia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Montenegro Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Namibia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Netherlands Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
New Allowed/Permitted Allowed/Permitted, Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Infrequently Practiced/
Performed
Nicaragua Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Nigeria Infrequently Practiced/Performed Commonly Practiced/
Performed
Allowed/Permitted Unknown Unknown
Norway Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Commonly Practiced/Performed




Commonly Practiced/Performed Commonly Practiced/Performed
Paraguay Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Commonly Practiced/Performed Commonly Practiced/Performed
Peru Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Philippines Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
Poland Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Portugal Allowed/Permitted Allowed/Permitted,
Unknown
Allowed/Permitted Allowed/Permitted, Unknown Allowed/Permitted
Infrequently Practiced/Performed Commonly Practiced/
Performed
Commonly Practiced/Performed
Romania Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Commonly Practiced/Performed Infrequently Practiced/Performed
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29
75
Chapter 6. Table 3a
(Continued)
Country
















Russian Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed




Never Practiced/Performed Infrequently Practiced/
Performed
Serbia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/
Performed
Singapore Allowed/Permitted Unknown Allowed/Permitted Never Practiced/Performed Allowed/Permitted








Never Practiced/Performed Commonly Practiced/Performed
South Africa Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
The Republic of
Korea
Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Spain Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted





Sweden Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Commonly Practiced/Performed
Switzerland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Commonly Practiced/Performed Commonly Practiced/Performed
Taiwan (China*) Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Thailand Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
Trinidad and
Tobago
Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Turkey Allowed/Permitted Never Practiced/
Performed
Allowed/Permitted Never Practiced/Performed Allowed/Permitted




Uganda Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
UAE Allowed/Permitted Commonly Practiced/
Performed
Allowed/Permitted Unknown Allowed/Permitted
UK Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Infrequently Practiced/
Performed
USA Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Uruguay Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Commonly Practiced/Performed




Never Practiced/Performed Infrequently Practiced/
Performed
Viet Nam Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Infrequently Practiced/
Performed
*Reporting separately for this report.
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Chapter 6. Table 3b
Is cryopreservation for fertility treatment or fertility preservation allowed/permitted or practiced/performed in your country?
Country










Argentina Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Commonly Practiced/
Performed
Armenia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Australia Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Austria Allowed/Permitted Never Practiced/Performed Allowed/Permitted Allowed/Permitted Allowed/Permitted
Commonly Practiced/Performed Infrequently Practiced/
Performed
Never Practiced/Performed Infrequently Practiced/
Performed
Bangladesh Allowed/Permitted Never Practiced/Performed Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Barbados Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed




Belarus Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Belgium Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Botswana Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Brazil Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Commonly Practiced/Performed Commonly Practiced/
Performed
Infrequently Practiced/Performed Infrequently Practiced/
Performed
Bulgaria Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown Unknown




Burkina Faso Commonly Practiced/Performed Unknown Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Cameroon Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/
Infrequently Practiced/Performed Infrequently Practiced/
Performed
Performed
Canada Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Chile Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
China Allowed/Permitted Never Practiced/Performed Allowed/Permitted Never Practiced/Performed Allowed/Permitted




Colombia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Czechia Allowed/Permitted Allowed/Permitted Allowed/Permitted Commonly Practiced/Performed Commonly Practiced/
Performed
Congo Allowed/Permitted Unknown Never Practiced/
Performed
Never Practiced/Performed Never Practiced/Performed
Ecuador Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Egypt Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown Allowed/Permitted
El Salvador Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Finland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Georgia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Infrequently Practiced/Performed Never Practiced/Performed Infrequently Practiced/
Performed
Never Practiced/Performed Never Practiced/Performed
Germany Unknown Unknown Allowed/Permitted Unknown Unknown
Ghana Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Greece Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Guatemala Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
Hong Kong Allowed/Permitted Unknown Allowed/Permitted Unknown Allowed/Permitted
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Iceland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
India Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Ireland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
Italy Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Côte d’Ivoire Allowed/Permitted Unknown Never Practiced/Performed, Never Practiced/
Infrequently Practiced/Performed Unknown Performed, Unknown
Japan Allowed/Permitted Infrequently Practiced/
Performed
Allowed/Permitted Unknown Allowed/Permitted
Jordan Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown
Commonly Practiced/Performed
Kazakhstan Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
Latvia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted, Unknown Allowed/Permitted, Unknown




Lithuania Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Never Practiced/Performed
Mali Infrequently Practiced/Performed Never Practiced/Performed Never Practiced/
Performed
Never Practiced/Performed Never Practiced/Performed
Mexico Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
Mongolia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Montenegro Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Namibia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Netherlands Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
New Zealand Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Infrequently Practiced/
Performed
Nicaragua Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Nigeria Infrequently Practiced/Performed infrequently Practiced/
Performed
Allowed/Permitted Unknown Unknown
Norway Allowed/Permitted Never Practiced/Performed Allowed/Permitted Never Practiced/Performed Allowed/Permitted
Commonly Practiced/Performed Commonly Practiced/
Performed




Never Practiced/Performed Infrequently Practiced/
Performed
Paraguay Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/





Peru Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Philippines Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/Performed Infrequently Practiced/
Performed
Poland Unknown Unknown Unknown Unknown Unknown
Portugal Allowed/Permitted Allowed/Permitted,
Unknown
Allowed/Permitted Allowed/Permitted, Unknown Allowed/Permitted




Romania Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/







Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Senegal Never Practiced/Performed Never Practiced/Performed Never Practiced/
Performed
Never Practiced/Performed Never Practiced/Performed
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Ireland, New Zealand, Switzerland, Taiwan [China, report-
ing separately for this report], Uganda, and United Kingdom
of Great Britain and Northern Ireland); and 25 years
(Greece);
• Oocytes: 2 years (Serbia); 5 years (Bulgaria, Nicaragua, and
Portugal); 10 years (Iceland, Ireland, New Zealand,
Switzerland, Taiwan [China, reporting separately for this
report], Uganda, and United Kingdom of Great Britain and
Northern Ireland);
• All Stages of preimplantation embryos: 5 years (Bulgaria and
The Republic of Korea); 10 years (Iceland, Ireland, New
Zealand, Switzerland, Taiwan [China, reporting separately
for this report], Uganda, and the United Kingdom of Great
Britain and Northern Ireland);
• Ovarian Tissue: 5 years (Nicaragua and Portugal); 10 years
(Iceland, New Zealand, and Switzerland); and
• Testicular tissue: 1 year (Serbia), 5 years (Bulgaria,Nicaragua, and
Portugal); 10 years (Iceland, New Zealand, and Switzerland).
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Serbia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Infrequently Practiced/
Performed
Singapore Allowed/Permitted Never Practiced/Performed Allowed/Permitted Never Practiced/Performed Allowed/Permitted




Slovenia Allowed/Permitted Never Practiced/Performed Commonly Practiced/
Performed
Never Practiced/Performed Commonly Practiced/
Performed
South Africa Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
The Republic of
Korea
Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Spain Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Sri Lanka Infrequently Practiced/Performed Unknown Infrequently Practiced/
Performed
Unknown Unknown
Sweden Allowed/Permitted Allowed/Permitted Allowed/Permitted,
Commonly
Allowed/Permitted Allowed/Permitted
Commonly Practiced/Performed Commonly Practiced/
Performed
Practiced/Performed Commonly Practiced/Performed Commonly Practiced/
Performed
Switzerland Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Commonly Practiced/Performed Commonly Practiced/
Performed
Taiwan (China*) Allowed/Permitted Allowed/Permitted Allowed/Permitted Never Practiced/Performed Never Practiced/Performed
Thailand Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Togo Infrequently Practiced/Performed Never Practiced/Performed Never Practiced/
Performed
Never Practiced/Performed Never Practiced/Performed
Trinidad and
Tobago
Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Turkey Allowed/Permitted Never Practiced/Performed Allowed/Permitted Never Practiced/Performed Allowed/Permitted








Infrequently Practiced/Performed Infrequently Practiced/
Performed
UAE Allowed/Permitted Infrequently Practiced/
Performed
Allowed/Permitted Never Practiced/Performed Infrequently Practiced/
Performed
UK Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Infrequently Practiced/
Performed
USA Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Infrequently Practiced/Performed Infrequently Practiced/
Performed
Uruguay Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Infrequently Practiced/
Performed




Never Practiced/Performed Never Practiced/Performed
Viet Nam Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted




Never Practiced/Performed Never Practiced/Performed
*Reporting separately for this report.
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Is cryopreservation for fertility treatment or fertility preservation











Australia Never Practiced/Performed Allowed/Permitted
Austria Never Practiced/Performed Allowed/Permitted, Infrequently
Practiced/Performed




















Burkina Faso Unknown Unknown
Cameroon Never Practiced/Performed Never Practiced/Performed
Canada Allowed/Permitted Allowed/Permitted








Congo Unknown Never Practiced/Performed
Ecuador Allowed/Permitted Allowed/Permitted
Egypt Allowed/Permitted Allowed/Permitted






























Côte d’Ivoire Never Practiced/Performed, Unknown Never Practiced/Performed,
Unknown
Japan Never Practiced/Performed Allowed/Permitted
Jordan Unknown Allowed/Permitted
Kazakhstan Allowed/Permitted Allowed/Permitted







Lithuania Allowed/Permitted, Never Practiced/
Performed
Allowed/Permitted


















Nigeria infrequently Practiced/Performed Allowed/Permitted
Norway Never Practiced/Performed Allowed/Permitted, Commonly
Practiced/Performed



















Senegal Never Practiced/Performed Never Practiced/Performed
Serbia Unknown Unknown
Singapore Never Practiced/Performed Allowed/Permitted, Infrequently
Practiced/Performed
Slovenia Never Practiced/Performed Commonly Practiced/Performed


















































*Reporting separately for this report.
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Discussion
Sperm cryopreservation is an established procedure, a standard
technique for donor insemination and for preservation of male
fertility in men who have a malignancy. Attempts are being made
to cryopreserve small numbers of sperm from men who are
infertile, and men with reduced fertility. Cryopreservation may
reduce the need for future surgical procedures or the use of
donor sperm.
Sperm can now be frozen using the freeze-drying technique,
lyophilization. This procedure can preserve sperm for longer
periods and more economically than current methods, without
affecting the integrity of sperm DNA[4]. Sperm banking is indi-
cated for cancer patients facing gonadotoxic therapy. Testicular
tissue has been obtained and preserved from prepubertal boys
undergoing gonadotoxic treatment and those with cryptorchid-
ism, but the procedure is experimental.
Some reviews have shown two procedures performed on
oocytes – slow freezing and vitrification – have comparable rates
when the oocytes are assessed for fertilization, pregnancy, and
implantation, but vitrification is preferred because of its simpli-
city[5]. The limited available studies suggest that the technique of
vitrification of oocytes yields higher pregnancy rates when com-
pared to slow-freezing[6].
Preliminary data on the safety of oocyte cryopreservation are
reassuring, and the procedure is no longer considered experi-
mental. Good evidence indicates that fertilization and pregnancy
rates are similar with fresh oocytes or frozen-thawed oocytes. No
increases in chromosomal abnormalities, birth defects, or devel-
opmental deficits have been noted in the children born from
cryopreserved oocytes. Oocyte freezing has developed sub-
stantially, finding wider applications and use. There are not yet
sufficient data to recommend oocyte cryopreservation as a
mainstream option to mitigate reproductive aging in healthy
women[7].
Also, oocyte freezing has simplified the oocyte donation process.
The advent of donor egg cryobanks with cryopreserved oocytes
facilitates creation of greater numbers of potential donor oocytes
and uncouples the donor stimulation process from the recipient
endometrial preparation cycle, which eliminates the need for cycle
synchronization[8]. Oocyte cryopreservation also allows for the
quarantining of human immunodeficiency virus (HIV)-exposed
oocytes[8,9]. Furthermore, it is a model for conserving potential
fertility in women with malignancy or those who seek elective
postponement of childbirth, potentially extending their reproduc-
tive lifespan in optimal circumstances[10].
Use of cryopreserved embryos appears to be increasing, and
many centres are now switching to a “freeze all” protocol, inwhich
all or almost all of the freshly created embryos are not transferred,
but cryopreserved for subsequent transfer in a programmed cycle.
A recent meta-analysis suggests that pregnancies after FET are
associated with better clinical outcomes, including lower risks of
placenta previa, placental abruption, low birth weight, very-low-
birth-weight-very-pre-term birth, short-for-gestation age, and
perinatal mortality, compared with fresh embryo transfer.
Conversely, pregnancies following FET were associated with
increased risks of pregnancy-induced hypertension, postpartum
hemorrhage, and large-for-gestational-age fetuses compared to
those produced with fresh embryo transfer[11].
Among the established methods for preserving fertility in
women diagnosed with cancer, cryopreservation is the preferred
option for the post-pubertal age group oocyte, and ovarian tissue
cryopreservation is generally the only available option for pre-
pubertal girls. Ovarian tissue cryopreservation before treatment
for malignancy has been performed, and has led to a small
number of live births following transplantation. The procedure of
ovarian tissue cryopreservation has been found to be safe, rela-
tively simple, and promising[12]. Cited advantages are that it may
eliminate certain ethical, moral, and potentially legal obstacles to
oocyte or embryo freezing in minors.
Ovarian tissue cryopreservation is still considered an experi-
mental procedure. It is an option for patients requiring immediate
gonadotoxic treatment who must forego oocyte or embryo freez-
ing, and it is the only option available for prepubertal girls.
Vitrification of ovarian tissue was found to be similar to slow
freezing, and both preserved the morphologic integrity of the
ovarian tissue[13]. Orthotopic transplantation of the cortical strips
from the tissue has been successful, and live births have been
reported[14]. In vitro-activated ovarian tissue cryopreservation and
transplantation is a new method requiring more clinical research.
This procedure involves stimulation of dormant follicles within the
cryopreserved tissue graft prior to transplantation, in order to
generate mature oocytes shortly after transplantation[15].
Summary
Advances in cryopreservation, most notably vitrification, have
led to wide adoption and successful application of cryopre-
servation of sperm, oocytes, and embryos. The 2018 Surveillance
questionnaire did not uncover any countries that expressly pro-
hibit cryopreservation of gametes or pre-implantation embryos
for fertility treatment or for fertility preservation performed for
medical or other indications. Approximately 65% to 80% of
respondent countries noted the existence of laws, regulations,
agency oversight, or professional guidelines that provided gov-
ernance. However, there is extensive variation among the country
respondents in terms of which practices are regulated, and how
they are regulated.
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CHAPTER 7: POSTHUMOUS REPRODUCTION
Introduction
Posthumous reproduction broaches a diverse scope of emotional,
medical, legal, and ethical concerns that represent one of themore
challenging and sensitive areas in reproductive medicine. There is
still substantial debate over the ethics and legality of several
aspects of posthumous reproduction, and the rights of the
deceased person’s parents, surviving partner, and any resulting
offspring.
Posthumous reproduction utilizes cryopreserved gametes, or
embryos created when the person was alive, but inseminated or
transferred after the person’s death. Posthumous reproduction can
occur in two distinctly separatemodes, referred to as (1) immediate
posthumous reproduction and (2) posthumous reproduction.
Immediate posthumous reproduction involves either the immedi-
ate harvesting of gametes from a person declared to be in a brain-
dead state, on life support; or the extraction of gametes from a
person declared dead within the previous 24 hours. Reports of
sperm retrieval post 24 hours have been described[1]. Posthumous
conception by artificial insemination using cryopreserved sperm
has been practiced since the 1950s[2].
The acceptance, legality, and utilization of posthumous repro-
duction varies from country to country (Table 1). With the advent
of more successful cryopreservation techniques, patients are cryo-
preserving gametes and embryos for a wider number of reasons,
including onco-banking, elective fertility preservation, and delayed
embryo transfer in in vitro fertilization (IVF), with or without pre-
implantation genetic testing. The actual use of cryopreserved
reproductive tissue after death depends on existing legislation, prior
written legal agreements, and/or consent documentation. Most
ART programmes now use consents that cover the deposition of
gametes and embryos after death. When immediate posthumous
reproduction is being considered, family input often is the only form
of intent available to interpret the wishes of the deceased person. In
some locales, gametes are considered an individual’s property, and
the gamete’s subsequent ownership must be documented in a will.
Otherwise, the burden to determine whether the person may have
trulywished to procreate after death devolves to the courts to decide.
This often precipitates the need for governments to update relevant
legislation.
The first data regarding posthumous reproduction were
reported in 2003, in the cryopreservation chapter. Surveillance
reports from 2007 through 2013 included data regarding only the
permissibility and utilization of posthumous insemination. The
2015 Surveillance questionnaire for the 2016 Surveillance report
was expanded to include questions about posthumous repro-
duction involving insemination of frozen sperm or frozen ova,
and implantation of frozen embryos from deceased persons.
Questions were added regarding legislation and the frequency of
use of posthumous reproduction. In 2018, responses regarding
posthumous reproduction were received from 82 countries – a
23% increase from the 2015 survey.
Analysis of the Survey
Of the 97 countries participating in the survey, respondents from
82 countries (85%) addressed questions regarding posthumous
reproduction governance. Fewer countries than in the 2016
Surveillance report said they had regulations that governed
immediate posthumous reproduction: 16 of 82 (20%). The report
broke down the governance data as follows: posthumous sperm
insemination: 19 of 82 (23%), posthumous insemination of fro-
zen ova: 19 of 82 (23%); and posthumous implantation of frozen
embryos: 23 of 28 (28%). An additional 7 of 82 (9%) (Belgium,
Côte d’Ivoire, Germany, Jordan, Mongolia, Namibia, and
Netherlands) reported it was “unknown” whether any type of
regulations existed to govern posthumous reproduction.
When regulations existed, posthumous reproduction proce-
dures were reportedly largely covered by federal law (immediate
posthumous reproduction, 13 of 19 (68%); insemination with
frozen sperm, 16 of 19 (84%); insemination of frozen ova, 14 of
19 (74%); and implantation of frozen embryos, 17 of 19 (89%).
Regulations were addressed by state, regional, or provincial laws,
5 of 39 (13%), municipal laws, 1 of 19 (5%); agency oversight, 4
of 60 (7%); a professional organization’s standards and guide-
lines, 12 of 60 (20%); cultural practice, 1 of 17 (6%); and reli-
gious decree 5 of 60 (8%).
In addition, respondents were then asked questions about the
permissibility and utilization of posthumous reproduction.
Immediate posthumous reproduction
Respondents from 41 countries reported data on immediate post-
humous reproduction procedures in their country. In 28 (68%) of
the respondent countries, it was “unknown” whether immediate
posthumous reproduction was “allowed/permitted or practiced/
performed”. In 11 of 41 (27%), posthumous reproduction proce-
dures were allowed/permitted, with 5 of 11 (45%) of these
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Argentina Allowed/Permitted Allowed/Permitted Allowed/Permitted Unknown
Australia Allowed/Permitted Allowed/Permitted, Practiced/Performed Allowed/Permitted Allowed/Permitted Practiced/
Performed
Practiced/Performed Practiced/Performed
Bolivia Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Botswana Unknown Unknown Unknown Unknown
Bulgaria Unknown Unknown Unknown Unknown
Burkina Faso Unknown Unknown Unknown Unknown
Canada Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Chile Unknown Unknown Unknown Unknown
Colombia Unknown Unknown Unknown Unknown
Congo Unknown Unknown Unknown Unknown
Ecuador Unknown Allowed/Permitted Allowed/Permitted Allowed/Permitted
El Salvador Unknown Unknown Unknown Unknown
Georgia Unknown Unknown Unknown Practiced/Performed
Germany Unknown Unknown Unknown Unknown
Ghana Unknown Unknown Unknown Unknown
Greece Practiced/Performed Allowed/Permitted Practiced/Performed Allowed/Permitted
Guatemala Unknown Unknown Unknown Unknown
Hungary Practiced/Performed Practiced/Performed
India Practiced/Performed Practiced/Performed Practiced/Performed Practiced/Performed
Ireland Unknown Practiced/Performed Practiced/Performed Practiced/Performed
Italy Unknown Unknown Unknown Unknown
Côte d’Ivoire Unknown Unknown Unknown Unknown
Jordan Unknown Unknown Unknown Unknown
Kenya Unknown Unknown Unknown Unknown






Mongolia Unknown Unknown Unknown Unknown
Netherlands Practiced/Performed Practiced/Performed Practiced/Performed
New Zealand Allowed/Permitted Allowed/Permitted Allowed/Permitted
Practiced/Performed Practiced/Performed
Nigeria allowed/Permitted allowed/Permitted allowed/Permitted
Panama Unknown Unknown Unknown Unknown
Paraguay Unknown Unknown Unknown Unknown
Portugal Unknown Allowed/Permitted
Russian Federation Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Senegal Unknown Unknown Unknown Unknown
South Africa Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Spain Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Taiwan (China*) Unknown Unknown Unknown Unknown
Thailand Allowed/Permitted
Trinidad and Tobago Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Uganda Unknown Unknown Unknown Unknown
United Arab
Emirates
Unknown Unknown Unknown Unknown
UK Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Practiced/Performed Practiced/Performed Practiced/Performed Practiced/Performed
USA Allowed/Permitted Allowed/Permitted Allowed/Permitted Allowed/Permitted
Practiced/Performed Practiced/Performed Practiced/Performed Practiced/Performed
Uruguay Unknown Allowed/Permitted Allowed/Permitted Allowed/Permitted
Venezuela Unknown Unknown Unknown Unknown
Viet Nam Unknown Unknown Unknown Allowed/Permitted
*Reporting separately for this report.
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countries practicing/performing immediate posthumous reproduc-
tion procedures, and another 1 of 5 (20%) reporting “unknown” if
this procedure was actually being practiced/performed. Two
countries did not report whether posthumous reproduction was
allowed/permitted, but did note that the procedure was being
practiced/performed in their country (Table 1).
Insemination with Frozen Sperm
Respondents from 44 countries reported data on insemination with
frozen sperm in their country. In 24 of 44 (54.5%), it was
“unknown” whether insemination with frozen sperm was allowed/
permitted or practiced/performed. In 16 of 44 (36%), insemination
with frozen sperm was allowed/permitted, with 4 of 16 (25%) of
these countries practicing/performing insemination with frozen
sperm and another 6%, 1 in 16, reporting “unknown” if this pro-
cedure was actually being practiced/performed. Four countries did
not report if insemination with frozen spermwas allowed/permitted
but reported that the procedure was being practiced/performed in
their country.
Insemination of Frozen Ova
Respondents from 43 countries provided data on insemination of
frozen ova in their country. In 24 of the 43 (56%), it was
“unknown” whether insemination of frozen ova was allowed/
permitted or practiced/performed. In 15 of the 43 (35%), inse-
mination of frozen ova was allowed/permitted, with 3 of 15
(20%) practicing/performing insemination of frozen ova, and
another 1 in 15 (7%) reporting “unknown” as to whether this
procedure was actually being practiced/performed. Four coun-
tries did not report if insemination of frozen ova was allowed/
permitted, but did report that the procedure was being practiced/
performed in their country.
Implantation of Frozen Embryos
Respondents from 46 countries reported data on implantation of
frozen embryos in their country. In 23 of the 46 (50%), it was
“unknown” whether implantation of frozen embryos was
allowed/permitted or practiced/performed. In 28 of the 46 (39%),
implantation of frozen embryos was allowed/permitted, with 4
out of 18 (22%) of these countries practicing/performing
implantation of frozen embryos, and another 1 out of 18 (6%)
reporting “unknown” as to whether this procedure was actually
being practiced/performed. Five countries did not report if frozen
embryo implantation was allowed/permitted, but did report that
the procedure was being practiced/performed in their country.
Summary
Compared to past Surveillance surveys, the use of any type of
posthumous reproduction procedures has increased over the last
3 years. While scientific and medical advances allow the practi-
tioner to retrieve and use gametes and embryos from deceased
persons, complex issues remain unresolved, when it comes to
clarifying who can decide when the retrieval and disposition of
these reproductive tissues is appropriate, and under what
circumstances.
In the 2016 Surveillance survey, more than a third of countries
reported legislation in place to govern posthumous reproduction.
In 2019, only about a quarter of the countries had governance. The
2019 Surveillance data illustrate the continued global need to
address the controversial and complex issues of ethics and legalities
associated with posthumous reproduction – especially now, when
the procedure is being used more frequently, under what continues
to be a limited extent of regulations and legislation.
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CHAPTER 8: DONATION AND ANONYMITY OF
DONORS
Introduction
Assisted reproductive technology (ART) programmes around the
world increasingly rely on male and female gamete donation in
ART cycles. From a cultural perspective, social trends leading to
progressive legislation have improved global access to ART and
widened the spectrum of potential users. In previous Surveillance
reports, changes in legislation pertaining to gamete donation,
marital status, and same-sex parenting policies, were observed in
about 23% of countries over a three-year interval[1]. Prospective
parents seeking medical care now comprise not only infertility
patients, carriers of genetic conditions, and HIV sero-discordant
couples, but also single women, single men, same-sex couples,
and transgender subjects. Enacting anti-discrimination policies
favors access for these groups, and a current trend leans toward
equal, inclusive, fair, safe, and efficient access to ART, most
notably in Europe[2].
An additional driver, from a biological standpoint, has been
the social phenomenon favoring delayed childhood in modern
societies. This has shifted the “reproductive window” to an age in
which ovarian follicular depletion impairs female fertility
potential. As a result, use of donated oocytes has increased
steadily over the last decades, a trend reflected in recently pub-
lished global registry data (ICMART, 2017)[3]. Oocyte donation
can also be performed with vitrified oocytes. Currently, more
programmes are using egg banking for donation, as IVF results
have been shown to be similar with the use of fresh and frozen
oocytes[4].
Analysis of the survey
The vast majority of countries surveyed allowed gamete donation
(Table 1, Charts 1 and 2). Sperm donation is allowed in 48 of 71
(68%), and is practiced in 41 of the 71 (58%). Oocyte donation is
permitted in 43 of 69 (62%), but is performed in only 39 of 69
(56.5%). Donation of an embryo created by another couple in a
previous IVF cycle is allowed in 31 of 53 (58%), but, surprisingly,
is performed in 25 of 53 (47%).
Less commonly allowed is creating embryos purely for dona-
tion, “de novo” generation of embryos from donor gametes.
Allowed in 21 of 50 countries (42%), it reportedly is practiced in
19 of 50 (38%). Overall, 49 of 71 (69%) reported “commonly
using” sperm; oocyte, 44 of 71 (62%); embryo, 17 of 66 (26%).
Less frequently allowed is cytoplasmic donation, 7 of 48 (14.5%),
and gamete tissue donation—usage with either ovarian tissue 12
of 51 (23.5%) or testicular tissue, 11 of 50 (22%) permitted but
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only performed cytoplasmic donation 3 of 48 (6%), ovarian tis-
sue donation, 3 of 51 (6%); or testicular tissue donation, 3 of 50
(6%); six countries reported “never having used” sperm, oocyte,
or embryo donation. The same six countries indicated they had
never used cytoplasmic and gamete tissue donation (Botswana,
Egypt, Jordan, Lithuania, Mali, and Senegal).
More than half the countries surveyed have regulations
addressing oocyte donation, 40 of 73 (55%), and sperm dona-
tion, 43 of 74 (58%) (Table 2). Many countries have regulations
pertaining to embryo donation, 29 of 69 (42%), including pre-
vious IVF; or de novo embryos, 26 of 68 (38%). 17% of coun-
tries, 11 of 65, have regulations for cytoplasmic donation
(Australia, Canada, Finland, Greece, Kazakhstan, New Zealand,
Nicaragua, Singapore, Thailand, United Kingdom of Great
Britain and Northern Ireland, and The United States of America),
and 20% have regulations regarding ovarian (13 of 65) and
testicular tissue donation, 13 of 66. Fourteen countries out of 65
(22%) reported allowing agencies to recruit and match third
party donors; including donors, recipients, surrogates and/or
gestational carriers. These countries are Australia, Canada,
Finland, Greece, India, Kazakhstan, Mexico, Nicaragua,
Portugal, Singapore, Thailand, United Arab Emirates, United
Kingdom of Great Britain and Northern Ireland, and Uruguay.
Themajority of countries allowed compensation for sperm and
oocyte donors; 67 responders (67%) vs 64 responders (72%) and
embryo donors 26% (n= 54) of the countries surveyed permit-
ting the practice (Chart 3). This includes reimbursement for
donors’ time and expenses only, as follows: for sperm, 54%;
oocyte, 55%; and for embryo, 2%. Compensation beyond
reimbursement occurred in 12% of sperm donors, 17% of oocyte
donors, and 7% of embryo donors. The eleven countries that
allowed compensation of oocyte donors beyond simple reim-
bursement include Argentina, Brazil, Bolivia, Colombia,
Ecuador, Georgia, Greece, India, Russian Federation, The United
States of America, and Venezuela. Embryo donation with reim-
bursement/compensation practices is permitted in Armenia,
Australia, Bolivia, Brazil, Georgia, Greece, Hong Kong [China,
reporting separately for this report], India, New Zealand,
Nigeria, Sri Lanka, The United States of America, Uruguay, and
Zimbabwe. Reimbursement for gamete tissue, and for cyto-
plasmic and testicular tissues, was reported in 3 of 43 (7%); and
for ovarian tissues, 4 out of 44 (9%). Such reimbursement is rare,
and reportedly occurred only in Australia, Colombia, Finland,
and Greece.
When addressing a specific value paid in terms of compensation
to donors, only a few countries reported minimum and maximum
amounts for gamete donors. For oocyte donors, amounts ranged
from US $ 700 to $ 2,000 in some countries (e.g., Ecuador,
Guatemala, Latvia, Hong Kong [China, reporting separately for
this report], and Spain) to $ 5,000 to $ 99,000 in others (Brazil,
Namibia, South Africa, Taiwan [China, reporting separately for
this report], and The United States of America). Some countries
reported no minimum or maximum values established, including
Argentina, Bulgaria, Chile, Hungary, India, Côte d’Ivoire,Mexico,
Panama, and Uganda. Twenty-one out of 41 countries (51%)
responded to the item as “not addressed” or “unknown”).
When asked if subjects were required to meet medical, mental
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Chapter 8. Chart 1. Is donation allowed/permitted or practiced/performed?
Chapter 8. Table 1
Percentage of countries surveyed allowing gamete and embryo donation practices.
Sperm Donation Oocyte Donation Embryo Donation from IVF “de Novo” Embryo Donation
Allowed Performed Allowed Performed Allowed Performed Allowed Performed
64% 85% 57% 80% 41% 54% 24% 34%
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Argentina No No No No No Yes No No
Armenia Yes
Australia Yes Yes






Botswana No No No No No No No No
Brazil Yes Yes
Bulgaria Unknown Yes Unknown Unknown Unknown Unknown Unknown Unknown
Burkina Faso No No No No No No No No




Colombia Yes No No No No No Yes No
Czechia Yes Yes No No Unknown No No
Ecuador Yes
Egypt Unknown Unknown Unknown Yes
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Never Performed Commonly Used Infrequently Used Unknown
A
B
Chapter 8. Chart 2a. How often is third party reproduction? Chart 2b. How often is third party reproduction performed in your country?
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Finland No Yes No No No No No No
Georgia Yes No No No No No No No
Germany No Yes No No Yes Yes Yes Yes
Ghana Yes









Italy No No No No No No No No
Côte d’Ivoire Yes Unknown Unknown Unknown Yes Yes Unknown Unknown
Japan Yes Yes
Jordan Yes Yes
Kazakhstan Yes Yes No No No Yes No No
Kenya Yes
Latvia Yes
Lithuania No Yes No No No No No No
Mali Yes Unknown Unknown Unknown Unknown Yes Unknown Unknown
Mexico No Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Mongolia Yes Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Montenegro Yes Yes
Namibia Yes
New Zealand No Yes Yes
Nicaragua Unknown Yes
Nigeria Unknown yes Unknown Unknown Unknown Unknown Unknown Unknown




Philippines Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Poland Yes Yes Yes
Portugal No Yes No No Yes Yes Unknown No




Senegal Yes Yes Yes Yes Yes Yes Unknown Unknown
Serbia No Yes No Yes Yes No No
Singapore Yes
Slovenia Yes




Spain No Yes No No No Yes No No
Sri Lanka No No No No Yes No No No








No No No No No No No No





USA No No No No No No No No
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responded affirmatively for sperm donation, 47 of 63 (75%)
for oocyte donation, and 28 out of 50 (56%) for embryo
donation.
Anonymity
Ten of 78 countries (13%) reported having no regulations per-
taining to the treatment of anonymity of donors; 37 of 65 (57%)
of countries reported the existence of national or federal laws; 6
of 65 countries (9%) have municipal or regional laws; 10 of 65
(15%) countries reported the presence of governmental agency
oversight, and 23 of 65 (35%) reported having professional
organization oversight (Table 2). Seven countries, Cameroon,
Colombia, Egypt, Germany, Greece, Jordan, and Switzerland,
reported regulation of anonymity via “cultural practice or reli-
gious decree.”
Disclosure of information about gamete donors to the off-
spring varied widely. Some countries, 22 of 46 (48%), allowed
non-identifying data to be provided by the donor to the offspring.
Another 14 of 43 (30%) allow identifying data to be disclosed,
including Australia, Austria, Cameroon, Canada, Finland,
Greece, Iceland, Kazakhstan, NewZealand, Nicaragua, Norway,
Russian Federation, Switzerland, and The United States of
America. Nonetheless, when queried if these practices were
“customary” only 8 of the former 22 countries (36%) and 6 of the
latter group of 14 (43%) responded affirmatively.
Disclosure of information from the offspring to the donor is
less frequently allowed. In 17 of 43 (40%) of countries surveyed,
non-identifying data from the offspring could be obtained by the
donors. Those countries include Australia, Barbados, Bolivia,
Colombia, Finland, Greece, Hungary, Iceland, Kazakhstan, New
Zealand, Russian Federation, Sri Lanka, Switzerland, Thailand,
The United States of America, United Kingdom of Great Britain
and Northern Ireland, and Uruguay. Identifying information
from the offspring, in contrast, was allowed to be obtained by
donors in only 6 out of 41 (15%) of other countries: Australia,
Cameroon, Kazakhstan, New Zealand, Russian Federation, and
The United States of America. Regarding how often these dis-
closure practices were observed, only 9 of 17 (53%) in the first
group—offspring to donor—and 2 out of 6 (33%) in the second
group—donor to offspring—responded positively.
Summary
Gamete and embryo donation are well established ART practices,
employed, if not sanctioned, by a large majority of the responding
countries. These donation trends are likely to continue due to
evolving social and cultural norms in developed and developing
countries. Most of the European countries, as well as Australia,
New Zealand, and some Asian countries, are extensively regu-
lated by national or regional laws and statutes. Overall, about
50% to 60% of countries surveyed report using gamete or
embryo donation, although “de novo” embryo donation is
somewhat less commonly accepted (about 25% to 35% of
countries). Cytoplasmic donation is infrequent, as is ovarian tis-
sue and testicular tissue donation, and used for the most part in
experimental environments.
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CHAPTER 9. OOCYTE MATURATION
Introduction
Utilization of in-vitromaturation (IVM) following the recovery of
immature oocytes was first suggested as a potential useful
application for women undergoing ART in the 1990s. This
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Chapter 8. Chart 3. Percentage of countries allowing compensation to gamete
donors.
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technology differs markedly from conventional in vitro fertiliza-
tion (IVF) in that oocytes are retrieved without prior controlled
ovarian hyperstimulation (COH), and the collected immature
oocytes are then cultured in vitro in enhanced culture environ-
ments until maturation is completed, which occurs when meta-
phase II (MII) stage is achieved.
Several advantages of IVM over conventional IVF have been
suggested. They include greater safety via elimination of COH,
with less risk of ovarian hyperstimulation syndrome (OHSS),
particularly with patients with polycystic ovarian syndrome
(PCOS); and lower cost, by reducing the need for additional
medications and monitoring. This advantage has an additional
benefit for the patient: potentially less stress. But broad accep-
tance of IVM techniques has been slow in coming, due to per-
ceived lower clinical success rates, and a relative dearth of data
regarding safety issues. The safety issues of concern include the
overall health of the resulting offspring, and the possibility of
inducing permanent changes in the expression of imprinted
genes[1].
Analysis of the survey
The 2018 survey included responses from 75 countries. IVMwas
permitted in 64 of the 75 (86%), and was disallowed in only 4
countries (Bangladesh, Germany, Mali, and Nigeria). Seven
countries (9%) stated that the status of IVM application in their
country was “unknown” (Chart 1). The procedure was infre-
quently used in 41 of 72 countries (57%), and was commonly
employed in only 15 of the 72 (21%). Reportedly, it was never
performed in 10 of the 72 countries (14%) (Chart 2).
IVM is regulated in 16 of 77 countries responding (21%), and is
unknown in 7 (9%) of the countries that responded. IVM is
regulated in 15 countries of the 75 (20%) by federal statute
(Belgium, Bulgaria, Egypt, Germany, Montenegro, New Zealand,
Norway, Portugal, Serbia, Spain, Taiwan [China, reporting sepa-
rately for this report], Togo, Turkey, United Kingdom of Great
Britain andNorthern Ireland, andVietNam); 2 of 75 (3%) by state
or provincial statute (Australia and Uruguay); and 9 of 75 (12%)
by professional guidelines or agency oversight (Ecuador, Ghana,
Guatemala, India, and Côte d’Ivoire). Agency regulations were
followed in Côte d’Ivoire and Portugal. Oocyte maturation was
being held as a “cultural practice” in Switzerland. The status of the
regulatory body was reported as “unknown” for Cameroon,
Jordan, Panama, and United Arab Emirates (Table 1).
Discussion
Although there have been no significant discernible technical
advances in IVM technology since the 2015 survey, there appears















Never Performed Commonly Used Infrequently Used Unknown
Chapter 9. Chart 2. How often is oocyte maturation performed?
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Chapter 9. Table 1





If Oocyte Maturation Regulated
in Your Country,







Argentina Yes Yes Infrequently Used
Australia Yes State/Provincial/Regional Laws/Statutes/Ordinances Unknown Commonly Used
Austria No Yes Infrequently Used
Bangladesh No
Barbados No Infrequently Used
Belarus No Yes Never Performed
Belgium Unknown Federal/National Laws/Statutes/Ordinances/Policies Yes Commonly Used
Bolivia No Yes Commonly Used
Botswana No Yes
Brazil No Yes Infrequently Used
Bulgaria Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Burkina Faso No Yes Commonly Used
Cameroon No Unknown Yes Infrequently Used
Canada No Yes Infrequently Used
Chile No Yes Infrequently Used
China Unknown Yes Infrequently Used
Colombia No Yes Infrequently Used
Czechia No Yes Infrequently Used
Ecuador No Professional Organization Standards/Guidelines Yes
Egypt Yes Federal/National Laws/Statutes/Ordinances/Policies,
Professional Organization Standards/Guidelines
Yes Infrequently Used
El Salvador No Yes Never Performed
Finland No Yes Infrequently Used
Georgia No Yes Never Performed
Germany Unknown Federal/National Laws/Statutes/Ordinances/Policies No Unknown
Ghana No Professional Organization Standards/Guidelines Yes Infrequently Used
Greece Yes Yes Commonly Used
Guatemala No Professional Organization Standards/Guidelines Yes Infrequently Used
Hong Kong (China*) No Yes Infrequently Used
Hungary No Unknown Infrequently Used
Iceland No Yes Never Performed
India Yes Professional Organization Standards/Guidelines Unknown Infrequently Used
Ireland No Yes Never Performed
Italy No Yes Commonly Used
Côte d’Ivoire Unknown Agency Regulations/Oversight, Professional Organization
Standards/Guidelines
Yes Commonly Used
Japan No Yes Infrequently Used
Jordan No Unknown Yes Infrequently Used
Kazakhstan No Yes
Kenya No Yes Infrequently Used
Latvia No Yes Infrequently Used
Lithuania No Unknown Never Performed
Mali No No Never Performed
Mexico No Yes Infrequently Used
Mongolia No Yes Commonly Used
Montenegro Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
New Zealand Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Nigeria No No commonly Used
Norway Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Panama Unknown Unknown Yes Infrequently Used
Paraguay No Yes Never Performed
Peru No Yes infrequently Used
Philippines No Yes Infrequently Used
Poland Unknown Unknown Unknown




Romania No Yes Never Performed
Russian Federation No Yes Infrequently Used
Senegal No Unknown Never Performed
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of IVM since 2010. Despite having more countries participating
in the 2018 survey, overall responses are similar to those received
in 2015. Respondents appear to be more reticent to adopt IVM to
the extent that other micromanipulation techniques have been
applied in the absence of evidence suggesting comparable or
superior results when compared to conventional IVF.
Summary
Oocyte maturation is a critical step for successful IVF, and it is
essential that recovered oocytes be mature, competent,
and viable, to achieve fertilization and ultimately produce a
healthy offspring. It is a fundamental molecular and cellular
process integral to IVF that largely occurs in vivo. Realizing the
true clinical potential of IVM and opening new opportunities in
ART awaits additional translational advances, likely to be
accomplished with animal models for IVM [2,3]. Widespread
clinical adoption will require considerable additional evidence
regarding live birth rates, cumulative outcomes from frozen
oocytes and embryos, and long-term follow up, to assess risk.
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Micromanipulation embraces several unrelated technologies
routinely used in the successful application of assisted repro-
duction technology (ART). Some technologies are essential to the
selective practice of ART; they include intracytoplasmic sperm
injection (ICSI), embryo biopsy (polar body, cleavage stage, or
trophectoderm), and, possibly, assisted hatching[1]. The intro-
duction of ICSI, with the first successful pregnancy achieved in
1991, was a transformative event for ART, enabling many men
who previously had no way to achieve biologic fatherhood, to
produce offspring[2].
Embryo biopsy has also been employed for an array of pre-
implantation testing (PGT) applications, including selection of
embryos without specific genetic diseases – a process known as
preimplantation genetic testing for monogenic (single-gene) dis-
orders (PGT-M). The first successful use of PGT-M was for
selecting embryos unaffected by X-linked disease, reported in
1991[3]. PGT has also been used to identify and exclude embryos
with structural rearrangements (PGT-SR). Its most challenging,
but potentially most impactful application, has been for detecting
and excluding aneuploid embryos (PGT-A) for embryo transfer.
The latter use has been hampered by the protracted development
of a robust, reliable platform for performing a complete kar-
yotype on a limited number of cells extracted from a developing






If Oocyte Maturation Regulated
in Your Country,







Serbia Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Singapore No Yes Infrequently Used
Slovenia No Yes Infrequently Used
South Africa No Yes Infrequently Used
The Republic of Korea No Yes Commonly Used
Spain Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Sri Lanka Yes Yes Infrequently Used
Sweden No Yes
Switzerland No Yes Commonly Used
Taiwan (China*) No Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Thailand Yes Yes Commonly Used
Togo No Federal/National Laws/Statutes/Ordinances/Policies,
Professional Organization Standards/Guidelines
Trinidad and Tobago No Yes Infrequently Used
Turkey Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
Uganda No Yes Commonly Used
United Arab Emirates Unknown Unknown Unknown Unknown
UK Yes Federal/National Laws/Statutes/Ordinances/Policies Yes Infrequently Used
USA No Yes Infrequently Used
Uruguay No State/Provincial/Regional Laws/Statutes/Ordinances Unknown
Venezuela No Yes Commonly Used
Viet Nam No Federal/National Laws/Statutes/Ordinances/Policies Yes Commonly Used
Zimbabwe No Yes Unknown
*Reporting separately for this report.
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Chapter 10. Table 1a








Argentina Yes Commonly Used Commonly Used Yes Commonly Used
Armenia Yes Commonly Used Infrequently Used Yes Infrequently Used
Australia Yes Commonly Used Commonly Used Yes Commonly Used
Austria Yes Commonly Used Infrequently Used Yes Commonly Used
Bangladesh Yes Commonly Used Commonly Used No
Barbados Yes Commonly Used Commonly Used Yes Commonly Used
Belarus Yes Commonly Used Commonly Used Yes Commonly Used
Belgium Yes Commonly Used Commonly Used Yes Commonly Used
Bolivia Yes Commonly Used Commonly Used Yes Commonly Used
Botswana Yes Yes
Brazil Yes Commonly Used Commonly Used Yes Commonly Used
Bulgaria Yes Commonly Used Infrequently Used Yes Infrequently Used
Burkina Faso Yes Commonly Used Commonly Used Yes
Cameroon Yes Commonly Used Infrequently Used Yes Never Performed
Canada Yes Commonly Used Commonly Used Yes Commonly Used
Chile Yes Commonly Used Commonly Used Yes Commonly Used
China Yes Commonly Used Commonly Used Yes Commonly Used
Colombia Yes Commonly Used Commonly Used Yes Commonly Used
Czechia Yes Commonly Used Commonly Used Yes Commonly Used
Ecuador Yes Commonly Used Commonly Used Yes Commonly Used
Egypt Yes Commonly Used Commonly Used Yes Commonly Used
El Salvador Yes Commonly Used Infrequently Used Yes Infrequently Used
Finland Yes Commonly Used Commonly Used Yes Infrequently Used
Georgia Yes Commonly Used Commonly Used Yes Infrequently Used
Germany Yes Commonly Used Infrequently Used Unknown Unknown
Ghana Yes Commonly Used Commonly Used Yes Commonly Used
Greece No Commonly Used Infrequently Used Yes Infrequently Used
Guatemala Yes Commonly Used Commonly Used Yes Infrequently Used
Hong Kong (China*) Yes Commonly Used Commonly Used Yes Infrequently Used
Hungary Yes Commonly Used Commonly Used Yes Commonly Used
Iceland Yes Commonly Used Infrequently Used Yes Never Performed
India Yes Commonly Used Commonly Used Yes Infrequently Used
Ireland Yes Commonly Used Commonly Used Yes Infrequently Used
Italy Yes Commonly Used Commonly Used Yes Commonly Used
Côte d’Ivoire Yes Commonly Used Infrequently Used Unknown Unknown
Japan Yes Commonly Used Commonly Used Yes Commonly Used
Jordan Yes Commonly Used Infrequently Used Yes Infrequently Used
Kazakhstan Yes Commonly Used Commonly Used Yes Commonly Used
Kenya Yes Commonly Used Infrequently Used Yes Infrequently Used
Latvia Yes Commonly Used Commonly Used Yes Commonly Used
Lithuania Yes Commonly Used Commonly Used Yes Commonly Used
Mali Yes Commonly Used Commonly Used No Never Performed
Mexico Yes Commonly Used Commonly Used Yes Infrequently Used
Mongolia Yes Commonly Used Infrequently Used Yes Commonly Used
Montenegro Yes Commonly Used Commonly Used Yes Infrequently Used
New Zealand Yes Commonly Used Commonly Used Yes Commonly Used
Nicaragua Yes Commonly Used Commonly Used
Nigeria Yes Commonly Used Infrequently Used No Unknown
Norway Yes Commonly Used Commonly Used No Never Performed
Panama Yes Commonly Used Commonly Used Yes Commonly Used
Paraguay Yes Commonly Used Commonly Used Yes Commonly Used
Peru Yes commonly Used infrequently Used Yes infrequently Used
Philippines Yes Commonly Used Commonly Used Yes Commonly Used
Poland Yes Commonly Used Commonly Used Unknown Unknown
Portugal Yes Commonly Used Commonly Used Yes Commonly Used
Romania Yes Commonly Used Infrequently Used Yes Commonly Used
Russian Federation Yes Commonly Used Commonly Used Yes Commonly Used
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embryo. Recent progress in this area may lead to much greater
implantation rates, with potentially much higher live birth rates.
It could also provide a chance to greatly reduce the primary risk of
ART, multiple pregnancy, if a single euploid embryo could be
transferred for all age groups.
Micromanipulation may also be used for several investigative,
more controversial applications. These include cytoplasmic
transfer, mitochondrial transfer, and the recently described “gene
editing” technology, CRISPR-Cas9. No reports of human
application of the latter existed when the survey was completed
(March 2018).
Analysis of the survey
Of the respondents representing the 97 countries that partici-
pated in the 2018 Surveillance questionnaire, more than 70%
provided specific responses regarding micromanipulation.
Techniques of micromanipulation queried in the survey included
the performance and legal status of ICSI with ejaculated or sur-
gically obtained sperm; PGT with polar body, blastomere, or
trophectoderm biopsy; assisted hatching; and cytoplasmic
transfer, mitochondrial transfer, and CRISPR-Cas9 technology.
ICSI was permitted in almost all countries that responded to
the survey – 79 of 80 (99%) – but it was performed in all. ICSI
with sperm recovered following ejaculation is a common
procedure in 77 countries, but it is infrequent in Sri Lanka, and is
never performed in that country on surgically recovered sperm.
Most countries commonly perform ICSI with surgically
retrieved sperm, but the procedure is infrequent in 21 of 78 (27%)
(Table 1a). There were no regulations for ICSI in most countries;
it was regulated in 27 out of 79 (34%). In 30 countries out of 79
(38%), ICSI was regulated by federal or national laws. Regional/
state laws were followed in 7 countries out of 79 (9%). In 16 out
of 79 (20%), countries, professional organization standards/
guidelines were followed, and in two countries (Italy and Senegal)
municipal laws were the regulation authority. ICSI was held as a
cultural practice in Switzerland, and also in Italy, where the
application of ICSI was interdicted by religious decree. In 6
countries of 79 (7.5%), agencies were used for regulation. The
regulating authority was reported as “unknown” in 4 countries
of 79 (5%).
Polar body biopsy was permitted in 54 of 75 countries (72%),
but was commonly used in only 5 out of 70 (41%); infrequently
used in 29 out of 70 (41%), and never performed in 26 out of 70
(15%). Polar body biopsy was not permitted in 10 out of 75
countries (13%). Blastomere 61 out of 77 (79%) and tro-
phectoderm biopsy 61 out of 76 (80%) were allowed in most
countries, but were not permitted in 14%: 11 of 77, and 10 of 76,
respectively. Blastomere biopsy was used commonly in 30 of 72









Senegal Yes Commonly Used Infrequently Used Unknown Never Performed
Serbia Yes Commonly Used Infrequently Used Yes Commonly Used
Singapore Yes Commonly Used Infrequently Used Yes Infrequently Used
Slovenia Yes Commonly Used Commonly Used Yes Infrequently Used
South Africa Yes Commonly Used Commonly Used Yes Infrequently Used
The Republic of
Korea
Yes Commonly Used Commonly Used Yes Commonly Used
Spain Yes Commonly Used Commonly Used Yes Commonly Used
Sri Lanka Yes Infrequently Used Never Performed Yes Infrequently Used
Sweden Yes Yes
Switzerland Yes Commonly Used Commonly Used Yes Infrequently Used
Taiwan (China*) Yes Commonly Used Commonly Used Yes Commonly Used
Thailand Yes Commonly Used Commonly Used Yes Commonly Used
Togo Yes Commonly Used Commonly Used Yes Commonly Used
Trinidad and
Tobago
Yes Commonly Used Commonly Used Yes Never Performed
Turkey Yes Commonly Used Commonly Used Yes Commonly Used
Uganda Yes Commonly Used Commonly Used Yes Infrequently Used
United Arab
Emirates
Yes Commonly Used Infrequently Used Yes Infrequently Used
UK Yes Commonly Used Infrequently Used Yes Infrequently Used
USA Yes Commonly Used Infrequently Used Yes Commonly Used
Uruguay Yes commonly Used commonly Used Yes infrequently Used
Venezuela Yes Commonly Used Commonly Used Yes Commonly Used
Viet Nam Yes Commonly Used Commonly Used Yes Commonly Used
Zimbabwe Yes Commonly Used Commonly Used Yes Unknown
*Reporting separately for this report.
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Chapter 10. Table 1b
Are these laboratory techniques allowed/permitted and practiced/performed in your country?
Polar Body Biopsy Blastomere Biopsy Trophectoderm Biopsy





Argentina Yes Unknown Yes Commonly Used Yes Commonly Used
Armenia Yes Yes Infrequently Used
Australia Unknown Unknown Unknown
Austria Yes Commonly Used Yes Never Performed Yes Commonly Used
Bangladesh No No No
Barbados Never Performed Never Performed Yes Commonly Used
Belarus No Infrequently Used Yes Infrequently Used Yes Commonly Used
Belgium Yes Commonly Used Yes Commonly Used Yes Unknown
Bolivia Yes Yes Commonly Used Yes Commonly Used
Botswana Yes Yes Yes
Brazil Yes Unknown Yes Commonly Used Yes Commonly Used
Bulgaria Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
Burkina Faso Yes Yes
Cameroon Unknown Never Performed No Never Performed No Never Performed
Canada Yes Infrequently Used Yes Infrequently Used Yes Commonly Used
Chile Yes Infrequently Used Yes Commonly Used Yes Commonly Used
China Yes Never Performed Yes Commonly Used Yes Never Performed
Colombia Unknown Never Performed Yes Infrequently Used Yes Commonly Used
Czechia Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Egypt Yes Never Performed Yes Commonly Used Yes Commonly Used
El Salvador No Never Performed No Never Performed No Never Performed
Finland Yes Unknown Yes Commonly Used Yes Commonly Used
Georgia Yes Unknown Yes Commonly Used Yes Commonly Used
Germany Yes Infrequently Used No Unknown No Never Performed
Ghana Yes Never Performed Yes Unknown Yes Unknown
Greece Yes Infrequently Used No Commonly Used Yes Commonly Used
Guatemala Yes Never Performed Yes Commonly Used Yes Commonly Used
Hong Kong (China*) Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Hungary Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
Iceland Yes Never Performed Yes Never Performed Yes Never Performed
India Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Ireland Yes Infrequently Used Yes Never Performed Yes Infrequently Used
Italy Yes Commonly Used Yes Commonly Used Commonly Used
Côte d’Ivoire No Unknown No Unknown No Unknown
Japan Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Jordan Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
Kazakhstan Yes Commonly Used Yes Yes
Kenya Unknown Infrequently Used Yes Infrequently Used Yes Infrequently Used
Latvia Yes Unknown Yes Commonly Used Yes Commonly Used
Lithuania Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
Mali No Never Performed No Never Performed No Never Performed
Mexico Unknown Unknown Yes Commonly Used Yes Commonly Used
Mongolia Yes Never Performed Yes Never Performed Yes Never Performed
Montenegro Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
New Zealand Yes Never Performed Yes Infrequently Used Yes Commonly Used
Nigeria No never Performed No never Performed No never Performed
Norway No Never Performed No Never Performed No Never Performed
Panama Unknown Infrequently Used Yes Commonly Used Yes Commonly Used
Paraguay Yes Never Performed Yes Commonly Used Yes Commonly Used
Peru Yes never Performed Yes commonly Used Yes commonly Used
Philippines Unknown Yes Unknown Yes Infrequently Used
Poland Unknown Unknown Unknown Unknown Unknown Unknown
Portugal Unknown Unknown Unknown Unknown Unknown Unknown
Romania No Never Performed No Never Performed No Never Performed
Russian Federation Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Senegal Unknown Never Performed Unknown Never Performed Unknown Never Performed
Serbia No Never Performed No Never Performed No Never Performed
Singapore No Never Performed Yes Infrequently Used Yes Infrequently Used
Slovenia Yes Never Performed Yes Commonly Used Yes Infrequently Used
South Africa Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29 Global Reproductive Health
94
Chapter 10. Table 1b
(Continued)
Polar Body Biopsy Blastomere Biopsy Trophectoderm Biopsy







Yes Commonly Used Yes Commonly Used Yes Commonly Used
Spain Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Sri Lanka Unknown Infrequently Used Unknown Infrequently Used Unknown Unknown
Sweden Yes Yes Yes
Switzerland Yes Infrequently Used Yes Infrequently Used Yes Commonly Used
Taiwan (China*) Yes Infrequently Used Yes Infrequently Used Yes Commonly Used
Thailand Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Togo Never Performed Never Performed Never Performed
Trinidad and Tobago Yes Never Performed Yes Never Performed Yes Never Performed
Turkey Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Uganda Yes Never Performed Yes Infrequently Used Yes Infrequently Used
United Arab
Emirates
Yes Never Performed Yes Infrequently Used Yes Commonly Used
UK Yes Infrequently Used Yes Infrequently Used Yes Commonly Used
USA Yes Infrequently Used Yes Infrequently Used Yes Commonly Used
Uruguay Yes infrequently Used Yes commonly Used Yes Unknown
Venezuela Yes Never Performed Yes Commonly Used Yes Commonly Used
Viet Nam Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Zimbabwe Yes Unknown Yes Unknown Yes Unknown
*Reporting separately for this report.
Chapter 10. Table 1c
Are these laboratory techniques allowed/permitted and practiced/performed in your country?
Cytoplasmic Transfer Mitochondrial Transfer CRISPR
Country Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Argentina Yes Unknown Yes Unknown Yes Unknown
Australia No No Never Performed No Never Performed
Austria Unknown Never Performed Unknown Never Performed No Never Performed
Bangladesh No No No
Barbados Never Performed Never Performed Never Performed
Belarus No Never Performed No Never Performed No Never Performed
Belgium Unknown Unknown Unknown Unknown Unknown Unknown
Bolivia Yes Infrequently Used Yes Never Performed Yes Unknown
Botswana Yes Yes Yes
Brazil No Unknown No Unknown Unknown Unknown
Bulgaria Unknown Unknown Unknown Unknown Unknown Unknown
Cameroon Unknown Never Performed No Never Performed No Never Performed
Canada Yes Infrequently Used Yes Infrequently Used Yes Unknown
Chile Unknown Unknown Unknown Unknown Unknown
China Yes Infrequently Used Yes Never Performed Unknown Never Performed
Colombia Yes Infrequently Used Yes Infrequently Used Yes Infrequently Used
Czechia No Unknown No Never Performed No Never Performed
Egypt Unknown Unknown Unknown Unknown Unknown Unknown
El Salvador No Never Performed No Never Performed Unknown Never Performed
Finland Unknown Unknown Unknown Unknown Yes Infrequently Used
Georgia Yes Never Performed Unknown Never Performed Unknown Never Performed
Germany Unknown Unknown No Unknown No Unknown
Ghana Unknown Never Performed Unknown Unknown Unknown Never Performed
Greece Yes Infrequently Used Yes Commonly Used Yes Commonly Used
Guatemala Yes Never Performed Yes Never Performed Yes Never Performed
Hong Kong (China*) Unknown Unknown Unknown
Hungary No Unknown Unknown Unknown Unknown Unknown
Iceland Unknown Never Performed Unknown Never Performed Unknown Never Performed
India Unknown Infrequently Used Unknown Never Performed Unknown Never Performed
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(42%) countries, infrequently used in 20 of 72 (28%), and never
performed in 15 of 72 (21%). Trophectoderm biopsy was used in
38 of 73 (52%) countries. It was infrequently used in 13 of 73
(18%) of countries, and never performed in 14 of 73 (19%)
(Table 1b).
Seventy-six countries responded to questions regarding the
regulation of these techniques; 15 countries (20%) regulated
polar body biopsy, 6 countries (21%) regulated blastomere
biopsy, and 19 countries (25%) regulated trophectoderm biopsy.
Biopsy procedures were regulated by federal or national laws in
19 of 35 (54%) countries, and state or regional laws in 3 of 8
(37.5%) of the reporting countries. Polar body biopsy is regu-
lated by municipal rules, agencies, and religious decree in Greece.
Brazil also had regulation of polar body biopsy, by agency reg-
ulations or oversight. Professional organization recommenda-
tions were used in 10 of 17 (59%) of reporting countries. Biopsy
Chapter 10. Table 1c
(Continued)
Cytoplasmic Transfer Mitochondrial Transfer CRISPR
Country Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Ireland No Never Performed No Never Performed No Never Performed
Italy No Commonly Used No Commonly Used No Commonly Used
Côte d’Ivoire Unknown Unknown No Unknown Unknown Unknown
Japan Unknown Infrequently Used Unknown Infrequently Used Unknown Never Performed
Jordan No Infrequently Used Unknown Unknown Unknown Unknown
Kazakhstan Yes Commonly Used Yes Yes
Kenya Unknown Unknown Unknown Unknown Unknown Unknown
Latvia Unknown Never Performed Unknown Never Performed Unknown Never Performed
Lithuania Unknown Never Performed Unknown Never Performed Unknown Never Performed
Mali No Never Performed No Never Performed No Never Performed
Mexico Unknown Unknown Unknown Infrequently Used Unknown Unknown
Mongolia Yes Never Performed Yes Never Performed Yes Never Performed
Montenegro Never Performed Never Performed Never Performed
New Zealand No Never Performed No Never Performed No Never Performed
Nigeria No Unknown No Unknown No Unknown
Norway No Never Performed No Never Performed No Never Performed
Panama Unknown Infrequently Used Unknown Unknown Unknown Unknown
Paraguay Unknown Never Performed Unknown Never Performed Unknown Never Performed
Peru Unknown Unknown Unknown Yes Unknown
Philippines Unknown Unknown Unknown Unknown Unknown Unknown
Poland Unknown Unknown Unknown Unknown Unknown Unknown
Portugal Yes Unknown Unknown Unknown Unknown Unknown
Romania No Never Performed No Never Performed No Never Performed
Russian Federation Yes Unknown Yes Unknown Yes Unknown
Senegal Unknown Never Performed Unknown Never Performed Unknown Never Performed
Serbia No Never Performed No Never Performed No Never Performed
Singapore No Never Performed No Never Performed No Never Performed
Slovenia Unknown Never Performed Unknown Never Performed Unknown Unknown
South Africa No Never Performed No Never Performed No Never Performed
The Republic of Korea No Commonly Used No Never Performed No Never Performed
Spain Unknown Unknown No Never Performed No Never Performed
Sri Lanka Unknown Unknown No Unknown Unknown Unknown
Sweden No No Yes
Switzerland No Never Performed No Unknown No Unknown
Taiwan (China*) No Never Performed No Never Performed No Never Performed
Thailand Yes Infrequently Used Yes Infrequently Used Yes Never Performed
Togo Never Performed Never Performed Never Performed
Trinidad and Tobago Unknown Never Performed Unknown Never Performed Unknown Never Performed
Turkey No Never Performed Unknown Never Performed Unknown Never Performed
Uganda Yes Never Performed Unknown Never Performed Unknown Unknown
United Arab Emirates Unknown Unknown Unknown Unknown Unknown Unknown
UK No Never Performed Yes Infrequently Used No Never Performed
USA No Never Performed No Never Performed Yes Infrequently Used
Uruguay Unknown Infrequently Used Unknown Unknown No Unknown
Venezuela Yes Never Performed Yes Never Performed Unknown Never Performed
Viet Nam Unknown Unknown Unknown Unknown Unknown Unknown
Zimbabwe Yes Unknown Yes Unknown Yes Unknown
*Reporting separately for this report.
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procedures were addressed as a cultural practice in Switzerland.
Respondents for 6 countries answered “unknown”.
In 71 of 79 (90%) of countries reporting, assisted hatching was
said to be allowed. Assisted hatching was commonly used in 40 of
75 (53%) of countries, and was infrequently done in another 24
(32%). Five countries (7%) reported “unknown”, and said it was
never performed in 6 countries (8%). Twenty-one countries - 78 -
did report the existence of regulations for assisted hatching. The
majority of countries – 21 (95%) – that cited regulation of
assisted hatching noted the presence of federal or national law,
and three (14%) were regulated by state/regional law. Only one
country, Portugal, had agency regulation for assisted hatching.
Professional organization standards or guidelines were used by 8
countries (38%). Assisted hatching was addressed as a cultural
practice in Switzerland and Greece. The regulating body was
reported as “unknown” by 4 countries.
Twenty five of 73 (34%) countries, but was allowed in 17
countries (23%). Cytoplasmic transfer was never performed in 33
of 71 (46%), and infrequently in 11 of 73 (15%). It was reported
to be commonly used in three countries – Italy, Kazakhstan, and
The Republic of Korea. Specific regulations for cytoplasmic
transfer existed in 12 of 75 countries (16%). Cytoplasmic transfer
was regulated by federal or national laws in 9 countries of 12
(75%). Portugal relied on agencies for regulation, and 6 countries
followed professional organization standards or guidelines. The
responsible regulatory body was reported as “unknown” for 6
countries (Table 1c).
Mitochondrial transfer was permitted in only 15 of 72 coun-
tries (21%).Mitochondrial transfer was never performed in 37 of
70 (53%), and infrequently in 6 countries (9%): Canada,
Colombia, Japan, Mexico, Thailand, and United Kingdom of
Great Britain and Northern Ireland. Mitochondrial transfer
applications were regulated by federal or national legislation in
Australia, Norway, Turkey, and United Kingdom of Great
Britain and Northern Ireland. Professional organization stan-
dards or guidelines were observed in 4 countries. The regulation
authority was “unknown” in seven countries (Table 1c).
CRISPR-Cas9 technology was permitted in 16 of 73 (22%).
CRISPR-Cas9 technology was reported to be commonly used in
Greece and Italy, according to 71 responders (3%), and infre-
quently used (4%) in Colombia, Finland, and The United States
of America. Regulations existed in 8 of 74 countries (11%) for
mitochondrial transfer, and in 6 of 75 (8%) countries for
CRISPR-Cas9 technology. Federal or national laws regulated
CRISPR-Cas9 technology in Australia, Norway, Singapore,
Turkey, and United Kingdom of Great Britain and Northern
Ireland. Professional organization standards or guidelines as
existing recommendations were followed in Guatemala,
Thailand, and The United States of America. Six countries replied
“unknown” (Table 1c).
Discussion
While all these technologies are micromanipulation techniques,
they have a much different status in the successful deployment of
ART. ICSI is an indispensable tool, widely embraced after vali-
dation and successful global application. It is almost universally
accepted, performed successfully, and used with minimal reg-
ulatory oversight. This has been the case for many years, and the
current survey has not revealed any significant changes.
PGT is a promising technology with successful, validated
applications for PGT-M and PGT-SR. After an earlier proble-
matic launch with a less successful technology, PGT-A may now
be poised to be the next great breakthrough. However, after
previous false starts, it is particularly critical that it be validated
with successful widespread application before it can be uni-
versally recommended. Assisted hatching has been practiced for
over 25 years, and has been shown to improve embryo implan-
tation rates in certain circumstances by certain labs. The lack of
clearly defined indications and the variable experience among
ART labs has precluded its universal application, thus far. PGT is
addressed in more detail in Chapter 13.
Cytoplasmic and mitochondrial transfer, and CRISPR-Cas9
are investigative technologies that hold great promise for
addressing some of the most challenging clinical problems. But all
are fraught with potential greater risks, and pose unique ethical
dilemmas. None appears to be ready for broad clinical applica-
tion at this time, as reflected by their limited use and acceptance.
The 2018 questionnaire did not identify any emerging trends
regarding these three technologies.
Summary
The ability to performmicromanipulation procedures on gametes
and embryos has vastly expanded the scope of ART, but the
various procedures are at different stages of development. ICSI is
a universally available procedure, performed in all responding
countries, but not officially sanctioned in one (Greece).
Micromanipulation procedures, including ICSI and PGT-M, are
now essential technologies; they are widely available in compre-
hensive ART centres. PGT-A and assisted hatching, shown to be
useful adjuncts in certain circumstances, are still being defined in
terms of their specific indications and overall value. The pre-
liminary experiences with cytoplasmic transfer, mitochondrial
transfer, and CRISPR-Cas9 technology have been promising, but
these applications remain investigative; an accurate assessment of
their true potential, limitations, and risks is awaited.
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CHAPTER 11: WELFARE OF THE CHILD AND
IDENTITY RIGHTS
Introduction
Safety, particularly for the offspring, has been of the utmost
concern since the advent of ART. As early as 1985[1], publications
have suggested that the risk of obstetrical and neonatal morbidity
might be increased after ART. Reports were many; they included
matched and non-matched studies of singletons and twins, and,
more recently, reviews and meta-analyses[2] comparing outcomes
of spontaneous pregnancies after various procedures. The pro-
cedures include intracytoplasmic sperm injection (ICSI), elective
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Chapter 11. Table 1























Argentina No No No No No Yes No No
Australia Yes Yes


















El Salvador No No No No No No No No
Finland No Yes No No No Yes No No
Georgia Yes
Germany No Yes Yes
Ghana Yes Yes
Greece No Yes Yes No Yes No Yes Yes








Italy No No No No No No No No





Latvia Yes No No Yes No
Lithuania No Yes No No No Yes No No
Mali No
Mexico No No No No No No No No
Mongolia Yes No No No No No No No
Montenegro No Yes
New Zealand Yes Yes
Nicaragua Yes
Nigeria Yes Yes Yes
Norway Yes Yes No No No No No No
Panama Yes Unknown Unknown Unknown Unknown Unknown Unknown
Paraguay No Yes No No Yes Yes Yes Yes
Peru No Yes Yes Yes Yes Yes Yes Yes
Philippines Yes Yes Yes Yes Yes
Poland Yes Yes Yes Yes Unknown Yes Yes Yes
Portugal No Yes No No Yes Yes Unknown Unknown
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single embryo transfer (eSET), frozen embryo transfer (FET), and
blastocyst transfers. A marked increase in cases of antepartum
hemorrhage, hypertensive disorders, prematurity, low birth
weight, and perinatal mortality has occurred in the latter groups.
Many current ART practices and techniques have the potential to
harm the embryo; these include extended culture beyond the
cleavage stage; invasive genetic testing; vitrification and warming
procedures; and expanded applications for ICSI. These unre-
solved concerns make careful follow-up of newborns and chil-
dren born from ART cycles, of paramount importance.
Much more recently, concern for the child’s welfare has been
expanded to include an assessment of social factors pertaining to
the prospective parents’ ability to provide a suitable home
environment, before embarking on treatment. A model for best
practice was enshrined in the Human Fertilisation and
Embryology Authority’s (HFEA’s) code of practice of the United
Kingdom of Great Britain and Northern Ireland. The model
provides guidance parameters for assessing, obtaining further
information, and refusing treatment[5]. These measures have been
adopted by many other countries, as well.






























Spain Yes Yes No No Yes No No
Sri Lanka Yes








No No No No No No No No
Turkey Yes Yes




UK No Yes No No No No No No
USA No No No No No Yes No No
Uruguay No Yes No No No No No No
Venezuela No No No No No Yes No No
Viet Nam Unknown No
Zimbabwe Yes Yes Yes Yes Yes Yes Yes






























Chapter 11. Chart 1. Are there practices or regulations that address the welfare of the child in your country?








Can fertility care be declined if there are concerns
regarding the welfare of any potential future children?
Is a formal assessment of the welfare of the child an
obligatory part of the fertility clinic evaluation of the
prospective parents?
Yes No Unknown
Chapter 11. Chart 2. Formal assessment of the welfare of a child.
Chapter 11. Table 2
































Argentina No No No Yes Yes Yes
Australia Yes Yes Yes Yes Yes Yes
Austria No No No Yes Yes No
Belarus Unknown Unknown Unknown Unknown Unknown Unknown
Bolivia Yes Yes Yes Yes Yes
Botswana No Yes No No Yes No
Brazil No No No Yes Yes Yes
Bulgaria Unknown Unknown Unknown Yes Yes Yes
Burkina
Faso
No No No No No No
Cameroon No No Yes Yes No Yes
Canada Unknown Unknown Unknown Unknown Unknown Unknown
Chile No No No No No No
China No No No No No
Colombia No No No Yes Yes Yes
Czechia Unknown Unknown Unknown Unknown Unknown Unknown
Ecuador No No No Yes Yes
Egypt No No No No No No
El Salvador Unknown Unknown Unknown Yes Yes Yes
Finland Unknown Unknown Yes Yes Yes Yes
Georgia No No No Yes Unknown Yes
Germany Unknown Unknown Unknown Unknown Unknown Unknown
Ghana No No No Yes Yes Yes
Greece No Yes Yes Yes Yes Yes
Guatemala No No No No No Yes
Hong Kong
(China*)
Yes Yes Yes Yes Yes Yes
Hungary No No No Yes Yes Yes
Iceland No Yes No Yes Yes Yes
India No No No No No
Ireland No No No Yes Yes Yes
Italy Yes Yes Yes Yes Yes Yes
Côte d’Ivoire Unknown Unknown Unknown Unknown Unknown Unknown
Japan No No No Yes Yes Yes
Jordan Unknown No Unknown Yes Unknown Unknown
Kazakhstan Yes No No No No No
Kenya No No No Yes Yes Yes
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29 Global Reproductive Health
100
Analysis of the survey
Respondents representing 78 countries provided data for the
2018 questionnaire about measures in place to address the wel-
fare of the child. Of this number, 41 of 55 (74.5%) noted the
existence of federal laws or statutes dealingwith the welfare of the
child. This situation was prevalent in most of the European
countries and in the United Kingdom of Great Britain and
Northern Ireland; Australia, Botswana, Canada, Côte d’Ivoire,
Ghana, Hong Kong [China, reporting separately for this report],
New Zealand, Nigeria, Philippines, Russian Federation,
Singapore, South Africa, Taiwan [China, reporting separately for
this report], Thailand, Uganda, United Arab Emirates, and

































Latvia No No No Yes No Yes
Lithuania No No No Yes Yes Yes
Mali Unknown Unknown Unknown Unknown Unknown Unknown
Mexico No No No No No No




Yes Yes Yes No Yes Yes
Nigeria No No No No No No
Norway Yes Yes Yes Yes Yes
Panama No No No No No No
Paraguay No No No No No No
Peru Unknown Unknown Unknown Yes Yes Yes
Philippines Unknown Unknown Unknown Unknown Unknown Unknown
Poland Unknown Unknown Unknown Unknown Unknown Unknown
Portugal Unknown Yes Unknown Yes Yes Yes
Romania No No No No No No
Russian Federation No No No Yes Yes
Yes
Senegal No No No No No No
Serbia Yes Yes Yes Yes Yes Yes
Singapore No No No Yes Yes Yes
Slovenia Yes Yes Yes Yes Yes Yes




Unknown Unknown Unknown Yes Yes
Spain No No No No Yes Yes
Sri Lanka Unknown Unknown Unknown Unknown Unknown Unknown
Switzerland No No Yes Yes Yes Yes
Taiwan
(China*)
Yes Yes Yes Yes Yes Yes
Thailand Yes No No Yes Yes Yes
Togo Unknown Unknown Unknown Unknown Unknown Unknown
Trinidad and
Tobago
Yes Yes Yes Yes Yes Yes
Turkey No No No No No No
Uganda No No No No No No
United Arab
Emirates
No No No Yes Yes Yes
UK Yes Yes Yes Yes Yes Yes
USA No No No Yes Yes Yes
Uruguay Yes Unknown Unknown Yes Yes Unknown
Venezuela No No Unknown Yes Yes Yes
Viet Nam Yes Yes Yes Yes Yes Yes
Zimbabwe No No No No No No
*Reporting separately for this report.
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Zimbabwe; also, several countries in South America: Colombia,
Nicaragua, Paraguay, Peru, and Uruguay. Some countries, 13 of
36 (36%), also had state or provincial laws in place. Twenty-
seven of 56 (48%) did not have any regulation regarding this
issue, and 17% (6/36) reported having only professional orga-
nization. These included Argentina, Ecuador, India, Japan, The
United States of America, and Venezuela. Two countries, Belarus
and Belgium, responded “unknown” (Table 1, Chart 1).
Formal assessment of the potential welfare of the child was
either not an obligatory part of the fertility clinic evaluation of
prospective parents, or the issue was “unknown” for the major-
ity, 74%, of responding countries (53 of 72). Nineteen countries
(26%) responded that a formal assessment of the welfare of the
child was a requirement, including Austria, Bolivia, Botswana,
Ecuador, El Salvador, Finland, Ghana, Greece, Hong Kong
[China, reporting separately for this report], Hungary, Norway,
Portugal, Serbia, Slovenia, Spain, Switzerland, Trinidad and
Tobago , Turkey, and the United Kingdom of Great Britain and
Northern Ireland (Chart 2).
Fertility care could be denied in 38 of 73 countries (52%) if
concerns about thewelfare of a potential future child existed. Eleven
responders (15%) reported that they could not deny treatment for
this reason, and the status was “unknown” for 24 (33%).
Additional questions surveyed prior background evaluations
of prospective parents’ clinical, psychiatric, and derelictive his-
tories (Table 2). Nine of 73 (12%) report asking about any pre-
vious convictions related to any of the following: harming a child,
history of family violence, social services contacts regarding care
of other children, alcohol or drug abuse, serious mental or phy-
sical illness that could impair child care, or counseling about the
child’s risk of a serious medical condition. These countries
include Australia, Hong Kong [China, reporting separately for
this report], Italy, Serbia, Slovenia, Taiwan [China, reporting
separately for this report], Trinidad and Tobago, United
Kingdom of Great Britain and Northern Ireland, and Viet Nam.
Another 12 of 73 (16%) declared prospective parents were not
asked about any of these issues. Spain and Ecuador reported
assessing the child’s risk of a serious medical condition, and the
existence of a serious mental or physical condition in prospective
parents that could impair child care. Botswana reported assessing
the existence of a seriousmental or physical condition, and asking
social services for contacts regarding care of other children
(Chart 3).
Discussion
Although a sizeable majority of countries have no requirements
for formally assessing the potential welfare of the child, some
countries that do the assessment have considerably expanded
their concerns. Increasingly, their assessment includes a rigorous
pre-conception evaluation of social risk factors, along with a
postnatal surveillance of neonatal and ongoing childhood
development, something that has long been in place in many
countries. While these pre-treatment measures now encompass
more, and include sanctions to deny care in some countries, their
impact has not been determined. In contrast, many of these
countries have comprehensive registries evaluating the sub-
sequent progress of ART children. And a clearer picture of the
risks of ART is beginning to emerge.
Congenital anomalies have reportedly increased in newborns,
after ART cycles[3]. After adjusting for parental factors, a relative
risk of 1.07 exists (95% CI, 0.90 to 1.26) for IVF and 1.57 (95%
CI, 1.30 to 1.90) for ICSI. In newborns conceived with ICSI, but
not with conventional IVF, an increase in de-novo sex chromo-
some anomalies and structural autonomic anomalies has been
reported, probably inherited through the paternal pathway[4].
A variety of possible factors may have contributed to this
putative increase in morbidity. These factors include parental
background unrelated to the ART process, clinical interventions
such as ovarian stimulation and endometrial preparation, and
technical issues involving manipulation of the early developing
embryo. While more recent reports have provided some reas-



















Previous convictions related to harming a child
Contact with social service regarding care of other children
A history of violance or serious discord within the family
Drug or alcohol abuse
The existence of serious mental or physical conditions that might impair their ability to
take care of a child
Risk to the child of a serious medical condition
Yes No Unknown
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singleton pregnancies than earlier reports, potential advantages
of programmed over fresh cycle transfers and more reliable
strategies to prevent ovarian hyperstimulation, a contemporary
estimate of neonatal and maternal risk is still forthcoming.
Summary
The results of the survey reflect a very heterogeneous scenario in
the importance given to the welfare of the child and the attention
given to the welfare, although it shows a trend towards more
attention paid to the correct assessment at time of prospective
parent assessment and consultation. Welfare of the child is
addressed mostly by federal or local laws/statutes, and, in coun-
tries without a law in place, professional organizations offer
guidelines and standards to properly assess prospective parents.
Sometimes these organizations also provide reporting mechan-
isms for monitoring newborn and child welfare.
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CHAPTER 12: FETAL REDUCTION AND SEX
SELECTION
Introduction
Historically, ART has been associated with an unacceptably high
multiple-pregnancy rate. This is a direct consequence of the
practice of transferring more than one embryo. Many countries
mandated the practice of single-embryo transfer more than fifteen
years ago, and recent advances in embryo culture and embryo
selection have further reduced the need for multiple transfer.
There has been a dramatic reduction in multiple-pregnancy
rates in many countries, but the reduction has not been universal.
Multiple pregnancies, especially those of high order, confer a
considerable risk of inherent complications and sequelae. Fetal
reduction is an established method to reduce the number of
fetuses, improve the live-birth rate, and reduce risks to the sur-
viving fetuses – risks of prematurity and other complications
associated with multiple pregnancy.
In many ART centres, with preimplantation genetic screening
for aneuploidy (PGT-A), has greatly improved the embryo
selection process, routinely offering a greater than 50% chance of
implanting a single euploid embryo. While these screening tools
have great benefits in distinguishing normal from abnormal
Chapter 12. Table 1
Is selective fetal reduction allowed permitted and practiced/




Argentina Not allowed Yes Infrequently used
Australia Allowed Yes Infrequently used
Austria Allowed Yes Infrequently used
Bangladesh Not Addressed Yes Infrequently used
Barbados Not Addressed No
Belarus Allowed Yes Infrequently used
Belgium Allowed Yes Frequently used
Bolivia Not allowed Unknown




Bulgaria Allowed Yes Frequently used
Burkina Faso Unknown Yes Infrequently used
Cameroon Allowed Yes Infrequently used
Canada Allowed Yes Infrequently used














El Salvador Not allowed No




Germany Not allowed No




Guatemala Not Addressed Unknown





India Allowed Yes Infrequently used
Ireland Not allowed No
Italy Allowed Yes Infrequently used
Côte d’Ivoire Unknown Unknown
Japan Not Addressed Yes Infrequently used
Jordan Allowed Yes Infrequently used
Kazakhstan Allowed Yes Infrequently used
Kenya Not Addressed Unknown
Latvia Allowed Yes Infrequently used
Lithuania Not allowed No
Mali Not Addressed No
Mexico Not allowed No
Mongolia Not Addressed Unknown
Montenegro Allowed Yes Infrequently used





Norway Allowed Yes Infrequently used
Panama Not allowed Unknown
Paraguay Not allowed No
Peru Not allowed No
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embryos, a potentially unanticipated or undesired result is the
disclosure of the gender of the embryo. This application has
become themost reliable method of selecting fetal gender, and has
been extensively used for this purpose in some countries, with its
attendant moral and ethical controversies.
Analysis of the survey
Regarding whether selective fetal reduction (SFR) was permitted, 47
of 77 countries (61%) responded positively, compared to 21 coun-
tries in the 2015 survey (Table 1, Chart 1). Of note, China and
Czechia acknowledged that their status had changed from“allowed,”
in the previous survey, to “allowed with conditions” in 2018.
The majority allowing SFR are in Europe. Another 17 (22%)
of the countries do not allow SFR at all, and, as noted in 2016,
most are in South America. Venezuela and the United Arab
Emirates are new additions. The issue has not been addressed in 7
(9%) of the countries. The status of SFR in the remaining 6 out of
77 (8%) of countries is “unknown”. Seventeen of the 47 per-
mitting countries (36%) allow SFR, with conditions applied.
SFR is performed in 52 of 78 countries (67%), but it is used
infrequently in most – 48 of 68 (62%), Exceptions include
Belgium, Bulgaria, Czechia, and Greece, where SFR is employed
“frequently”. This trend toward SFR use has carried forward
since the last survey. Italy responded in the last survey that SFR
was not used, but in 2018 noted that it is used, but infrequently.
Venezuela was the only country that responded in 2018 that SFR
is not allowed – but is performed.
Fifty-five percent n=Twenty-six of 47 countries responding
(55%) have federal or national regulations governing the practice
of SFR. Of these 26, 2 also have state laws and ordinances;
Bolivia has municipal laws, as well. One country (2%) has agency
regulations, and 16 countries (34%) have professional organi-
zational guidelines for SFR. Of these 16 with guidelines, 7 (44%)
have no federal or state requirements, only professional organi-
zational guidelines. Four countries have cultural and religious
policies addressing SFR, in addition to other governances.
Only 19 of 66 surveyed (29%) consistently monitor or docu-
ment SFR outcomes. That group includes several European

























Slovenia Allowed Yes Infrequently used
South Africa Allowed Yes Infrequently used
The Republic of
Korea
Allowed Yes Infrequently used
Spain Allowed Yes Infrequently used
Sri Lanka Not allowed No
Switzerland Allowed Yes Infrequently used
Taiwan (China*) Allowed Yes Infrequently used
Thailand Not allowed Unknown
Togo Unknown Unknown




Uganda Unknown Yes Infrequently used
United Arab Emirates Not allowed No
UK Allowed Yes Infrequently used




Venezuela Not allowed Yes Infrequently used
Viet Nam Allowed Yes Infrequently used
Zimbabwe Unknown No
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countries, New Zealand, and Singapore. Nine countries of 66
(14%) conduct partial or inconsistent monitoring, while 25
countries (38%) do not monitor at all. Remarkably, several
countries – including China, India, Russian Federation, and The
United States of America – conducted regular monitoring and
documentation in 2015, but reported “inconsistent” document-
ing and monitoring in 2018.
Twenty one of 48 (44%) permit sex selection with PGT-A.
Another 6 countries (12.5%), Chile, Ecuador, Guatemala,
Mexico, Panama, and Peru, perform PGT-A, although the survey
did not address whether using it for sex selection is legally per-
missible. Twenty-one of 50 countries (42%) also allow sex
selection via sperm sorting; 4 countries (8%) actually use it.
Thirteen countries out of 52 (25%) have regulations covering
PGT-A use, 10 countries out of 55 (18%), for sperm sorting, and
15 countries out of 55 (59%) for SFR. Only 5 countries, Bulgaria,
Hong Kong [China, reporting separately for this report], New
Zealand, Singapore, and South Africa have regulations for all 3
categories (Table 2, Chart 2).
For PGT-A, 8 countries of 13 (61.5%) reported having gov-
ernance regulated by federal or national statutes, ordinances or
policies: 2 (15%) by state or provincial policies or legislation, 1
(8%) by municipal laws, statutes or ordinances, 2 (15%) by pro-
fessional organizations standards or guidelines, one (8%) by
existing cultural practices, and one (8%) by religious decrees. For
sperm sorting, 8 countries (n=13) reported having governance
regulated by federal or national statutes, ordinances or policies,
and 1 (8%) by state or provincial policies or legislation. For SFR,
15 responders in 15 countries (100%) reported having governance
regulated by federal or national statutes, ordinances or policies, 2
(21%), by state or provincial policies or legislation, 1 (7%) by
municipal laws, statutes or ordinances, 2 (21%) by agency reg-
ulation or oversight, 2 (21%) by professional organizations stan-
dards or guidelines, and one (8%) by existing cultural practices.
Regarding centres where sex selection techniques were
allowed, there was no significant difference in the type of clinic
reporting. This applied to sole practitioners, small and large
private clinics, public hospitals, and university hospitals. China
was the only country that did not allow sex selection or fetal
reduction procedures to be conducted in private clinics; a hospital
or university setting was required.
Only two countries in the survey, Australia and Kazakhstan,
reported that all three procedures are considered established
medical practice. In Greece and The Republic of Korea, (2 of 58
or 3%) considered PGT-A an experimental method of sex selec-
tion; four countries of 52 (8%) considered sperm sorting to be
experimental, and only Greece (1 of 56 or 2%) considered SFR to
be experimental. Twenty-five of 58 countries (43%) thought of
PGT-A as established medical practice, and 25 of 56 (44%) held
that opinion of SFR. Only 9 of 52 (17%) considered sperm
sorting to be established medical practice.
Regarding sex selection: 24 out of 64 (38%) conducted sex
selection only during IVF/ICSI procedures; 8 out of 60 (13%)
conducted it with IUI, and only 5 of 58 (9%) did it with SFR.
Discussion
Sex selection has historically been used in many countries for
non-medical reasons, such as “family balancing” and patient
preference. Sex selection is a contentious issue, but it is culturally
endorsed and offered in several countries. The practice of sex
selection with ART has steadily increased with the reliability and
availability of PGT-A.
A recent survey[1] noted that 92% of 493 clinics in The United
States of America offered PGT-A. Of these clinics, 94% offered sex
selection for family balancing; 82% for elective reasons, such as
patient preference; and 84% for patients without pre-existing infer-
tility. Recent literature attests to greater acceptance and performance
of sex selection for a variety of cultural and economic reasons. This is
true in countries as diverse as The Republic of Korea, Ukraine, and
Viet Nam. Essentially, a two-fold increase has occurred over the past
decade, primarily favoring selection of males[2–4].
These trends may have profound demographic and cultural
implications, yet to be addressed. Since 1990, the number of
calculated “missing females” has risen by 43 percent (38 million)
to 126 million in 2010[4]. According to Bongaarts and
Guilmoto[4], this trend is expected to peak in 2035, with a further
increase of 24 million to 150 million, before declining slightly in
2050 to 142 million.
This study also outlines the 3 factors that are essential for
prenatal sex selection to reach significant levels in any country:
• Strong preference for a son
• Easy access to prenatal diagnosis
• Low fertility
SFR has evolved over the past few years from a rarely used pro-
cedure, to avoid higher-order multiple births, to a more commonly
performed practice in some countries for patients undergoing ART.
In other countries, such as The United States of America, its avail-
ability has become more restricted as multiple pregnancy rates have
fallen. In still others it is not permitted at all, although occasionally
performed nevertheless by some practitioners.
PGT-A is performed primarily to identify euploid embryos, but
gender is determined during the procedure, and this information
injects gender selection into the decision options for many couples
pursuing ART. Evans et al[5] found that although in the late 80’s
and early 90’s there was a definite son preference among indivi-
duals in The United States of America, the trend has now been
declining steadily, with as many patients now preferring females
to males.
Over the past 25 years, fetal reduction has been granted greater
acceptance as a safe and preferred procedure in some societies.
While reduction of pregnancies of triplets and higher order, to
reduce fetal morbidity, has been widely accepted as an essential
goal over the past two decades, now, even reduction of twins to
singletons is gaining medical and social acceptance.
Summary
SFR remained a very contentious issue in 2018, with 39% of 77
responding countries permitting it outright. An additional 22%
allowed SFR conditionally, and 22%banned it. The status of SFR
was reported by 17%of responding countries as not addressed or
“unknown”. While there has been some change in access in a few
countries, no significant new trend over the past three years was
discernible.
Recent literature suggests that sex selection, particularly with
PGT-A, has become much more widely performed, and is almost
universally available. Despite this trend, the minority of reporting
countries (44%) expressly permit PGT-A for sex selection; even
fewer (25%) have regulations restricting it. Sperm sorting
and SFR, while available in a few countries, are infrequently
practiced.
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Chapter 12. Table 2
Is sex selection allowed permitted and practiced/performed in your country?
PGT-A Sex Selection Sperm Sorting Selective Fetal Reduction
Country Allowed/Permitted Practiced Performed Allowed/Permitted Practiced Performed Allowed/Permitted Practiced Performed





Belgium Unknown Unknown Unknown
Bolivia Allowed/Permitted Allowed/Permitted Unknown
Botswana Allowed/Permitted Allowed/Permitted Allowed/Permitted
Brazil Allowed/Permitted Practiced/Performed
Bulgaria Unknown Unknown Unknown
Burkina Faso Unknown Unknown Unknown
Chile Practiced/Performed Unknown
China Unknown Unknown Unknown
Colombia Allowed/Permitted Practiced/Performed Practiced/Performed
Ecuador Practiced/Performed Practiced/Performed
Egypt Allowed/Permitted Practiced/Performed Allowed/Permitted Allowed/Permitted Practiced/Performed
El Salvador Unknown Unknown Unknown
Finland Allowed/Permitted Unknown Allowed/Permitted Practiced/Performed
Germany Unknown Unknown Unknown
Ghana Allowed/Permitted Allowed/Permitted Allowed/Permitted
Greece Allowed/Permitted Allowed/Permitted Allowed/Permitted
Guatemala Practiced/Performed Practiced/Performed Unknown
Hong Kong (China*) Allowed/Permitted Practiced/Performed Allowed/Permitted Allowed/Permitted
Hungary Allowed/Permitted
Iceland Allowed/Permitted Allowed/Permitted Allowed/Permitted
Italy Unknown Unknown Unknown
Côte d’Ivoire Unknown Allowed/Permitted Unknown
Japan Unknown Unknown Practiced/Performed
Jordan Allowed/Permitted Practiced/Performed Unknown Unknown
Kazakhstan Unknown Allowed/Permitted Allowed/Permitted
Kenya Unknown Unknown Unknown
Latvia Unknown
Mexico Practiced/Performed Unknown Unknown
Mongolia Allowed/Permitted Allowed/Permitted Allowed/Permitted
New Zealand Allowed/Permitted Practiced/Performed
Nigeria Allowed/Permitted allowed/Permitted Unknown
Norway Unknown Unknown Unknown
Panama Practiced/Performed Practiced/Performed Unknown
Paraguay Allowed/Permitted Unknown Unknown
Peru Practiced/Performed Unknown Unknown
Philippines Unknown Unknown Unknown
Poland Unknown Unknown Unknown
Portugal Unknown Unknown Allowed/Permitted
Romania Unknown Allowed/Permitted Practiced/Performed
Russian Federation Allowed/Permitted
Senegal Unknown Unknown Allowed/Permitted
Singapore Allowed/Permitted Practiced/Performed
Slovenia Unknown Unknown Unknown
South Africa Allowed/Permitted Allowed/Permitted Allowed/Permitted
Spain Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Switzerland Unknown Allowed/Permitted Practiced/Performed
Taiwan (China*) Allowed/Permitted
Trinidad and Tobago Allowed/Permitted Allowed/Permitted
Uganda Unknown Unknown Unknown
United Arab Emirates Allowed/Permitted Allowed/Permitted
UK Allowed/Permitted Practiced/Performed
USA Allowed/Permitted Practiced/Performed Allowed/Permitted Allowed/Permitted Practiced/Performed
Venezuela Allowed/Permitted Allowed/Permitted Unknown
Viet Nam Unknown Unknown Allowed/Permitted Practiced/Performed
Zimbabwe Unknown Unknown Unknown
*Reporting separately for this report.
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CHAPTER 13: PREIMPLANTATION GENETIC
TESTING
Introduction
Preimplantation genetic testing (PGT) was introduced as a
method for embryonic diagnosis of molecular genetic defects
linked to specific inherited diseases. Non-affected embryos were
selected and transferred to the patient, with the expectation of
producing a child free of that disease[1]. Early in the history of
PGT, other applications emerged. For example, PGT was used to
produce a child selected by HLA haplotyping as a “savior sib-
ling” for a family member afflicted with an incurable disease.
Other non-traditional social and medical paradigms have been
reported[1]. Currently, PGT is used most commonly to identify a
vast number of autosomal single-gene disorders (preimplantation
genetic testing for monogenic/single gene disorders, PGT-M), for
aneuploidy (preimplantation genetic testing for aneuploidy, PGT-
A), and for structural rearrangements (PGT-SR).
PGT-A has been promoted as an adjunct to improve IVF
implantation and birth rates, and to reduce risk of miscarriage[2–6].
It is used to identify structural or numerical chromosomal
abnormalities[2–6], because euploid blastocysts are presumed to be
optimal for transfer, by increasing implantation and live-birth rates
per embryo transferred. As such, PGT-A could play an essential role
in selecting embryos for single-embryo transfers (SET), and for
avoiding multiple pregnancy[2].
Initially, PGT involved removal of one or two blastomeres from
the embryo at the cleavage stage, typically on day three of in vitro
development[2–6]. ART centres performing PGT today have for the
most part abandoned day three biopsies, and now perform tro-
phectodermbiopsy at the blastocyst stage. Removal of five to ten of
the more than 150 cells normally available at this stage is far more
than was possible with cleavage-stage embryos[2–6].
Other advantages of blastocyst biopsy include improved sur-
vival after biopsy; the need for fewer procedures, because day-five
embryos have survived some of the natural selection process; and
less mosaicism, because earlier mosaic embryos seem to have the
potential to self-correct with advancing embryonic maturity.
Biopsied blastocysts are usually cryopreserved with vitrification,
with the intent of later replacement after the result of the mole-
cular analysis is received. Molecular methods have evolved sub-
stantially over the past three years.
Molecular diagnosis is now performed on 24 chromosomes,
using an array of advanced technologies. These include fluor-
escent in situ hybridization (FISH), polymerase chain reaction
(PCR), array comparative genome hybridization (aCGH), single
nucleotide polymorphism arrays (SNP arrays), next-generation
sequencing technology (NGS), and preimplantation genetic
haplotyping (PGH)[2–10]. Unaffected (normal) blastocysts are
transferred after thaw. Because embryos with genetic abnormal-
ities are disposed of, PGT allows couples to discard affected or
abnormal embryos, rather than having to consider terminating an
established pregnancy[2–10].
Earlier versions of PGT-A that relied solely on FISH limited
analysis to smaller subsets of chromosomes – typically five to ten,
rather than the 24 chromosomes analyzed with newer molecular
technology. But clinical outcomes were disappointing. When
24-chromosome technology emerged, and three early rando-
mized clinical trials using either qPCR-based CCS or rapid aCGH
described higher birth rates, and single-pregnancy rates with
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in a larger clinical patient population. Although the 2018
Surveillance questionnaire reflects increasing global interest and
application of PGT-A, evidence of improved outcomes is lacking,
except in small series and selected cohorts, even with increasingly
sophisticated molecular technology. Nevertheless, world-wide
PGT-A utilization is again expanding, although it has not yet
been confirmed to be an effective adjunct for IVF[2].
PGT is now typically performed for nine indications:
1. Autosomal single gene disorders[8,14] (PGT-M)
2. Some chromosomal rearrangements[2,4] (PGT-SR)
3. X-linked diseases
4. Human leukocyte antigen (HLA) typing
5. Cancer predisposition genes[15]
6. Mitochondrial DNA disorders
7. Preimplantation genetic testing for aneuploidy (PGT-A)
8. Adult onset disorders[8,15]
9. Non-medical sex selection
Analysis of the survey
Fifty-three of 70 responders (76%) indicated that PGT-M
(Table 1) is expressly allowed, by statutes, laws, and guidelines.
The status of PGT-Mwas not addressed in 17 of the 70 (24%); its
status is indicated “unknown” in 16% – but PGT-M is not
known to be specifically prohibited in any of the countries that
responded.
When PGT-M is allowed, 24 of 53 countries responding (45%)
have guidelines governing its use; use is not regulated in 26
countries responding (49%); and the procedure has a “not-
known” status in three countries (6%). PGT-M for single gene
disorders is commonly performed as a clinical service in 47 of 67
countries (70%), performed only experimentally in three coun-
tries (4%), and not addressed, or unknown, in 17 (25%) of the
countries (Table 2, Charts 1 and 2).
PGT-M for single gene disorders is considered acceptable for
preventing disease in offspring produced with ART – that is the
opinion of 46 of 68 responders (68%). Twenty-one of 65 con-
sider it acceptable to allow the disease in the offspring produced
with ART. That was the response chosen in 18 of 64 (28%).
Twenty-one of 65 (32%) say that it is permitted for helping to
generate an embryo for any immunologically donor-matched
diseased child, but it is prohibited in 17 (26%) of the countries.
Twenty-three of 65 (35%) say it is considered acceptable in
helping to generate a child for any immunologically donor-mat-
ched diseased child. It is also allowed for assisting in generating
an embryo on behalf of a diseased sibling in 24 of 66 (36%) of the
countries and for generating a child on behalf of a deceased sib-
ling in 26 of 66 responders (39%). It is permitted to generate an
embryo with a specific disease for research or experimentation,
according to 5 in 65 responders (8%), but that is prohibited in 37
of 65 responding countries (57%).
PGT-A is expressly allowed by statutes, laws, and guidelines in
48 of 67 (72%) responding to that question; the status was not
addressed or was marked “unknown” in 19 of the 67 (28%).
When allowed, it is regulated by guidelines that govern its use in
20 of 48 countries responding (42%), not regulated in 24 of the
48 (50%); its status is not known in 1 of the 48 (2%).
PGT-A for single gene disorders is commonly performed as a
clinical service in 42 of 65 countries (65%), performed only
experimentally in 4 countries (6%), and is not addressed, or
unknown, in 19 of the countries (29%). PGT-A is commonly
performed in tandem with PGT-M in 38 of 62 countries (61%).
Regulatory bodies with oversight for PGT-M and PGT-A
range from none to combinations of federal, provincial and
municipal statutes; various government agencies; and guidelines
from professional organizations (Chart 3).
For PGT-M, 100% of 24 responders reported having gov-
ernance by federal or national statutes, ordinances or policies; in
4 (17%), this was accomplished by state or provincial policies or
legislation; in 2 (8%), by municipal laws, statutes or ordinances;
in another 2 (8%), by agency regulations or oversight; in 12,
(50%) by professional organizations standards or guidelines; in 2
(8%), by existing cultural practices; and in another 2 (8%) by
religious decrees.
For PGT-A, all of 20 responders (100%) reported having
governance by federal or national statutes, ordinances or policies;
3 (15%) accomplished this by state, regional or provincial poli-
cies or legislation; 1 (5%) by municipal laws, statutes or ordi-
nances; 1 (5%) by agency regulations or oversight, 11 (55%) by
standards or guidelines professional organization; 1 (5%), by
existing cultural practices; and 1 (5%) by religious decrees.
Centres providing PGT-M and PGT-A services, respectively,
include sole practitioners in private clinics, 19 responders (95%
and 100%); 26 responders, (92% and 88%), small private phy-
sician clinics; large multiple practitioner clinics, 27 responders
(96% and 93%); hospital based clinics, 22 responders (86% and
100%); university clinics, 28 (93% and 82%); and public hos-
pitals, 19, (95% for both responding countries.
Discussion
Compared to the 2015 Surveillance questionnaire, PGT-M now
comprises an increasing percentage of ART services throughout
the world. Its application is often regulated or restricted by statute
or local clinical tradition. It is allowed in all countries surveyed.
PGT-M was commonly performed in 43% of the 90 responding
countries in 2018, compared to 34% of 67 countries in 2015. It is
now a well-established and reliable procedure with a low error
rate. Drawbacks remain the high cost and inefficiency of IVF as a
requisite platform, requirements for extended culture to the
blastocyst stage, and relatively reduced birth rates even among
fertile women because of the more limited number of embryos
available for transfer.
In the United States of America, PGT is frequently deemed
experimental by insurance carriers and is usually not covered
except for single gene disorders and selected chromosomal
defects. Demand for PGT-M in The United States of America,
European Union, and Middle East, however, is expanding to
include couples that are not infertile but are carriers at risk for
transmission of genetic disorders to their progeny. Many of these
couples have previously had affected offspring andwere reluctant
to consider additional pregnancies without PGT-M and others
were unwilling to attempt pregnancy at all without some assur-
ance of reduced risk. PGT-M also offers the opportunity to
identify embryos carrying relatively common genetic conditions
including oncogenes with high penetrance, such as BRCA, that
pose risk for devastating diseases later in life. The availability of
new molecular genetic tests, public initiatives surrounding spe-
cific genetic diseases, and increasing internet marketing of tests
and identification of carriers are expected to increased demand
for PGT-M worldwide[4,6].
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Chapter 13. Table 1
Is preimplantation genetic testing allowed/permitted and practiced/performed?
PGT-M PGT-A
Country Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed










Bulgaria Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed





Czechia Allowed/Permitted Allowed/Permitted Practiced/Performed
Ecuador Practiced/Performed Practiced/Performed
Egypt Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed












Italy Allowed/Permitted Allowed/Permitted Unknown
Côte d’Ivoire Unknown Unknown
Japan Allowed/Permitted Practiced/Performed Practiced/Performed
Jordan Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Kazakhstan Allowed/Permitted Allowed/Permitted
Kenya Unknown Unknown


















Singapore Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Slovenia Allowed/Permitted Unknown
South Africa Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
The Republic of Korea
Spain Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Switzerland Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
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Chapter 13. Table 1
(Continued)
PGT-M PGT-A
Country Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Taiwan (China*) Allowed/Permitted Allowed/Permitted
Thailand Allowed/Permitted
Trinidad and Tobago Allowed/Permitted Allowed/Permitted
Turkey Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Uganda Unknown Unknown
United Arab Emirates Allowed/Permitted Allowed/Permitted
UK Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
USA Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Uruguay Allowed/Permitted Allowed/Permitted
Venezuela Allowed/Permitted Allowed/Permitted
Viet Nam Allowed/Permitted Practiced/Performed Allowed/Permitted Practiced/Performed
Zimbabwe Unknown Unknown
*Reporting separately for this report.
Chapter 13. Table 2
Are these techniques considered experimental or part of established medical practice?
Country PGT-M PGT-A PGT-M with PGT-A
Argentina Established medical practice Established medical practice Established medical practice
Australia Established medical practice Established medical practice Established medical practice
Austria Established medical practice Established medical practice Established medical practice
Belarus Established medical practice Established medical practice Established medical practice
Bolivia Established medical practice Established medical practice Established medical practice
Botswana Not addressed Not addressed Not addressed
Brazil Established medical practice Established medical practice Established medical practice
Bulgaria Established medical practice Established medical practice Established medical practice
Burkina Faso Unknown Unknown Unknown
Cameroon Not addressed Not addressed Not addressed
Canada Established medical practice Established medical practice Established medical practice
Chile Established medical practice Established medical practice Established medical practice
China Established medical practice Established medical practice Established medical practice
Colombia Established medical practice Established medical practice Established medical practice
Ecuador Established medical practice Established medical practice Established medical practice
Egypt Established medical practice Established medical practice Established medical practice
Finland Established medical practice Established medical practice Established medical practice
Georgia Not addressed Not addressed Not addressed
Germany Established medical practice Established medical practice Established medical practice
Ghana Established medical practice Established medical practice Established medical practice
Greece Experimental Experimental Experimental
Guatemala Not addressed Not addressed Not addressed
Hong Kong (China*) Established medical practice Established medical practice Established medical practice
Hungary Established medical practice Experimental Experimental
Iceland Not addressed Not addressed Not addressed
India Established medical practice Established medical practice Established medical practice
Ireland Established medical practice
Côte d’Ivoire Not addressed Not addressed Not addressed
Japan Experimental
Jordan Established medical practice Established medical practice Established medical practice
Kazakhstan Established medical practice Established medical practice Established medical practice
Latvia Established medical practice Established medical practice Established medical practice
Lithuania Experimental Not addressed Not addressed
Mexico Unknown Established medical practice Established medical practice
Mongolia Not addressed Not addressed Not addressed
Montenegro Established medical practice Established medical practice Established medical practice
New Zealand Established medical practice Established medical practice Established medical practice
Nigeria Unknown Unknown Unknown
Norway Established medical practice Unknown Unknown
Panama Established medical practice Established medical practice Established medical practice
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PGT-A appears to be universally available in all 90 countries
participating in the questionnaire but is commonly performed in
only 50% (Table 1). In 2015, it was commonly performed in 38%
of countries. If the newer technologies are proven to truly
improve implantation rates, application is likely to be vastly
expanded, as was the case with ICSI. However, available current
data, while offering preliminary encouragement, are too inade-
quate and inconclusive to justify broader use.
Summary
Surveillance 2019 confirms an ongoing trend of increased
accessibility and use of PGT-M and PGT-A worldwide. PGT,
and especially PGT-M, provide proven benefits. Both are gen-
erally considered safe, and are associated with a low frequency
of errors. PGT-M largely prevents women from delivering off-
spring with serious genetic disorders, avoids the potential need
for pregnancy termination, and provides critical reassurance
Chapter 13. Table 2
(Continued)
Country PGT-M PGT-A PGT-M with PGT-A
Paraguay Established medical practice Established medical practice Established medical practice
Peru established medical practice established medical practice established medical practice
Philippines Unknown Unknown Unknown
Poland Unknown Unknown Unknown
Portugal Established medical practice Established medical practice
Russian Federation Established medical practice Established medical practice Established medical practice
Senegal Not addressed Not addressed Not addressed
Singapore Established medical practice Experimental
Slovenia Established medical practice Not addressed Not addressed
South Africa Established medical practice Established medical practice Established medical practice
The Republic of Korea Established medical practice Established medical practice Experimental
Spain Established medical practice Established medical practice Established medical practice
Sri Lanka Established medical practice Established medical practice Established medical practice
Switzerland Established medical practice Established medical practice Established medical practice
Taiwan (China*) Established medical practice Established medical practice Not addressed
Thailand Established medical practice Established medical practice Established medical practice
Togo Not addressed Not addressed
Trinidad and Tobago Established medical practice Established medical practice Established medical practice
Turkey Established medical practice Established medical practice Unknown
Uganda Unknown Unknown Unknown
United Arab Emirates Established medical practice Established medical practice Established medical practice
UK Established medical practice Experimental Experimental
USA Established medical practice Established medical practice Established medical practice
Uruguay Established medical practice Established medical practice Established medical practice
Venezuela Established medical practice Established medical practice Established medical practice
Viet Nam Unknown Unknown Unknown
Zimbabwe Not addressed Not addressed Not addressed
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to fearful couples who otherwise would not choose to
have children.
Since Surveillance 2016was published, advances have occurred in
the discovery of genetic linkages to common diseases. Examples
include many cancers, diabetes, cardiovascular disease, degenerative
disorders of old age, somemental illnesses, and even autism spectrum
disorders. It seems likely that there will be expanded indications and
greater use of PGT-M for some of these common disorders.
PGT-A, more widely used in embryo selection now than in
2016, remains controversial. Although it is claimed to be a
valuable tool for embryo selection, and many ART centres have
attributed improved clinical success to its use, results have not
been widely replicated in appropriately designed clinical trials.
The potential value and role of PGT-A will likely become
clearer during the next triennial.
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Surrogacy is an arrangement in which a woman (the surrogate)
becomes pregnant, then carries and gives birth to a child or
children, with the intention of giving the child to another person
or couple (the intended parent or parents), whowill rear the child.
The 2018 IFFS Surveillance questionnaire considered “gesta-
tional” and “traditional” surrogacy.
Gestational surrogacy, sometimes referred to as full surrogacy,
or “IVF surrogacy”, the gametes of both intended parents, or of
one intended parent and a donor egg and/or sperm, are used to
create the embryo. Alternatively, a donated embryo created from
unrelated gametes is used. The surrogate is genetically unrelated
to the offspring intended to be produced by this arrangement.
Traditional surrogacy, sometimes termed natural surrogacy,
or partial surrogacy, the surrogate is inseminated with the semen
of an intended parent, and the surrogate’s own oocyte is fertilized
Chapter 14. Table 1
Are there regulations that govern gestational carriers in your
country?










Burkina Faso No No
Cameroon No No
Canada Yes Yes
Chapter 14. Table 1
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Sri Lanka No No
Switzerland No No
Taiwan (China*) No No
Thailand Yes Yes
Togo No No
Trinidad and Tobago No No
Uganda No No





Viet Nam Yes Unknown
Zimbabwe No No
*Reporting separately for this report.
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29
113
Chapter 14. Table 2















































Mexico Yes Yes Yes
Mongolia Yes
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in vivo. This may involve reproductive assistance, most often in
the form of artificial or intrauterine insemination performed at a
fertility clinic. Usually, however, the procedure is performed at
home. The resulting child or children are genetically related to the
surrogate, as her oocytes are used.
The laws that govern IVF surrogacy are complex, and vary
among jurisdictions. Determining the local legal status is the
usual first step. Full and informed legal advice from someone
familiar with the laws of the country where the treatment will
occur, or, if different, the country of domicile of the couple, is
mandatory. Also essential is careful medical assessment and
thorough counseling of all parties involved in an IVF surrogacy
arrangement.
The principal reasons people enter into surrogacy arrange-
ments are:
[1] Medical reasons in which the female intended parent:
(a) Is without a uterus but has one or both ovaries functioning.
This may include women with congenital absence of the
uterus, and women who have had a hysterectomy for
carcinoma or other reasons;
(b) has had repeated miscarriages, and the potential for
carrying a baby to term is remote. This may include
women who have repeatedly failed to become pregnant
after IVF treatment;
(c) has a medical condition that may make pregnancy life
threatening, but whose long-term health prospects are good.
[2] Non-medical or social reasons, such as same-sex coupling,
or ongoing single status. This is permitted in only some
jurisdictions.
Analysis of the survey
In the 2018 IFFS surveillance of the 89 participating countries, 73
countries (82%) sent responses to at least one question pertaining
to surrogacy. This is in comparison to 65 countries in 2016, and
62 countries in 2013.
Differential responding to questions may have reflected the
respondents’ knowledge of surrogacy regulation and/or practices
in their countries. For example, some respondents knew whether
or not there were laws, but did not know whether surrogacy was
practiced in their country.
Of the countries that responded to the question “are there
regulations that govern IVF surrogacy in your country”, in
relation to gestational surrogacy, answers were: yes, 31 out of 72
(43%); no, 35 (49%) and “Unknown”, 6 (8%). In relation to
traditional surrogacy: yes, 22 of 68 (32%) no, 40 (59%), and
“Unknown,” 6 (9%) (Table 1).1
Twenty-seven countries specified the type or types of regula-
tion used for gestational surrogacy, as follows: 13 respondents
(48%), only federal laws; 2 (7%), only state laws; and 5 (19%),
only professional standards/guidelines. Seven (26%) of these
countries reported a combination of these regulatory instruments
(Table 2).
Seventeen countries specified the type or types of regulation
used for traditional surrogacy: six (35%) reported having only
federal laws; 3 (18%) reported having only state laws, and
another 3 (18%) said they had only professional standards/
guidelines. Five (29%) of these countries reported a combination
of these regulatory instruments.
Regarding the question “is surrogacy permitted or practiced in
your country”, 53 countries responded regarding gestational
surrogacy, and 45 countries responded regarding traditional
surrogacy (Table 3).
To the topic of gestational surrogacy, 24 countries (45%)
reported that it was allowed/permitted; 22 (41.5%) reported it
was practiced/performed, and 16 (30%) reported “unknown”.
For traditional surrogacy, sixteen countries (36%) reported that
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Mongolia Yes
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Chapter 14. Table 3
Is surrogacy allowed/permitted and practiced/performed in your
country?





















































Russian Federation Allowed/Permitted, Practiced/
Performed
Senegal Unknown Unknown
South Africa Allowed/Permitted, Practiced/
Performed
South Korea Practiced/Performed
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(Continued)
Country Gestational Surrogacy Traditional Surrogacy
Viet Nam Allowed/Permitted Unknown
Zimbabwe Practiced/Performed Unknown
*Reporting separately for this report.
Chapter 14. Table 4
How often is surrogacy performed in programmes within your
country?
Country Gestational Surrogacy Traditional Surrogacy
Argentina Infrequently Used Infrequently Used
Armenia Infrequently Used Never Performed
Australia Commonly Used Infrequently Used
Austria Never Performed Never Performed
Barbados Never Performed Never Performed
Belarus Infrequently Used Never Performed
Bolivia Infrequently Used Infrequently Used
Botswana Never Performed Never Performed
Brazil Infrequently Used Infrequently Used
Bulgaria Never Performed Never Performed
Cameroon Never Performed Never Performed
Canada Commonly Used Infrequently Used
Chile Never Performed Never Performed
China Never Performed Never Performed
Colombia Infrequently Used
Czechia Infrequently Used Never Performed
Ecuador Commonly Used Infrequently Used
Egypt Never Performed Never Performed
El Salvador Unknown Unknown
Finland Never Performed Never Performed
Georgia Commonly Used Never Performed
Germany Unknown Unknown
Ghana Commonly Used Infrequently Used
Greece Commonly Used Commonly Used
Guatemala Commonly Used Commonly Used
Hong Kong (China*) Never Performed Never Performed
Hungary Never Performed Never Performed
Iceland Never Performed Never Performed
India Commonly Used Never Performed
Ireland Never Performed Never Performed
Italy Unknown Unknown
Côte d’Ivoire Unknown Unknown
Japan Never Performed Never Performed
Jordan Never Performed Never Performed
Kazakhstan Commonly Used Unknown
Kenya Unknown Unknown
Lithuania Never Performed Never Performed
Mali Never Performed Never Performed
Mexico Infrequently Used Infrequently Used
Mongolia Unknown Unknown
Namibia Unknown Unknown
New Zealand Commonly Used Infrequently Used
Nicaragua Never Performed Never Performed
Nigeria commonly Used commonly Used
Panama Unknown Unknown
Paraguay Never Performed Never Performed
Philippines Infrequently Used Infrequently Used
Portugal Infrequently Used Infrequently Used
Romania Unknown Unknown
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29 Global Reproductive Health
116
it was allowed/permitted; 12 (27%) said, practiced/performed;
and 22 (49%) reported “unknown”.
Sixty-eight countries participated in the survey regarding the
frequency of usage of gestational and traditional surrogacy, 14
(20%) reported that gestational surrogacy was commonly used,
17 (25%) said it was infrequently used; 27 (40%) indicated it was
never performed, and 10 (15%) reported “unknown”. As for
traditional surrogacy, 3 (4%) said that it was commonly used, 18
(26%) it was infrequently used, 35 (51%) that it was never per-
formed, and 12 (19%) reported “unknown” (Table 4, Chart 1).
In response to the question, “if surrogacy is allowed in your
country, are surrogates compensated”, was asked in two ways: for
gestational surrogacy and for traditional surrogacy (Table 5).
For gestational surrogacy compensation, 48 responses were
received (as opposed to 61 in 2016). Of these responses, 9
countries (19%) reported that compensation beyond reimburse-
ment was permitted; 14 countries (29%) reported that no com-
pensation was allowed; 14 countries (29%) reported
reimbursement was allowed for time and expenses only; and 11
countries (23%) responded “unknown”.
As for “traditional surrogacy”, 44 responses were received; 4
countries (9%) reported that compensation beyond reimburse-
ment was permitted; 15 countries (34%) indicated no compen-
sation was allowed; 12 countries (27%) said reimbursement for
time and expense was permitted; and 13 countries (30%)
responded “unknown”.
In relation to limits on compensation existed, and if so, the
range; respondents replied with only limited data. Regarding
gestational surrogacy, 33 countries responded. Three countries
(9%) replied yes, 4 countries (12%) responded that there was no
minimum or maximum amount for compensation, 17 countries
(52%) responded that compensation was not addressed, and 9
countries (27%) responded “unknown”.
With regards to traditional surrogacy, 30 countries responded.
One country (3%) replied yes, 2 countries (7%) indicated there
was no minimum or maximum amount for compensation, 19
countries (63%) responded that compensation was not addres-
sed, and 8 countries (27%) responded “unknown”.
Regarding the topic, “if third party reproduction is permitted
in your country, are the qualifications to be a surrogate, based
upon medical and/or any lifestyle criteria”, 26 countries (51%)
replied yes for gestational surrogacy, and 17 of 45 countries
(38%) for traditional surrogacy.
Discussion
Surrogacy remains a contentious issue worldwide. Respondents
from the countries that replied to the current survey reported that
neither gestational nor traditional surrogacy were commonly used.
When surrogacy was used, gestational surrogacy was used slightly
more frequently than traditional surrogacy. Approximately one-
third of respondents noted that gestational surrogacy was com-
monly or infrequently performed in their countries. In many
Chapter 14. Table 4
(Continued)
Country Gestational Surrogacy Traditional Surrogacy
Russian Federation Commonly Used Never Performed
Senegal Never Performed Never Performed
Singapore Never Performed Never Performed
Slovenia Never Performed Never Performed
South Africa Infrequently Used Never Performed
South Korea Infrequently Used
Spain Never Performed Never Performed
Sri Lanka Infrequently Used Infrequently Used
Switzerland Never Performed Never Performed
Taiwan (China*) Never Performed Never Performed
Thailand Infrequently Used Never Performed
Togo Never Performed Never Performed
Trinidad and Tobago Never Performed Never Performed
Uganda Commonly Used Infrequently Used
UK Infrequently Used Infrequently Used
USA Commonly Used Infrequently Used
Uruguay Infrequently Used Infrequently Used
Venezuela Unknown Unknown
Viet Nam Infrequently Used Unknown
Zimbabwe Infrequently Used Infrequently Used








Commonly Infrequently Never Unknown
%
Gestational Traditional
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countries, neither gestational nor traditional surrogacy are used at
all. As discussed inChapter 15 (Cross Border Reproduction), some
countries will treat intended parent(s) from other countries that
prohibit or do not offer surrogacy, or that provide surrogacy, but
at high costs.
Both gestational and traditional surrogacy are fraught with
multiple potential conflicts when the interests of the various sta-
keholders clash. These issues are further exacerbated when con-
ducted in an international arena, as several highly publicized
cases have demonstrated.
Payment of surrogates continues to be an issue that provokes
much debate.Many countries prohibit any form of compensation
as a way to prevent the commodification or exploitation of
children or reproductive capabilities. In countries where payment
is not allowed, surrogates are usually relatives or personal friends
of the intended parent(s), and may be permitted to receive reim-
bursement for “reasonable expenses”. Where there are no laws,
practices may occur that are of particular concern, particularly in
less developed countries with greater potential for exploitation.
Some limited studies have offered reassurance regarding the
psychological and physical well-being of children produced with
gestational surrogacy, the surrogate mothers, and the intended
parents[1,2]. In most countries, the “birth mother” has always
been the legal mother of a child. This issue has been resolved in
many countries or states by legislation enabling the genetic par-
ents to become legal parents at the birth of the child. Most sur-
rogacy cases reportedly proceeded without problems, and
provided a positive and successful treatment option for a small
group of women who otherwise would be unable to have their
own genetic children.
Both the European Society of Human Reproduction and
Embryology (ESHRE)[3] and the American Society of Reproductive
Medicine (ASRM) have published ethical and clinical guidelines
pertaining to surrogacy[4,5], advocating thorough evaluation and
provisions for managing the small group of women who need this
specialized treatment.
Summary
IVF or gestational surrogacy is a useful and effective treatment
option for women who have no uterus or are otherwise unable to
bear children. It allows the commissioning (genetic) couple to
have their own children. Gestational surrogacy is practiced in
42% of responding countries; fewer perform traditional surro-
gacy, a procedure that remains controversial and is permitted in
relatively few countries, usually with significant limitations,
particularly regarding compensation. The topic engenders con-
siderable international debate about indications for its applica-
tion, and the potential for exploiting its participants.
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CHAPTER 15: CROSS BORDER REPRODUCTIVE
CARE
Introduction
The term cross-border reproduction (CBR) pertains to ART or
related services sought by citizens of one country from within
another country. When this situation arises, it usually means that
ART procedures are unavailable or encumbered by legal or
economic barriers in one country, but not in the other.
CBR is a contentious, largely unregulated area, making data
collection particularly challenging. Some topics pertaining to CBR
were covered in the 2018 Surveillance questionnaire; the purpose
was to find out if people traveled to or from the respondent’s
country to engage in ART, and, if they did so, the motive was to
seek lower cost services, higher quality services, or services not
available in their home country. Some queries sought information
about egg, embryo, and sperm donation, and gestational and
traditional surrogacy. Some of the information gathered explored
whether any regulations applied to inbound and outbound tra-
velers wishing to engage in CBR; other information regarded the
importation and exportation of gametes and embryos.
Analysis of the survey
Seventy-five respondents replied to some or all the questions
about CBR. The following analysis includes data from the
country respondents who provided at least one relevant answer to
the issues mentioned.
Do people visit your country to seek cross-border
reproduction? (Table 1, Charts 1–3)
Incoming for lower cost ART services
Fifty-six of the 75 countries (75%) responding to this question
reported that people traveled to their country to seek lower cost ART
services. Austria, Botswana, Ireland, Japan, New Zealand, Norway,
Serbia, Singapore, the United Arab Emirates, and The United States
of America (13%) reported that people do not travel to their country
for lower cost services. In Australia, Chile, Mali, Nigeria, Poland,
Switzerland, and Venezuela, the respondents answered “unknown”
(9%). Two countries, Finland and Portugal (3%), provided
responses to other questions on cross-border reproduction, but said
this issue was “not addressed” in their country.
Incoming for higher quality ART services
Fifty-six of the 71 respondent countries (79%) reported that
people travel to their country for higher quality services. Nigeria,
Botswana, Ireland, Norway, Serbia, El Salvador, Greece,Mexico,
Trinidad and Tobago (13%) responded that people do not travel
IFFS Surveillance 2019. Global Reproductive Health (2019) 4:e29 Global Reproductive Health
118
to their country for higher quality services. In Australia, Poland,
Lithuania, Venezuela, and the Philippines, the response was
“unknown” (7%). One country, Portugal, reported that this was
“not addressed” (1%).
Incoming for ART services unavailable in their home country
Forty-eight of the 72 respondents (66%) that answered questions
about CBR reported that people travel to their country to access
services that are not available in their home country. Fifteen
countries (21%) reported that people do not engage in CBR and
come to their country for these purposes. One country,
Mongolia, answered that this was “not addressed” (1%); and
eight countries (11%) replied “unknown”.
Incoming for egg donation
Thirty-four respondents out of 72 (47%) reported that people travel to
their country to access egg donation.Twenty-three respondents (32%)
reported that potential recipients from other countries do not travel to
their country for egg donation. Eleven countries (15%) reported
“unknown”. Four countries (5.5%) selected “not addressed”.
Incoming for embryo donation
Twenty-six of 70 respondents (37%) that answered questions
concerning CBR reported that people travel to their country to
access embryo donation; 27 (39%) reported that people from
other countries do not travel to their country to seek embryo
donation; 6 (9%) selected that this was “not addressed” in their
country; and 11 (16%) reported that the status of this practice
was “unknown”.
Incoming for sperm donation
Thirty-six of 71 who responded to this question (51%) reported
that people travel to their country to access sperm donation; 21
(29%) said that people from other countries do not travel to their
country to receive sperm donation; 12 (17%) reported this as
“unknown”, and 2 (3%) selected the answer “not addressed”.
Incoming for gestational surrogacy
Respondents were asked if people travelled to their country to
engage in gestational surrogacy. Twenty of the 71 respondents
answering questions on cross-border surrogacy (28%) answered
Chapter 14. Table 5
Are gestational carriers compensated?
Country Gestational Surrogacy Traditional Surrogacy
Argentina Unknown Unknown
Armenia Reimbursement for time and
expenses
Australia Reimbursement for time and
expenses








Brazil Reimbursement for time and
expenses





















Ghana Reimbursement for time and
expenses
Reimbursement for time and
expenses
Greece Reimbursement for time and
expenses
Reimbursement for time and
expenses
Guatemala Reimbursement for time and
expenses














Mexico Reimbursement for time and
expenses




New Zealand Reimbursement for time and
expenses





Portugal Reimbursement for time and
expenses








South Africa Reimbursement for time and
expenses
South Korea Reimbursement for time and
expenses
Spain No No
Sri Lanka Reimbursement for time and
expenses
Reimbursement for time and
expenses
Chapter 14. Table 5
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UK Reimbursement for time and
expenses








Viet Nam No Unknown
Zimbabwe Reimbursement for time and
expenses
Reimbursement for time and
expenses
*Reporting separately for this report.
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Argentina Yes Yes No Yes Yes Yes Unknown Unknown
Australia Unknown Unknown Unknown Unknown Unknown Unknown No No
Austria No Yes Yes Yes No Yes No No
Bangladesh Yes
Barbados Yes Yes Yes Yes Yes Yes No No
Belarus Yes Yes Yes No Yes Yes No
Belgium Yes Yes No Unknown Unknown
Bolivia Yes Yes Yes Yes Yes Yes Yes Yes
Botswana No No No No No No No No
Brazil Yes Yes Yes No Yes No Yes Yes
Bulgaria Yes Yes Yes Yes Not addressed Yes No No
Burkina Faso Yes Yes Yes Yes No Yes No No
Cameroon Yes Yes Yes Yes No Yes No Unknown
Canada Yes Yes Yes No No No Unknown Unknown
Chile Unknown Yes Yes Yes Yes Yes No No
China Yes
Colombia Yes Yes Yes Yes Not addressed No Yes Yes
Czechia Yes Yes Yes Yes Yes Yes Yes No
Ecuador Yes Yes Yes Yes Yes Yes Yes
Egypt Yes Yes Yes No No No No No
El Salvador Yes No Yes No No No Yes Yes
Finland Not
addressed
Yes Yes Yes Yes Yes No No
Georgia Yes Yes Yes Yes Yes Yes Yes No
Germany Yes Yes Yes Not
addressed
Not addressed Unknown Unknown Unknown
Greece Yes No Yes Yes Yes Yes No No
Guatemala Yes Yes Yes Yes Yes Yes Yes Yes
Hong Kong (China*) Yes Yes Yes Yes Yes No No
Hungary Yes Yes No Not
addressed
Not addressed Unknown Not addressed Not addressed
India Yes Yes Yes Yes Yes Yes
Ireland No No No No No No No No
Italy Yes Yes Yes Yes Yes Yes Yes Yes
Côte d’Ivoire Yes Yes Unknown Yes Yes Yes No No
Japan No Yes No No No No No No
Jordan Yes Yes Yes No No No No No
Kazakhstan Yes Yes No Yes Yes Yes Yes Yes
Kenya Yes Yes Yes Yes Yes Yes Yes Yes
Latvia Yes Yes Yes Yes Yes Yes No No
Lithuania Yes Unknown Unknown No No No No No
Mali Unknown Yes Yes Unknown No No Not addressed Not addressed
Mexico Yes No No Yes Unknown Yes Yes Yes
Mongolia Yes Yes Not addressed Yes Yes Yes Yes Yes
Montenegro Yes
New Zealand No Yes Yes No No Yes No No
Nicaragua Yes Yes Yes
Nigeria Unknown No Unknown Unknown Unknown Unknown Unknown Unknown
Norway No No No No No No No No
Panama Yes Yes Yes Yes Yes Yes Unknown Unknown
Paraguay Yes Yes No Not
addressed
Not addressed Not addressed Not addressed Not addressed
Peru Yes Yes Yes Unknown Unknown Unknown
Philippines Yes Unknown Unknown Unknown Unknown Unknown Unknown Unknown







Not addressed Not addressed Not addressed Not addressed
Romania Yes Yes Unknown No No No No No
Russian Federation Yes Yes Yes Yes Yes Yes Yes No
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in the affirmative; thirty-six countries (51%) answered “no”;
eleven respondents (15%) said that the status was “unknown”;
and four (6%) selected the answer “not addressed”.
Incoming for traditional surrogacy
Respondents were asked if people travelled to their countries to
engage in traditional surrogacy. Of the 68 who answered, 13
(19%) replied in the affirmative; 39 countries (57%) answered
“no”; 12 respondents (18%) answered “unknown”; and 4 (6%)
selected the answer “not addressed”.
Dopeople travel from your country to another country to seek
cross-border reproduction? (Table 2, Charts 4–6)
Outgoing for lower cost ART services
Of the 29 countries that responded, (43%) reported that people
traveled from their country to seek lower cost ART services;
twenty-one (31%) indicated that people do not travel from their
























Senegal Yes Yes Yes No No No No No
Serbia No No No No No No No No
Singapore No Yes No No No No No No
Slovenia Yes Yes Yes No No No No No
South Africa Yes Yes Yes Yes No Yes No No
South Korea Yes Yes Unknown Unknown Yes Unknown
Spain Yes Yes Yes Yes Yes Yes No No
Sri Lanka Yes Yes Yes Unknown Unknown Unknown Unknown Unknown
Switzerland Unknown Yes No No No Yes No No
Taiwan (China*) Yes Yes Yes Yes No Yes No No
Thailand Yes Yes Yes Unknown Unknown Unknown Unknown Unknown
Togo Yes Yes Yes Yes Yes Yes No No
Trinidad and Tobago Yes No Yes Yes No Yes No No
Turkey Yes Yes Yes No No No No No
Uganda Yes Yes Yes Yes Yes Yes Yes Yes
United Arab Emirates No Yes Yes No No No No No
UK Yes Yes Yes No No No Yes Yes
USA No Yes No Yes Yes Yes Yes Yes
Uruguay Yes Yes No Yes Yes Yes No No
Venezuela Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Viet Nam Yes Yes Yes Unknown Unknown Unknown Unknown Unknown
Zimbabwe Yes Yes No No No No No No











Lower Cost Services Higher Quality  Services Seeking ART not available at
home
%
Yes No Unknown Not addressed
Chapter 15. Chart 1. Incoming for services.
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country for lower cost services; and 14 (21%) chose the answer
“unknown”. Three countries (5%) responded “not addressed”.
Outgoing for higher quality ART services
of 72 respondents (60%) affirmed that people travel from their
country for higher quality services; 12 (17%) responded that
people do not travel from their country for higher quality ser-
vices;14 respondents (19%) chose “unknown”, and three (4%),
“not addressed”.
Outgoing for ART services unavailable in their home country
Forty-two of the 69 respondents (61%) that answered questions
pertaining to CBR reported that people travel from their country
to access services that are not available in their home country; 16
country respondents (23%) said that people do not travel from
their country to engage in CBR elsewhere; 4 (6%) answered that
this was “not addressed”; and 7 respondents (10%) replied
“unknown”.
Outgoing for egg donation
Forty-six of 71 responding countries, 46 (65%) reported that
people travel from their country to another country to access egg
donation; 12 (16%) indicated that people from their countries do
not travel to other countries to seek egg donation; 11 (16%) said
that this was “unknown”; and 2 countries (3%) responding to
questions on CBR selected “not addressed”.
Outgoing for embryo donation
Thirty-six of 69 responding (52%) reported that people travel from
their country to another country to access embryo donation; 12
respondents (17%) said that people from their country do not travel
to other countries for embryo donation; 19 (27%) said that the status
was “unknown”; and 2 respondents (3%) selected “not addressed”.
Outgoing for sperm donation
Thirty-six of 70 country respondents (51%) reported that people








Incoming Egg Donation Incoming Embryo Donation Incoming Sperm Donation
%
Yes No Unkown Not Addressed








Gestational Surrogacy Traditional Surrogacy
%
Yes No Unknown Not addressed
Chapter 15. Chart 3. Incoming for surrogacy.
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Chapter 15. Table 2














Argentina No Yes Yes Yes Yes Yes Yes Yes
Australia Yes No Yes Yes Yes Yes Yes Yes
Austria Yes No Yes Yes Yes No Yes Yes
Bangladesh Yes Yes Yes Yes Yes
Barbados Unknown Unknown Yes Yes
Belarus Yes Yes Yes Yes No Unknown
Belgium Unknown Unknown Yes Yes Unknown Unknown Yes Unknown
Bolivia Yes Yes Yes Yes Yes Yes Yes Yes
Botswana Yes Yes Yes Yes Yes Yes Yes Yes
Brazil No Yes Yes Yes No No Yes No
Bulgaria No No No Unknown No Yes Yes
Burkina Faso Yes Yes No Yes No Yes Yes
Cameroon Not addressed Yes Yes Yes Yes Yes Unknown Unknown
Canada Yes Unknown No Yes Yes Unknown Yes Unknown
Chile Unknown No Yes No No No Yes Yes
China Unknown Yes Yes Yes Yes Unknown Yes Yes
Colombia No Yes Yes No No No Yes Yes
Czechia No Unknown Unknown No Unknown Unknown No Yes
Ecuador Yes Yes Yes Yes Yes Yes
Egypt No Yes No Unknown Unknown Unknown Unknown Unknown
El Salvador No Yes No Yes Yes Yes Yes Yes
Finland Yes No Yes Yes Yes Yes Yes Yes
Georgia No Unknown No Unknown Unknown Unknown No Unknown
Germany No Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Greece Yes Yes Yes No Yes Yes Yes Yes
Guatemala No Yes Yes Yes Yes Yes Yes Yes
Hong Kong (China*) Yes Yes Yes Yes Unknown Yes Yes Unknown
Hungary No Unknown No Yes Yes Unknown Yes Yes
India Yes Yes
Ireland Yes Yes Yes Yes Yes Yes Yes Yes
Italy Yes Yes Yes Yes Yes Yes Not addressed Not addressed
Côte d’Ivoire Yes Yes Unknown Yes Yes Yes No No
Japan No Yes Yes No No Yes No
Jordan No Yes No No No No No
Kazakhstan No Yes Yes No No Yes Yes
Kenya Unknown Yes Unknown Yes Yes Yes Unknown Unknown
Latvia Unknown Unknown Yes Unknown Unknown Unknown Unknown Unknown
Lithuania Yes Yes Yes Yes Unknown Yes Unknown Unknown
Mali Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Mexico Yes Yes Unknown Yes Unknown Unknown
Mongolia Not addressed Not addressed Not addressed Not addressed Not addressed Not addressed Not addressed Not addressed
Montenegro No No No Yes Yes Yes Yes Yes
New Zealand No No Yes Yes No Yes Yes No
Nigeria Yes Yes Yes Yes Yes Yes Yes Yes
Norway Unknown Unknown Yes Yes Yes Yes Yes Yes
Panama No Yes No No No No Unknown Unknown
Paraguay Yes Not addressed Not addressed Not addressed Not addressed Not addressed Not addressed Not addressed
Philippines Yes Yes Not addressed Unknown Unknown Unknown Unknown Unknown
Poland Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Portugal Not addressed Not addressed Yes Yes Not addressed Yes Not addressed Not addressed
Romania Yes No Yes Yes No No No
Russian Federation Yes Yes No No No No No No
Senegal Yes Yes No No No No No No
Serbia Yes Yes Yes Yes Yes Yes No No
Singapore Yes No Yes Yes Yes Unknown Yes Unknown
Slovenia Unknown No Yes Yes Unknown No No No
South Africa Yes Yes Yes Yes No Yes No No
South Korea No Yes Yes Unknown Unknown Unknown Unknown Unknown
Spain Yes Yes Yes Yes Yes Yes No No
Sri Lanka Yes Yes No Yes Yes Yes Yes Yes
Switzerland Yes No Yes Yes Yes Yes Yes Yes
Taiwan (China*) Unknown Unknown Yes Yes Yes Yes Yes Yes
Togo Unknown Yes Yes Yes Yes Yes Yes Yes
Trinidad and Tobago No Yes No Yes Unknown Unknown Yes Yes
Turkey No Yes Yes Yes Yes Yes Yes Yes
Uganda No Yes Not addressed Unknown Unknown Unknown Unknown Unknown
United Arab Emirates Yes No Yes Yes Yes Yes Yes Yes
UK Yes Unknown Yes Yes Yes Yes Yes Yes
USA Yes No No No No No No No
Uruguay Yes Yes Yes Yes Yes Yes Yes
Venezuela Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Viet Nam Unknown Yes Yes Unknown Unknown Unknown Yes Yes
Zimbabwe No Yes No Yes Yes Yes Yes Yes
*Reporting separately for this report.









Gestational Surrogacy Traditional Surrogacy
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Yes No Unknown Not addressed









Outgoing Egg Donation Outgoing Embryo Donation Outgoing Sperm Donation
%
Yes No Unknown Not Addressed









Lower Cost Services Higher Quality Services Seeking services not available in
home country
%
Yes No Unknown Not addressed
Chapter 15. Chart 4. Outgoing for services.
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Chapter 15. Table 3
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donation; 14 respondents (20%) said that people from other
countries do not travel to their country to engage with sperm
donation; 18 respondents (26%) reported status “unknown”;
and 2 (3%) selected “not addressed”.
Outgoing for gestational surrogacy
Of 70 countries, forty respondent countries (57%) answered
“yes”; 12 (17%), “no”; 14 (20%), “unknown”; 4 (6%), “not
addressed”.
Outgoing for traditional surrogacy
Of 69 countries, 32 (46%) responded in the affirmative (“yes”);
13 (19%), “no”; 20 (29%) said status was “unknown”; and 4
respondents (6%) selected “not addressed”.
Regulation of cross-border reproduction (Table 3)
Respondents were asked if their country had regulations that
governed cross-border surrogacy. Specifically, they were asked
about regulations governing citizens that visit other countries
seeking treatment, and people visiting their home country seeking
treatment (Table 3).
Four respondents (6%) (Austria, Italy, Spain, and the United
Kingdom of Great Britain and Northern Ireland) answered that
they did not have regulations governing people who travel to
other countries to access assisted reproduction. Four respondents
(6%) (Bulgaria, Romania, Slovenia, and Zimbabwe) said that
they do not have regulations governing people coming to their
countries for ART. Forty-two respondents (60%) reported that
they had neither.
Five respondents (6%) reported having laws that govern only
inbound people, not outbound people seeking ART; 1 country,
Italy, said it had laws governing only outbound people; 9
respondents (13%) reported having laws that governed both
inbound and outbound people seeking treatment. Of these
countries there was a mixture between federal laws, state/muni-
cipal laws, or both. In general, people travelling to a country to
access ART are governed by the laws and regulations of that
country.
Columbia and Senegal reported that cultural practices were
relevant, and Greece and Italy reported that cultural practices
and/or religious decrees were relevant for CBR.
Regulation of the import and export of tissue (Table 4 and 5)
Import
Ova: Thirty-four out of 73 respondents (47%) said that regula-
tions covered the importing of oocytes into their countries, while
20 (27%) reported no regulations; 12 (16%) claimed an
“unknown” status, and 7 (10%) selected “not addressed”.
Thirty five out of 73 (48%) said that regulations applied to the
importing of spermatozoa into their countries; 19 respondent


























































*Reporting separately for this report.
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Chapter 15. Table 4
Are there regulations regarding the import of reproductive tissue
into your country?
Country Ova Spermatozoa Zygotes
Argentina Yes Yes Yes
Australia Yes Yes Yes
Austria Unknown Unknown Unknown
Bangladesh Not addressed Not addressed Not addressed
Barbados No No No
Belarus No No No
Belgium Unknown Unknown Unknown
Bolivia Yes Yes Yes
Botswana No No No
Brazil Yes Yes Yes
Bulgaria Yes Yes Yes
Burkina Faso No No No
Cameroon No No No
Canada No Yes Unknown
Chile No No No
China Unknown Unknown Unknown
Colombia Yes Yes
Czechia Yes Yes Yes
Ecuador Yes Yes Yes
Egypt Not addressed Not addressed Not addressed
El Salvador No No No
Finland Yes Yes Yes
Georgia No No No
Germany Unknown Unknown Unknown
Greece Yes No Yes
Guatemala Yes Yes Yes
Hong Kong (China*) Yes Yes Yes
Hungary Unknown Unknown Not addressed
India Yes Yes Yes
Ireland Yes Yes Yes
Italy Yes Yes Yes
Côte d’Ivoire Unknown Unknown Unknown
Japan No No No
Jordan Not addressed Not addressed Not addressed
Kenya No No No
Latvia Yes Yes Yes
Lithuania Yes Yes Yes
Mali No No No
Mexico Yes Yes Yes
Mongolia Not addressed Not addressed Not addressed
Montenegro No No No
New Zealand Yes Yes Yes
Nigeria Yes Yes Yes
Norway Yes Yes Yes
Panama Yes Yes Yes
Paraguay Not addressed Not addressed Not addressed
Peru No No No
Philippines Unknown Unknown
Poland Unknown Unknown Unknown
Portugal Yes Yes Yes
Romania No Yes No
Russian Federation Yes Yes Yes
Senegal No No No
Serbia No No No
Singapore Yes Yes Yes
Slovenia Not addressed Not addressed Not addressed
South Africa Yes Yes Yes
South Korea Not addressed Not addressed Not addressed
Spain Yes Yes Yes
Sri Lanka No No No
Switzerland Yes Yes Yes
Chapter 15. Table 4
(Continued)
Country Ova Spermatozoa Zygotes
Taiwan (China*) Yes Yes Yes
Togo Unknown Unknown Unknown
Trinidad and Tobago Yes Yes Unknown
Turkey Unknown Unknown Unknown
Uganda No No No
United Arab Emirates Yes Yes Yes
UK Yes Yes Yes
USA Yes Yes Yes
Uruguay No No No
Venezuela Unknown Unknown Unknown
Viet Nam Unknown Unknown Unknown
Zimbabwe Yes Yes Yes
*Reporting separately for this report.
Chapter 15. Table 5
Are there regulations regarding the export of reproductive tissue
from your country?
Country Ova Spermatozoa Zygotes
Argentina Yes Yes Yes
Australia Yes Yes Yes
Austria Unknown Unknown Unknown
Bangladesh Not addressed Not addressed Not addressed
Barbados No No No
Belarus No No No
Belgium Unknown Unknown Unknown
Bolivia Yes Yes Yes
Botswana No No No
Brazil Yes Yes Yes
Bulgaria Yes Yes Yes
Burkina Faso No No No
Cameroon No No No
Canada No No No
Chile No No No
China Unknown Unknown Unknown
Colombia Yes Yes Yes
Czechia Yes Yes Yes
Ecuador Yes Yes Yes
Egypt Not addressed Not addressed Not addressed
El Salvador No No No
Finland Yes Yes Yes
Georgia No No No
Germany Unknown Unknown Unknown
Greece Yes Yes Yes
Guatemala Yes Yes Yes
Hong Kong (China*) Yes Yes Yes
Hungary Unknown Unknown Unknown
India Yes Yes Yes
Ireland Yes Yes Yes
Italy Yes Yes Yes
Côte d’Ivoire Unknown Unknown Unknown
Japan No No No
Jordan Not addressed Not addressed Not addressed
Kenya No No No
Latvia Yes Yes Yes
Lithuania Yes Yes Yes
Mali No No No
Mexico Yes Yes Yes
Mongolia Not addressed Not addressed Not addressed
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countries (26%) reported no regulations; 12 (16%) claimed
“unknown” status, and 7 respondents (10%) selected “not
addressed”.
Zygotes: 32 respondents of 71 (45%) said there were regulations
for importing zygotes into their countries; 19 countries (27%)
reported no regulations; 12 (17%) reported the status as
“unknown”; and eight respondents (11%) selected “not addressed”.
Export
Ova: Of 74 respondents, 33 (44%) said there were regulations
addressing the exportation of ova from their countries; and 22
(30%) countries reported the absence of regulations. Eleven
respondents (15%) answered “unknown”; and eight (11%)
selected the response “not addressed”.
Spermatozoa: 33 of 74 respondents (44%) said there were
regulations for the exportation of spermatozoa from their coun-
tries; 22 (30%) reported no regulations; 11 respondents (15%)
answered “unknown”; and 8 (11%) selected the response “not
addressed”.
Zygotes: 31 of 74 respondents (42%) affirmed the existence of
regulations pertaining to export of ova from their countries; 22
(30%) reported no regulations; 13 respondents (17%) answered
“unknown”; 8 (11%) selected the response “not addressed”.
Discussion
Overall, a rather large proportion of respondents reported that
individuals and couples were travelling to the respondents’ home
country to seek treatments that were lower cost (75%), or of
higher quality (79%) than those in their own home country, or
not available there (66%). Fewer respondents reported people
travelling to their country to donate tissue (egg, 47%; embryo,
37%, or sperm, 51%); and even fewer for gestational surrogacy
(28%) or traditional surrogacy (19%). These data confirm the
existence of these practices, but provide no data about the extent
or volume of such services.
A smaller proportion of respondents reported people travelling
from their home country to seek treatment that was lower cost
(65%), of higher quality (51%), or services not available at home
(51%). Figures for seeking egg, embryo and sperm donation were
higher for outbound for egg and embryos than inbound, (47%vs,
65%, 37% vs, 52% respectively) and equal for spermatozoa
(51%). Rates for outbound people seeking surrogacy were higher
than inbound figures, with 57% vs. 28%of respondents reporting
people travelling out of the country for gestational surrogacy, and
46% vs. 19% reporting people travelling out of the country for
traditional surrogacy. This reflects the desire of individuals to
seek services that are otherwise unavailable to them in their own
countries.
In regard to regulation, despite a perception of significantly
higher levels of movement across borders, the responses indicated
that there was little regulation of people travelling to or from
other countries to seek ART treatment. Regulation of the import
and export of tissue appeared more prevalent; however, several
respondents reported no regulation or did not know if regulation
existed.
The lack of regulation and lack of knowledge about regulation,
may be relevant to egg, embryo and sperm donation, and sur-
rogacy stakeholders. This would likely come about when children
born as a result may seek information about their donors or
surrogate mothers in the future. This is occurring more frequently
all over the world. Tracking and reporting of treatments and
treatment outcomes may also become difficult. Patient follow up
across borders is considerably more challenging.
Summary
CBR appears to be increasingly prevalent; most country respon-
dents noted that individuals traveled to their country seeking
ART services that were less expensive, perceived to be of higher
quality, or unavailable in their home country. A much smaller
group noted patients seeking CBR for sperm, egg, or embryo
donation, and even fewer for any type of surrogacy. A relatively
smaller proportion reported patients traveling from their country
for any of these services. Almost two-thirds (64%) of responding
countries reported the absence of regulations for patients either
coming to or leaving a country to seek CBR services. These data
suggest that a substantial amount of CBR care is being provided,
but no data are available regarding the actual volume, and
oversight is limited.
Chapter 15. Table 5
(Continued)
Country Ova Spermatozoa Zygotes
Montenegro No No No
New Zealand No No No
Nigeria Yes Yes Unknown
Norway Yes Yes Yes
Panama Yes Yes Yes
Paraguay Not addressed Not addressed Not addressed
Peru Not addressed Not addressed Not addressed
Philippines Unknown Unknown Unknown
Poland Unknown Unknown Unknown
Portugal Yes Yes Yes
Romania No No No
Russian Federation Yes Yes Yes
Senegal No No No
Serbia No No No
Singapore Yes Yes Yes
Slovenia Not addressed Not addressed Not addressed
South Africa Yes Yes Yes
South Korea Not addressed Not addressed Not addressed
Spain Yes Yes Yes
Sri Lanka No No No
Switzerland No No No
Taiwan (China*) Yes Yes Yes
Thailand Yes Yes Yes
Togo No No No
Trinidad and Tobago Yes Yes Unknown
Turkey Unknown Unknown Unknown
Uganda No No No
United Arab Emirates Yes Yes Yes
UK Yes Yes Yes
USA Yes Yes Yes
Uruguay No No No
Venezuela Unknown Unknown Unknown
Viet Nam Unknown Unknown Unknown
Zimbabwe Yes Yes Yes
*Reporting separately for this report.
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CHAPTER 16: HUMAN PRE-IMPLANTATION EMBRYO
RESEARCH
Introduction
In the United States of America, pre-implantation embryos that
are not intended for pregnancy are protected by federal mandates
of the “Common Rule” at a level surpassing that of surgically
removed organs and tissues. Adaptations and interpretations
from “Common Rule” governance appear to have been adapted
by local and national regulatory bodies as templates for regula-
tion of embryo research internationally, and are reflected in the
responses included in the 2018 Surveillance survey.
“CommonRule” regulations emerged after the introduction of
IVF. The two major US bodies charged with oversight are the
Office of HumanResearch Protections (OHRP) and the Food and
Drug Administration (FDA). Additionally, theNational Institutes
of Health (NIH), a primary source of funding for research, has
regulations and policies that are followed to the extent that a
research project (or institution) is funded by the NIH. Subpart A
of the regulations, known as the “Common Rule,” has been
adopted and separately codified by fourteen agencies other than
Health andHuman Services (HHS). Its tenants are well known to
researchers working in western Europe and in The United States
of America, and are likely followed by most of the survey
respondents, some of whom trained in these regions.
The questions posed by the Surveillance 2018 questionnaire to
the respondents of the 90 countries are based on Common Rule
standards. The questions were expected to highlight embryo
research as practiced internationally and influenced by federal
and regional customs, and interpreted by governments, munici-
palities, and scholarly committees.
Analysis of the survey
Is experimentation/research on the pre-implantation embryo
allowed/permitted in your country?
Research involving donated, unused pre-implantation embryos is
allowed in 29 countries out of 74 (39%), and not allowed in 30
countries (41%); its status was marked “unknown” in 15 countries
(20%). Research on donated, unused pre-implantation embryos for
stem cell research is allowed in 25 of 72 countries (35%), and not
allowed in 32 countries (44%); its status was “unknown” in 15
countries (21%). Reproductive cloning generating a human clone is
allowed in 2 of 72 countries (3%), and not allowed in 59 (82%); its
status was “unknown” in 11 countries (15%). Therapeutic cloning is
allowed in in8of 72 countries (11%), andnot allowed in51 countries
(71%); its status was “unknown” in 13 countries (18%). Embryonic
stem cell research is allowed in 13 of 72 countries (18%), and not
allowed in 45 (63%); its status was “unknown” in 14 countries
(19%) (Table 1, Chart 1).
Is there a requirement for specific approval of
experimentation/research proposals? If the answer is yes,
is the following allowed or not allowed?
Research involving donated, unused pre-implantation embryos is
allowed with specific approval in 26 of 36 countries (72%) not
allowed in 5 countries (14%); the status wasmarked “unknown” in
5 countries (14%). Research on donated, unused pre-implantation
embryos for stem cell research is allowed, with specific approval, in
28 countries out of 37 (76%); not allowed in 5 countries (13%); and
the status was “unknown” in 4 countries (11%). Reproductive
cloning generating a human clone is allowed, with specific approval,
in 6 of 18 countries (33%), not allowed in 7, (39%); the status was
marked “unknown” in 5 countries (28%) (Chart 2).
In 2015, a single country, Uruguay, responded that human
cloning was permitted. Therapeutic cloning is allowed with spe-
cific approval in 8 of 21 countries (38%), not allowed in 7 (33%),
and the status was “unknown” in 6 countries (29%). Embryonic
stem cell research is allowed, with specific approval, in 11 of 24
countries (46%), not allowed in 4 (17%); and the status was
“unknown” in 9 countries (37%), compared to five countries
responding affirmatively in the 2015 survey.
What body or agency approves experimentation/research?
Research involving donated, unused pre-implantation embryos was
reviewed for specific approval by a local or national institutional
review board in 14 of 48 countries (29%), by a national ethics or
oversight panel in 24 countries (50%), and by an ethics panel in 12
countries (25%); the status wasmarked “unknown” in 11 countries
(23%). Research on donated, unused pre-implantation embryos for
stem cell research is reviewed for specific approval by a local or
national institutional review board in 14 countries out of 46 (30%),
by national ethics or oversight panels in 25 countries (54%); by
ethics panels in 12 countries (26%); and the status was marked
“unknown” in 10 countries (22%). Reproductive cloning intended
to generate a human clone was reviewed for specific approval by a
local or national institutional review board in 1 country of 25 (4%);
by national ethics or oversight panels in 12 countries (48%); and by
ethics panels in 2 countries (8%). The status was “unknown” in 12
countries (48%), and 1 country reported “other” without addi-
tional description. Therapeutic cloning is reviewed for specific
approval by a local or national institutional review board in 3
countries out of 27 (11%), by national ethics or oversight panels in
10 countries (37%), and by ethics panels in 5 countries (18.5%).
The status was marked “unknown” in 12 countries (44%), and 1
country reported “other” as federal regulations. Embryonic stem
cell research is reviewed for specific approval by local or national
oversight panels in 6 of 33 countries (18%), by national ethics or
oversight panels in 14 countries (42%), and by ethics panel in 6
countries (18%). The status was marked “unknown” in 11 coun-
tries (33%), and 2 countries responded “other”.
In your country up to what age development in days can
experimentation be performed on a developing non-
implanted embryo?
There were 20 responses to this question. The full range of
responses was 0 to 45 days, with a median of 23 days.
Is experimentation/research on the pre-implantation embryo
performed in your country?
Research involving donated unused pre-implantation embryos is
underway in 24 countries out of 65 responders (37%). In compar-
ison, 6 countries cited ongoing stem cell research from donated pre-
embryos in 2015. Research on donated, unused pre-implantation
embryos for stem cell research was performed in 21 of 63 countries
(33%). Reproductive cloning generating a human clone was
reportedly performed in 2 countries out of 60 (3%). Therapeutic
cloning was performed in 7 of 61 countries (11%). Embryonic stem
cell research was performed in 12 of 60 countries (20%).
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Chapter 16. Table 1
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Argentina Yes Unknown Yes Unknown Unknown Unknown Unknown Unknown Yes Unknown





















No No No No
Belgium Unknown Yes Unknown Unknown Unknown
Bolivia No No No No No No No No No No
Botswana Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Brazil No No Yes, with
restrictions





No No No No No No No No
Burkina Faso No Unknown No Unknown No Unknown No Unknown No Unknown
Cameroon No No No No No
Canada Yes Yes Yes Yes No No No No No Yes








Colombia Unknown No Unknown No No No No No Unknown No
Czechia No No Yes Yes No No No No No No
Ecuador No No No No No








El Salvador No No No No No No No No No No
Finland Yes Yes Yes Yes No No No No No No
Georgia Unknown No Unknown No No No No No No No
Germany No No No No No No No No No
Ghana Yes Yes Yes Unknown Unknown Unknown Unknown Unknown Unknown
Greece Yes, with
restrictions
Unknown Yes Yes, with
restrictions
Yes Yes Yes Yes Yes, with
restrictions
Yes
























No No No No No No No
Ireland No No No No No No No No No No
Italy Unknown No Unknown No Unknown No Unknown No Unknown Unknown
Côte d’Ivoire Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown




No No No No Yes Yes, with
restrictions
Jordan No No No No No No No No No No
Kazakhstan No No No No No No No No No
Kenya
Latvia Yes Yes Unknown Unknown No No No No No No
Lithuania No No No No No No No No No No
Mali No No No No No No No No No No

























No No No No No No No
New Zealand No No No No No
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Are there regulations that address experimentation on the
pre-implantation embryo in your country?
Research involving donated, unused pre-implantation embryos
was regulated in 34 of 66 countries (52%). Reproductive cloning
generating a human clone was regulated in 41 of 68 countries
(60%). Therapeutic cloning was regulated 40 of 61 countries
(61%). Embryonic stem cell research was regulated in 33 of 63
countries (52%).
Countries that regulated research involving donated, unused
preimplantation embryos reported having federal or national laws,
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Unknown No Unknown No No No Unknown
Norway Yes Yes, with
restrictions
No No No No No No Yes No
Panama No No No No No No No No Yes, with
restrictions
Paraguay Unknown No Unknown No Unknown No Unknown No Unknown No
Peru No No No No No No No No No No
Philippines No No No No No No No No No No
Poland No No No No No No No No No No




No No No No No No
Romania No No No No No No No No No
Russian
Federation
Unknown Unknown Unknown Unknown No Unknown No Unknown Unknown Unknown
Senegal No No No No No
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Unknown No No No No No No
Sri Lanka No No No No No















Thailand Yes Yes Yes Yes, with
restrictions




Unknown No Unknown No Unknown No Unknown No Unknown No
Turkey No No No No No No No No No No
Uganda Unknown No Unknown No Unknown No Unknown No Unknown No
UAE No No No No No No No No No





















Uruguay No No No No No No No No No
Venezuela Unknown No Unknown No No No No No No No
Viet Nam Unknown Yes Unknown Unknown Unknown Unknown Unknown Unknown Unknown Unknown
Zimbabwe Unknown No Unknown No Unknown No Unknown No Unknown No
*Reporting separately for this report.
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Chapter 16. Chart 3. How frequently is experimentation performed?
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statutes, ordinances, or policies in 19 out of 34 (56%); state, pro-
vincial, or regional laws, statutes, or ordinances in 2 (6%); agency
regulations or oversight in 2 (6%); professional organization stan-
dards and guidelines in 5 (15%); cultural practices in 1 (3%); and
religious decrees in 1 (3%).Countries that regulated embryonic stem
cell research reported having federal or national laws, statutes,
ordinances, or policies in 18 of 33 (55%); state, provincial, or
regional laws, statutes or ordinances in 2 (6%); municipal laws,
statutes, or ordinances in 1 (3%); agency regulations or oversight in
1 (3%); and professional organization standards and guidelines in 4
(12%). Countries that regulated therapeutic cloning reported hav-
ing federal or national laws, statutes, ordinances, or policies in 16
out of 40 (40%); state, provincial, or regional laws, statutes, or
ordinances in 2 (5%); and professional organization standards and
guidelines in 2 (5%). Countries that regulated reproductive cloning
reported having federal or national laws, statutes, ordinances, or
policies in 15 out of 41 (37%); state, provincial or regional laws,
statutes, or ordinances in 2 (5%); professional organization stan-
dards and guidelines in 2 (5%); cultural practice in 1 (2%); and
religious decrees in 1 (2%).
Are clinical research programmes in your country performing
experimentation on the pre-implantation embryo?
Research on donated, unused pre-implantation embryos for stem
cell research is commonly performed in only 2 countries out of 66
reporting (3%), infrequently performed in 12 countries (18%),
and never performed in 36 countries (55%); the status was
marked “unknown” in 16 countries (24%) (Table 1).
Reproductive cloning generating a human clone is commonly
performed in only 1 country out of 67 (2%), infrequently per-
formed in 2 countries (3%), and never performed in 54 countries
(81%); the status was marked “unknown” in 10 countries (15%).
Therapeutic cloning is commonly performed in only 2 countries of
65 (3%), infrequently performed in 4 (6%), and never performed
in 49 countries (75%); the status was marked “unknown” in 10
countries (16%). Embryonic stem cell research is commonly per-
formed in only 7 of 67 countries (11%), infrequently performed in
9 countries (13%), and never performed in 36 countries (54%); the
status was “unknown” in 15 countries (22%) (Chart 3).
Discussion
The United Nations Declaration on Human Cloning, which
prohibits all forms of human cloning, was passed in 2005
with 84-member nations voting in support, 34 in opposition, and
37 abstaining. No global consensus emerged because there were
concerns expressed regarding its interpretation and potential
application to various types of cloning. The 2018 Surveillance
survey was intended to assess, in part, the extent of observance of
the United Nations resolution 13 years later, and not to seek
responses regarding specific research initiatives. As expected,
nations that had prior experience with Common Rule tended to
have the most strenuous infrastructures for managing research
funds, legislation, publication, and enforcement standards. The
majority of responding countries now have some form of over-
sight for research in place.
The 2018 survey reflects an increased amount of investigative
activity with donated, unused embryos, usually with restrictions
in place and a still small but growing number of countries actively
involved in embryonic stem cell research. Most of the countries
involved in this research have existing oversight that has evolved,
in part, from the Common Rule. Surprisingly, one country,
Greece, reported ongoing research pertaining to human repro-
ductive cloning.
In November 2018, the U.S. National Academy of Sciences,
including the U.S. National Academy of Medicine, the Royal
Society of the United Kingdom of Great Britain and Northern
Ireland, and the Academy of Sciences of HongKong, convened an
international summit to address human genome editing and other
aspects of embryo research. More than 500 researchers, ethicists,
policymakers, patient group representatives, and others from
around the world took part. The potential benefits and risks of
human genome editing, ethical and cultural perspectives, reg-
ulatory and policy considerations, and public outreach and
engagement efforts were considered, and their recommendations
were recently published[1].
Summary
Human pre-implantation embryo research remains a contentious
topic, with a small minority of countries actively involved in its
investigation.With recent advances in clinical application of stem
cell research, a small but growing number of countries are con-
ducting studies using embryonic stem cells provided by donated,
unused embryos, with restrictions. Human reproductive cloning
remains almost universally prohibited[1].
Reference
[1] Available at: https://www.nap.edu/catalog/25343/second-inter
national-summit-on-human-genome-editing-continuing-the-glo
bal-discussion. Accessed January 26, 2019.
CHAPTER 17: STATUS OF THE EMBRYO
Introduction
One of the first issues to be addressed with the inception of life
created outside of the mother’s body was the status to be accor-
ded the embryo. Determining when life begins is a topic that has
preoccupied theologians, biologists, and legal scholars for mil-
lennia, but no one had anticipated the advent of in vitro fertili-
zation. Universal moral and ethical principles govern the
treatment of individuals, and are embraced by governments and
societies, but ART poses unique potential conflicts of interest for
prospective mother and child when their mutual welfare does not
overlap. Thesemoral dilemmas are not easily resolved by classical
ethical tenets. These issues revolve around the question of whe-
ther there is a point in embryonic or fetal development when
personhood is conveyed, with its inherent legal rights, before
which time a person is not considered to exist. The striking dif-
ferences in how various countries reconcile these dilemmas
highlight some of the most significant issues in the international
governance of ART.
In the 2018 questionnaire, the following questions were posed:
1. “Is there a recognized point in time during human develop-
ment in which a human exists and thus provided human
rights?”
2. “Through which governing bodies or agencies is this time of
human existence determined?”
3. “Is there a recognized point in time during human develop-
ment before which a human person is considered not to exist
and thus not provided human rights?”
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4. “Through which governing bodies or agencies is this time of
human non-existence determined?”
Analysis of the survey
Representatives of 74 countries responded to the first question.
Thirty-one (42%) noted that such a point existed (Table 1). It was
day “0” (pre-fertilization), stated five nations (7%): Australia,
Greece, Ireland, Spain, and Uruguay. Day “1” (post-fertilization)
was the choice of 13 countries (18%): Bolivia, Brazil, Ecuador, El
Salvador, Guatemala, Mexico, Nigeria, Peru, Philippines,
Poland, Portugal, Senegal, and Zimbabwe. A time between day 2
and 126, said 9 countries (12%). The Russian Federation,
Thailand, and The United States of America (4%) chose
280 days, and United Kingdom of Great Britain and Northern
Ireland (1%) specified 281 days as the point at which human
rights are conveyed (Chart 1).
Of the 31 countries that have chosen a point at which a human
is recognized to exist, the majority of countries – 28 of them –
(90%) back up their decision with federal or national statutes,
ordinances, or policies, and 7 (23%) do so by state or provincial
policies or legislation. Only 3 (10%) rely on municipal laws,
statutes, or ordinances. Eight (26%) use professional organiza-
tions’ standards or guidelines, 9 (29%), existing cultural prac-
tices; and thirteen (42%), religious decrees.
Regarding question 3, responses were received from 66
countries; responders from 14 countries (21%) acknowledged a
specific point before which a person was not considered to exist.
Thirty-five respondents (53%) did not recognize such a point or
time, and 17 (26%) reported “unknown” (Table 2). Among
countries that did recognize such a point, it was day 0 for
Ecuador, Ireland, and Senegal; day 1 for Argentina; and 280 days
for Canada, Finland, The United States of America, and the
United Kingdom of Great Britain and Northern Ireland. For
Egypt, Kazakhstan, Georgia, Norway, Austria, and Germany,
the time ranged from 41 to 97 days (Chart 1). The point was
determined in most countries (13 out of 14; 93%) by federal or
national statutes, laws, or ordinances.
Chapter 17. Table 1
Is there a recognized point in time during human development at
which a human exists and thus provided human rights?
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Chapter 17. Table 1
(Continued)
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Trinidad and Tobago Unknown
Turkey Unknown
Uganda Unknown







*Reporting separately for this report.











Chapter 17. Chart 1. Is there a recognized point in time during human development at which a human person is considered to exist or not exist?
Chapter 17. Table 2
Is there a recognized point in time during human development
before which a human person is considered not to exist and thus
not provided human rights?
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Trinidad and Tobago Unknown
Turkey Unknown
Uganda Unknown






*Reporting separately for this report.
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Discussion
In the 2018 survey, 10 more countries responded to the first
question than had done so 3 years earlier (74 versus 64 responses).
Considerably more countries now recognize a point at which
personhood is acknowledged (42% vs 28%). There was less dif-
ference in the response rate to question 2 (66 vs 64 responses) and
this time only 21% acknowledged that there was a point before
which a personwas not considered to exist. In 2015, the figure was
33%. The response “unknown” was given for question 1 by 20
responders (27%) and for question 3 by 17 responders (26%); in
2015, the responses for the same questions were 30% and 17%,
respectively. The results suggest a greater emphasis currently on
determining a time personhood is reached, but they still show great
variability in when that time is recognized.
Since the original ruling of the Inter-American Court of
Human Rights (IACHR) in Costa Rica, granting the rights of 18
plaintiffs to access ART, was upheld in February 2016. Since that
time, Costa Rica has established two ART centres and partici-
pated in this most recent survey. No countries are currently
known to continue to pose statutory obstacles to access of ART.
Summary
IVF now appears to be universally available, but marked differ-
ences exist among countries regarding the status and protection
given to the embryo. An increasing proportion of countries now
recognize a point at which an embryo or fetus reaches personhood,
with attendant legal rights; and fewer countries are defining a point
before which a person is said to not exist. Considerable variation
continues among nations as to when these points are defined, and
there does not seem to be a trend towards consensus.
CHAPTER 18: CONCLUSIONS
The 2018 questionnaire used to produce the International
Federation of Fertility Societies’ Surveillance (IFFS) 2019: Global
Trends in Reproductive Policy and Practice, 8th Edition, suc-
ceeded in engaging respondents from 97 countries to complete all
or a portion of the 94 questions in the survey. With 22 more
countries responding than was the case with the 2015 project, the
8th edition offers a more complete depiction of the international
status of the practice of ART. But the opportunity to make
meaningful comparisons over the three years is limited, because
the two editions include some different participating countries.
The data collected suggest that several countries, primarily in
Africa, have recently started their inaugural ART programmes; that
overall the number of new ART centres around the world has
leveled off, with most countries recording modest increases in the
number of centres; and that several nations now have fewer centres
than in 2015. If the latter finding is validated, uncovering the
contributing factors will be a query for the next triennial review.
The proportion of countries that have some regulatory over-
sight continues to increase. More than 86% of respondents now
cite a regulatory oversight system, including national or federal
legislation, provincial or municipal statutes, agency inspections,
and professional guidelines. New regulatory efforts have
addressed anonymous donation, cross-border reproduction,
IVF surrogacy, pre-implantation genetic diagnosis, and experi-
mentation on embryos, and cover issues such as marital
status, micromanipulation, and same-sex parenting. Additional
licensing and monitoring requirements have been imposed, and
certification and examination processes expanded. What has not
taken place is a marked increase in the proportion of countries
with legislation or clinical guidelines that restrict the number of
embryos permissible for transfer to women undergoing IVF/ART
cycles (currently 59%, vs. 56% in 2015). More countries (35%
vs. 24% in 2015) now report penalties for non-compliance
regarding the number of embryos transferred.
Insurance coverage for ART is offered by a minority of coun-
tries, with only 47%providing support for any infertility therapy.
There are significant regional variations for eligibility and the
extent of coverage offered. Greater support does seem to be
provided for genetic screening. No significant changes were
identified in the proportion of countries that tie reimbursement to
the number of embryos transferred.
The majority of countries (62%) do not require couples or
individuals to be in a recognized or stable relationship to access
ART services. Countries accepting single women (68%) and
female same-sex couples (45%) for provision of ART services is
more prevalent than those extending the same access to men
(32%) or male same-sex couples (21%).
Technologic advances in ART have been broadly adopted.
ICSI is widely accepted and universally available. PGT-M is
expressly permitted in about 75% of respondent countries, not
prohibited by any, and performed in about half. PGT-A and
assisted hatching have been shown to be valuable adjuncts for
some types of patients, but their indications and overall value are
still being defined. PGT-A for aneuploidy was available in all
responding countries, but is actively performed in 50% (45 of
90), compared to 42% in 2015.
Considerable ongoing interest remains for IVM, but there has
been no recent significant clinical progress, and clinical adoption
awaits translational investigations and clinical validation. The
same is true for cytoplasmic transfer, mitochondrial transfer, and
CRISPR-Cas9 technology – for which there is ongoing research;
but all are considered investigative. Human preimplantation
embryo research remains controversial; relatively few countries
are participants. This number is likely to increase, however, with
recent advances in stem cell research. A growing number of
countries use embryonic stem cells provided by donated, unused
embryos, with restrictions. Human reproductive cloning remains
almost universally prohibited.
Gamete and embryo donation are well established ART
practices, and are employed, if not sanctioned, by a large majority
of the responding countries. Overall, about 50% to 60% of
countries surveyed report using gamete or embryo donation,
although “de novo” embryo donation is used less often, accepted
in around 25% to 35%of countries. The vast majority of country
respondents (71%) noted acceptance and successful application
of cryopreservation of sperm, oocytes, and embryos. However,
extensive variation continues among the country respondents in
terms of which practices are regulated and how they are regu-
lated. Gamete and embryo donation have been well established
ART practices, and are used by a large majority of countries.
Overall, 50% to 60% of countries offer gamete or embryo
donation. In contrast, “de novo” embryo donation is less com-
monly accepted, and available only in 25% to 35% of countries.
The 2018 Surveillance questionnaire reaffirmed the con-
troversial aspects of several ART practices, including gestational
surrogacy, posthumous reproduction, cross-border reproduction
(CBR), and selective fetal reduction (SFR). About one-third of
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countries practice gestational surrogacy; fewer, traditional sur-
rogacy. Most have measures in place prohibiting or sharply
curtailing the practice.
Surveillance 2019 notes an increased application of all types of
posthumous reproduction, including insemination of cryopreserved
sperm and oocytes, and transfer of cryopreserved embryos – despite
the apparent decline in the number of countries that have legislation
or other measures in place pertaining to posthumous reproduction.
CBR has become increasingly prevalent. Most country
respondents noted that individuals have traveled to their country
for ART services that were less costly, perceived to be of better
quality, or unavailable at home. About two thirds (64%) of
respondents cited the absence of regulations for patients seeking
CBR services entering or leaving a country. Only a third of the 89
responding countries permit SFR outright; another 19% allow it
conditionally, and 19% ban it completely. Sex selection, usually
performed with PGT-A, is being applied more frequently, and is
almost universally available. Despite this, relatively few countries
(24%) expressly permit PGT-A for sex selection; even fewer have
regulations restricting it. Sperm sorting and SFR, while available
in a few countries, is infrequently practiced.
There has been ongoing interest and legislative activity have
addressed several social, legal, and non-technical aspects of ART.
While possibly less contentious, they have widely different appli-
cations. Some countries have enacted extensive measures to ensure
the welfare of the child; a discernible trend has been directed
towards more intensive assessment of the prospective parents
before treatment begins. Yet 74% of countries require no formal
assessment. At a later stage in the ART process, an increasing
proportion of countries are recognizing a point in embryo devel-
opment at which personhood is achieved and specific legal rights
are assigned. These points vary widely among countries, and there
does not appear to be an identifiable trend towards consensus.
The International Federation of Fertility Societies’ Surveillance
(IFFS) 2019: Global Trends inReproductive Policy and Practice, 8th
Edition, provides a more complete rendering of the global status of
ART. It captures more data from a greater number of respondents,
and makes the first effort to define the extent of the ART frontier by
listing countries not thought to be engaged in the practice of ART.
The publication provides a vast amount of data for a variety of
stakeholders – including clinicians, researchers, patients, policy
makers, and health ministers. It depicts considerable progress in
technical application, access to ART services, and consensus around
issues pertaining to safety and social justice, but also highlights some
inconsistencies between intent and actual application of some ART
policy. It attests to the dynamic aspects of a still rapidly evolving
transformative field.
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